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  I 
Abstract 
	
Breast cancer represents a heterogeneous collection of different diseases 
characterized by different pathological and biological features, clinical 
presentation, clinical behaviour, response to treatment and outcome. In 
current practice, pathological diagnosis and classification of breast cancer is 
based mainly on well-established traditional morphologic features. However, 
morphological features alone do not adequately reveal the molecular 
heterogeneity and complexity of breast cancer. 
 
Still, there are relatively few biomarkers widely used in prognostication in 
invasive breast cancer and in predicting response to targeted therapies, and 
even fewer of value in the clinical management of the pre-invasive disease of 
ductal carcinoma in situ (DCIS). There is therefore an unmet need for 
biomarkers for better classification, better prediction of prognosis and of 
prediction of response to therapy for both invasive breast carcinoma and 
DCIS. 
 
The co-expression of a HER2/HER3 combination results in more aggressive 
tumour growth and is associated with endocrine and chemotherapy 
resistance, driven not simply by receptor expression but also by signalling via 
the receptors dimers. Therefore, methods which directly query signalling 
pathway activation in breast cancer specimens are anticipated to provide 
important insights into the molecular ‘‘logic’’ that distinguishes cancer from 
normal tissues and potentially to have an important impact on personalized 
intervention strategies.  
 
The aim of this thesis has been directed at evaluating candidate biomarkers in 
breast cancer. This has been targeted at examining attributes associated with 
known functional properties of candidate drivers of disease or resistance to 
treatment rather than those traditionally based on altered expression of these 
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biomarkers. Specifically, the work was directed at the HER1-3 members of the 
EGFR family of growth factor receptor in breast cancer. 
 
In this project I have in part developed, tested and evaluated two methods, 
which have the ability to detect protein-protein complexes at a single molecule 
level and thus allow the study of signalling pathways in situ. The first method 
is an in-house coincidence detection technology created from two 
recombinant fusion proteins and the second is a commercially available 
proximity ligation assay (PLA) method. Both approaches were able to detect 
the target proteins with high sensitivity and specificity, however the proximity 
ligation assay was subsequently used here to assess the protein complexes 
and activation status of the EGFR family in breast cancer patient’s samples.  
 
The patient study cohort is derived from a consecutive series of approximately   
293 cases of primary operable invasive breast cancers obtained from the 
Guy’s and St Thomas (King’s Health Partner’s) Breast Cancer Biobank 
archive presenting between 1990 and 1992. In these cases, 9 different 
biomarkers were studied for HER family expression level, dimer expression 
and activation status using proximity ligation assays (PLAs). The relationship 
between HER activation status, dimer expression and relapse free survival 
(RFS) was investigated and stratified multivariate regression analysis 
identified factors influencing patient prognosis. 
  
In conclusion, PLA successfully and reproducibly detected HER protein 
complexes and phosphorylation in vivo. A significant association was 
identified between high levels of phosphorylated HER2 and reduced 
recurrence-free survival (RFS) in invasive lobular carcinoma (p = 0.04, HR 
0.99, 95% CI: 0.997-1.002). High levels of HER1/HER3 dimers were 
associated with reduced RFS in T1 (<2cm) breast cancer patients, (p = 0.02, 
HR 1.84, 95% CI: 1.08-3.13). Similarly, high levels of HER1/HER3 and 
HER2/HER3 dimers were associated with reduced RFS in breast cancer 
patients with N1 nodal status (p <0.0001, HR 1.84, 95% CI: 0.58-1.93) and   
(p <0.0001, HR 0.64, 95% CI: 0.45-0.90) respectively). 
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 Work in this thesis demonstrates that in situ detection of HER protein 
complexes and activation status can be monitored robustly and with specificity 
in clinical specimens, providing novel prognostic information. This technique 
was also applied successfully to assess the HER family in a smaller number 
of DCIS cases.  
This novel technique and approach could potentially be applied for patient 
stratification and assist in the selection of more individualized treatment 
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1.1 Breast cancer 	
“Now mark me how I am undone”. 
William Shakespeare, Richard II 
 
The burden on women of developing breast cancer is substantial, since it is 
the most common female malignancy, estimated to comprise approximately 
30% of all female cancers (Cancer Research UK, 2014) (Figure1:1), and is 
the second most common cause of cancer-related mortality in women after 
lung cancer. In the UK between 2010 and 2011 almost 50,000 women were 
diagnosed with invasive breast cancer and almost 6,000 women were 
diagnosed with in situ breast carcinoma (Cancer Research UK, 2014). The 
apparent incidence of in situ breast carcinoma has increased five fold since 
the late 1970s, largely due to the introduction of mammographic breast 
screening programmes in the 1980s and its increased detection. In such 
programmes 20-25% of cancers detected are in the form of ductal carcinoma 
in situ (DCIS) (Pinder 2010, Brown and Pinder 2012).  
 
Breast cancer is also the commonest cause of cancer death world wide 
among females; in UK there are around 36 breast cancer deaths for every 
100,000 females (Cancer Research UK, 2014). However, an encouraging 
trend in the mortality rate has been observed, a decline in female breast 
mortality since the 1970s can be attributed to early detection with screening 
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Figure 1:1 The 10 most common malignancies among women. Breast cancer comprises 
30% of all female cancers (Chart adapted from Cancer Research UK, 2014). 
 
 
  1.2 Breast cancer and risk factors 
 
Although the causes of breast cancer are complex, many risk factors have 
been identified that can influence the development of the disease. These 
include genetic background, personally characteristics and life style. 
	
	1.2.1 Genetic Background 	
Ripperger & colleagues reported that up to 15% of healthy women have at 
least one first degree relative with breast cancer, and the risk of developing 
breast cancer doubles in these women (Polyak 2007, Ripperger, Gadzicki et 
al. 2009). In western countries up to 10% of breast cancer in women is 
believed to be associated with a genetic predisposition (McPherson, Steel et 
al. 2000).  
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A markedly increased risk of developing breast cancer is associated with the 
inheritance of germ-line mutations in genes such as breast cancer associated 
genes 1 (BRCA1) or 2 (BRCA2 (King, Marks et al. 2003, Foulkes and Shuen 
2013). Such inherited mutations can increase the risk of developing the 
disease up to 60-85% (Polyak 2007, Ripperger, Gadzicki et al. 2009). In 
addition, there are rare cancer predisposition syndromes associated with a 
moderate to high increased risk of developing breast cancer (Table 1-1). 
These include syndromes due to gene mutations in tumour protein 53 (TP53), 
cadherin1 (CDH1) and phosphatase and tensin homolog gene (PTEN) 
(McPherson, Steel et al. 2000, Lei, Sjoberg-Margolin et al. 2002, Ripperger, 
Gadzicki et al. 2009). Women with heterozygous mutations in DNA repair 
genes such as CHEK2, BRIP1, ATM and PALB2 are also at moderately 
increased risk of developing breast cancer (Ripperger, Gadzicki et al. 2009).  
 
A lower degree of increased risk of developing breast cancer has been 
associated with a number of Single Nucleotide Polymorphisms (SNPs). For 
example, two SNPs in intron 2 of FGFR2 gene have been observed in two 
independent studies as leading to an increased risk of having a breast cancer, 
with an odds ratio in a heterozygous situation of 1.23-1.24 (Ripperger et al., 
2009). 
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 Table 1-1. Increased breast cancer risk with predisposition syndromes. 
 
Syndrome Gene Location Breast cancer risk 
Li-Fraumeni syndrome 1 TP53 17p13.1 50-60%risk by the 
age of 45 years 
Hereditary diffuse gastric 
cancer/familial lobular breast 
cancer 
CDH1 16q22.1 52% risk by the 
age of 75 for 
2398delC. 
Cowden syndrome PTEN 10q23.3 30-50% risk by the 
age of 70 years 
Neurofibromatosis type 1 
 




NBN 8q21-24 OR: 2.8 for 
657del5 
Peutz-Jeghers Syndrome STK11 19p13.3 45% risk by the 
age of 70 years 
Table from (Ripperger, Gadzicki et al. 2009) 
SIR: Standardized incidence ratio 
OR: Odds ratio. 
 
 
1.2.2 Previous benign breast disease 	
The risk of developing breast cancer is higher among women with a previous 
diagnosis of atypical epithelial proliferation in the breast, including atypical 
ductal hyperplasia (4x increased risk) (McPherson, Steel et al. 2000).  The 
risk is also increased in women diagnosed with atypical lobular hyperplasia 
(3x increased risk) and lobular carcinoma in situ (10x increased risk). Lesser 
degrees of risk are seen with florid epithelial hyperplasia (up to 2x) 
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  1.2.3 Age and life style habits 	
The risk of developing breast cancer increases with age, doubling about every 
10 years until the menopause. Furthermore, the increased risk is reported to 
be higher among women who start menstruating early in life or who have a 
late menopause (McPherson, Steel et al. 2000). Full-term pregnancy at a 
younger age (<30), multiple pregnancies, as well as long duration of 
breastfeeding have been observed to reduce the risk of developing breast 
cancer. The latter is potentially due to high prolactin levels produced after 
pregnancy, as high prolactin levels results in less exposure of the breast to 
oestrogen level (Key, Verkasalo et al. 2001, Hulka and Moorman 2008).  
 
Current use of oral contraceptives and hormonal therapy increases the risk of 
breast cancer (McPherson, Steel et al. 2000, Key, Verkasalo et al. 2001). 
Specifically, the prolonged use of oral contraceptives by younger women 
before their first full-term pregnancy increases their risk of developing the 
disease (Beaber, Malone et al. 2014). In addition, older women who have had 
oestrogen for at least 5 years have an increased risk of developing breast 
cancer compared to women who reported no hormone use. Moreover, the use 
of combined progesterone and oestrogen HRT increases the risk of 
developing breast cancer (McPherson, Steel et al. 2000, Anderson, Limacher 
et al. 2004). 
 
Exposure to ionising radiation, particularly during breast formation increases 
the risk of developing breast cancer, as observed among teenage girls 
exposed to radiation during World War II (Vogel 2000).  
 
Certain life-style habits can also have a significant influence on a woman’s 
risk of developing breast cancer; for instance, smoking and a diet with high 
consumption of alcohol, dietary fat and calories, as well as deficiency in 
vitamin B12 and folic acid have been shown to increase the risk of developing 
breast cancer (Rogers, Zeisel et al. 1993, MacMahon 2006, Hulka and 
Moorman 2008).  
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  1.3 Breast cancer treatment; 
from Ancient Egypt through to the current time 
 
“Then came a gash long and deep, first on the side of my breast, then on the 
other.  Deep sickness seized me, and deprived me of my breakfast.  This was 
followed by extreme faintness.  My sufferings were no longer local.  There 
was a general feeling of agony throughout the whole operation."   
 
The above excerpt was written by Lucy Goodale Thurston (1795-1876) a 
missionary living in Hawaii describing her mastectomy treatment ordeal 
performed without anesthesia (Cott 1996). 
 
1.3.1 Antiquity 	
Breast cancer is an old disease. It exceeds race, class and time, a horror 
known to every culture in every age. First mentioned by the Ancient Egyptians 
more than 3,500 years ago in which the “Edwin smith surgical papyrus” (one 
of the oldest surviving medical texts) described the management of eight 
breast cancer cases by cauterization with the use of “the fire drill”. Hippocrate 
of Cos (460-377 B.C.) was the first to recognize the difference between 
benign and malignant tumours (Olson 2002, Ekmektzoglou, Xanthos et al. 
2009).  
 
Classification of breast cancer and enlargement of axillary lymph nodes 
accompanying breast cancer was first described during the Roman periods by 
Aulus Cornelius Celsus (25 B.C- 50 A.D). He classified breast cancer 
beginning with cacoethes, followed by carcinoma without skin ulceration, 
carcinoma with ulceration and finally thymium. He also described swellings in 
the armpits and their spread throughout the body, recognized today as 
features of metastatic breast cancer (Ekmektzoglou, Xanthos et al. 2009). 
Galen of Pergamum (second century A.D.) reported that in the early stages of 
breast cancer conservative therapy was the treatment of choice while surgery 
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could be the choice for advanced cases. He advised the use of scalpel for 
incisions, placing pressure on the operative area and proceeding into 
cauterization for haemostasis. For healing cancerous growth, he used 
compound medicines drawing materials from different sources including zinc 
oxide, lead mixed with wine or olive oil. Also, during that era, Leonides was 
the first to describe the characteristics of nipple retraction (Ekmektzoglou, 
Xanthos et al. 2009). 
 
1.3.2 Byzantine and Islamic medicine 	
Breast cancer surgery with organ conservation was first reported by Paul of 
Aegina while Ibn Sina (981-1037) reported breast tumour growth and tissue 
invasion. He did not recommend mastectomy as surgical treatment. 
Moreover, Abulcasis (936-1013) recommended excision only for early stage 
breast tumours as well as the cauterization of tissues surrounding the affected 
area.  	
1.3.3 Middle Ages & Renaissance 	
During the middle ages, William of Saliceto (1210-1277) introduced the use of 
a surgical knife for the removal of breast tumours instead of cauterizing only 
when complete excision was possible. The concept of mastectomy was firstly 
presented by Michael Servetus (1511-1553) in the middle ages. He also 
suggested lymph node excision with the removal of the pectoralis major 
(Ekmektzoglou, Xanthos et al. 2009).  
 
The differentiation between benign from cancerous breast tumours was also 
noted in the 17th century by Marcus Aurelius Severinus (1580-1656) in which 
he advised the surgical removal of fibroadenomas due to their degenerative 
potential.  
	1.3.4 18th and 19th Centuries 	
During the 18th century Lorenz Heister (1683-1758) also described 
mastectomy, reporting removing ribs when necessary. Sir Charles Bell (1774-
1842) supported removal of the entire breast regardless of tumour size. The 
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characteristics of inflammatory breast cancer with “orange peel” or peau 
d’orange was described first by Alexis Boyer (1757-1833). Henri-Francois 
leDran (1685-1770) mentioned the local origin of cancer and thereafter 
lymphatic spread, the theory explaining tumour metastasis to the lungs 
(Ekmektzoglou, Xanthos et al. 2009).  
 
In the 19th century, William Stewart Halsted (1852-1922) reported what is 
known as “radical mastectomy” which was considered the standard for breast 
surgery for more than 70 years. The procedure involves removal of the entire 
breast, the axillary lymph nodes and the pectoralis major muscle (Figure 1:2).    
 
X-rays were introduced in 1895 by Conrad Rontgen (1845-1923), providing 
the basis for both mammography and radiotherapy. Radium was discovered 
by Pierre and Marie Curie in 1898 and subsequently interstitial radiation was 
added to the therapeutic options (Olson 2002, Ekmektzoglou, Xanthos et al. 
2009). 
 1.3.5 20th Century and current practices 	
During the 20th century, physicians turned to the possibilities of endocrine 
surgery as a therapeutic modality after they observed that the breast cancer 
growth sometimes fluctuated with the menstrual cycle and the disease grow 
slowly in postmenopausal women. There was temporary regression of 
metastatic breast cancer in patients treated with surgical oophorectomy 
reported by George Beatson (1848-1933). Secondary endocrine surgery was 
subsequently developed, including oophorectomy, adrenalectomy and 
hypophysectomy (Ekmektzoglou, Xanthos et al. 2009). 
 
Eventually, hormone therapy replaced endocrine surgery with pharmacologic 
methods of reducing estrogen production or its effects, with luteininzing 
hormone-releasing hormone agonists, estrogen receptor modulators and 
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Figure 1:2  Halsted’s radical mastectomy, image from (Ekmektzoglou, Xanthos et al. 2009) 
  
 
In 1967, Elwood Jensen discovered estrogen receptors, enabling patients 
benefiting from hormone therapy to be distinguished from those who could 
not. Francois Baclesse (1896-1967) suggested radiotherapy for early stage 
breast cancer in combination with local tumour excision as a substitute to 
mastectomy and, in 1989, Bernard Fisher showed that lumpectomy followed 
by irradiation, was an appropriate therapy for breast cancer patients with 
stage I or II disease (Ekmektzoglou, Xanthos et al. 2009).  
Thus different types of treatment options are available today. These include 
surgery and radiotherapy to control local disease and systemic therapy that 
includes chemotherapy and /or anti-hormonal therapy for disease which has 
potentially metastasized; these latter can be also administered as 
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neoadjuvant treatment to shrink the size of tumour before surgery (Hortobagyi 
1998). 
 
1.3.6 Present Day Surgery & Radiotherapy 
 
In the present day, the first step for treating breast cancer is usually surgery. 
The main goal being to completely remove the tumour and to define 
accurately the disease stage (Hammer, Fanning et al. 2008).  
 
There are different extents of surgery performed: 
 
Breast conserving surgery (BCS) involves the removal of the tumour only, 
not the entire breast (with lymph node surgery also performed for those 
women with invasive breast cancer), and can include either lumpectomy, the 
removal of a tumour (lump) with minimal adjacent tissue, or partial 
mastectomy (or segmentectomy), the removal of the tumour and a greater 
amount of surrounding normal tissues. BCS and simple mastectomy (SM) 
have equivalent recurrence rate and outcome (10-year survival rate for BCS 
and SM is 80.56% and 77.4% respectively) (Mitov and Molov 2006).  
 
BCS is usually followed by radiotherapy. Post surgery radiation plays an 
important role in reducing the local recurrence of the disease (Bartelink, Horiot 
et al. 2001). 
 
Total mastectomy (TM) or simple mastectomy is the complete removal of 
breast; lymph nodes may be removed through a separate incision as a 
separate procedure (Hortobagyi 1998, Hammer, Fanning et al. 2008). 
 
Modified radical mastectomy (MRM) is the removal of the whole breast, all 
axillary lymph nodes, with preservation of the pectoralis major and minor 
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1.3.7 Chemotherapy 	
Chemotherapy comprises the administration of cytotoxic drugs and can be 
used in three ways. Adjuvant chemotherapy is given after surgical treatment 
for the management of patients with node positive or high-risk node negative 
early breast cancer to fight potential occult micrometastatic cancer and to 
improve survival. Neoadjuvant chemotherapy can be offered to patients with 
potentially ‘curable’ disease, in order to down-stage the tumour with the 
opportunity for conservative surgery rather than mastectomy, and improve 
survival (as for adjuvant chemotherapy), or to make locally inoperable disease 
operable (Connolly and Stearns 2013, Rampurwala, Rocque et al. 2014, Jin, 
Han et al. 2015). Finally, chemotherapy can be also administered to patients 
with metastatic disease as a palliative care and to improve the quality and 
quantity of life (Hudis 2005, O'Shaughnessy 2005).  
 
Numerous drugs are available for use, including cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF) (which constitute the foundation of 
modern adjuvant chemotherapy). Anthracyclines, which include 
cyclophosphamide/doxorubicin (AC) and cyclophosphamide/doxorubicin/5-
fluorouracil (CAF) have been incorporated to improve on CMF (Hudis 2005).  
However, several specific risks like cardiomyopathy and leukemia are 
associated with anthracyclines (Hudis 2005). The taxanes, which include 
paclitaxel, docetaxel, and nano-particle albumen-bound paclitaxel (Nabholtz 
and Riva 2001, Hudis 2005) are now also widely used. 
 
  1.3.8 Endocrine therapy 	
Endocrine therapy is an important treatment for women with ER positive 
tumours, the goal of endocrine therapy is to reduce the activation of estrogen 
on the tumour cells, either by inhibiting estrogen from binding to its receptors 
or by inhibiting its synthesis. Endocrine therapy has many forms, including: 
selective ER modulators (SERMs), aromatase inhibitors (AIs), and ovarian 
suppressive drugs (Lumachi, Luisetto et al. 2011).  
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Tamoxifen is a selective estrogen receptor modulator drug used for treating 
patients with ER positive tumours. It may be given to patients with early stage 
breast cancer or those with metastatic disease. Patients with ER positive 
tumours receiving tamoxifen as adjuvant treatment have a better overall 
survival (Lumachi, Luisetto et al. 2011, Lumachi, Santeufemia et al. 2015).  
 
However, tamoxifen can act as an estrogen agonist, leading to an increased 
incidence of secondary tumours, e.g. of the endometrium (Daniel, Inbar et al. 
1996, Kloos, Delaloge et al. 2002, Lorizio, Wu et al. 2012). Aromatase 
inhibitors work differently and block the synthesis of estrogen in post-
menopausal women by inhibiting aromatase, the enzyme responsible for the 
synthesis of estrogens from androgenic substrates (Smith and Dowsett 2003, 
Takei, Kurosumi et al. 2011). Of note, the overexpression of HER-2 with low 
levels of hormone receptors is associated with low response to endocrine 
therapy (Mouridsen, Rose et al. 2003, Esteva and Hortobagyi 2004) and 
hormone receptors and HER-2 expression should not be considered in 
isolation of each other. 
 
		1.3.9 Targeted therapy 	
Understanding the underlying biology of breast cancer better has resulted in 
the identification of several-targeted therapies. This approach uses drugs or 
other substances to identify and attack cancer cells without harming normal 
cells and thus such targeted therapy has the advantage of maximizing 
effectiveness whilst reducing toxicity compared to chemotherapeutic agents. 
Amongst these are monoclonal antibodies, tyrosine kinase inhibitors, 
inhibitors of intracellular pathways and angiogenesis inhibitors. Some of these 
agents have become part of the breast cancer patient’s standard of care 
including trastuzumab and lapatinib, both directed at HER-2 (Atalay, Cardoso 
et al. 2003, Higgins, Baselga et al. 2011, Iqbal and Iqbal 2014, Pandey and 
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  1.4 Breast cancer progression.	
 
The transition from a normal breast epithelial cell to an invasive carcinoma is 
the result of multiple genetic mutation accumulation in the terminal duct 
lobular unit (TDLU) (Bombonati and Sgroi 2011, Brown and Pinder 2012). The 
majority of breast cancers are either of ductal or lobular sub-types, with the 
ductal sub-type accounting for 40-75% of all cases (Bombonati and Sgroi 
2011). It had been suggested that breast cancer develops along multi-step 
pathways that involve a spectrum of epithelial proliferative lesions similar to 
the Vogelstein colon cancer model (Vogelstein, Fearon et al. 1988, Brown and 
Pinder 2012).  
 
Two specific models have been proposed for the development of invasive 
ductal (no special type) carcinoma. The first model proposes a transition from 
flat epithelial atypia (FEA) through atypical ductal hyperplasia (ADH) and 
ductal carcinoma in situ (DCIS) (the latter as a non-obligate precursor) to 
invasive ductal carcinoma, or simply from DCIS to invasive carcinoma. The 
second model proposes usual epithelial ductal hyperplasia (UDH) is a 
precursor of ADH and thence progression to DCIS and invasive breast 
cancer, although reports indicate that UDH has a distinct 
immunohistochemical and molecular profile from the atypical epithelial 
proliferations and the second model could be invalid (Bombonati and Sgroi 
2011, Brown and Pinder 2012). Nevertheless, there is clinical and molecular 
evidence that DCIS is a precursor of invasive cancer (Brown and Pinder 
2012).  
 
For the lobular subtype of invasive breast cancer a progression from atypical 
lobular hyperplasia (ALH), lobular carcinoma in situ (as the non-obligate 
precursor) to invasive lobular carcinoma is proposed (Figure 1:3) (Boecker, 
Moll et al. 2002, Brown and Pinder 2012, Maeda, Kanemaki et al. 2014). 				
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Figure 1:3 Breast cancer progression models. (A) Represents the classic model for the 
development of the ductal subtype of invasive breast cancer. Normal epithelium advances to 
flat epithelial atypia (FEA), which advances to atypical ductal hyperplasia (ADH) and evolves 
to ductal carcinoma in situ (DCIS) then to invasive ductal carcinoma (IDC). (B) Proposes 
usual ductal hyperplasia (UDH) instead of FEA as the precursor of ADH based mostly on 
epidemiological observations. (C) The proposed model for the transition of lobular breast 
carcinoma which starts as atypical lobular hyperplasia (ALH) and lobular carcinoma in situ 
(LCIS) through to invasive lobular carcinoma (ILC). Image from (Bombonati and Sgroi 2011).  
 
Significantly, differences have been shown between high grade and low grade 
lesions by genomic research technologies such as chromosomal and array 
comparative genomic hybridisation (CGH & aCGH) studies (Natrajan, 
Lambros et al. 2009, Brown and Pinder 2012). Approximately 70-80% of both 
low grade DCIS and grade 1 invasive carcinoma are often diploid, with 
recurrent deletions in chromosome 16q and gains of 1q, 16p and 8q, whereas 
high grade tumours show recurrent losses of 8p, 11q, 13q, 1p and 18q, 
recurrent gains of 8q, 17q, 20q and 16p. Intermediate grade disease shows a 
combination of low grade and high grade genomic alterations. These findings 
suggest that progression from a low grade lesion to a high grade cancer 
would be uncommon (Gupta, Douglas-Jones et al. 1997, Bombonati and 
Sgroi 2011, Brown and Pinder 2012) and that these represent different 
pathways of developing invasive breast cancer. 
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	1.5 Pathological classification of breast cancer 
 
All breast cancers are classified on the basis of their histological and/or 
cytological appearance into in situ or invasive malignancies.   
 
  1.5.1 In Situ Breast Carcinoma 	
This is a pre-invasive stage of breast cancer and it refers to the proliferation of 
malignant cells that are confined by the basement membrane and have not 
invaded neighboring tissues. In situ carcinomas are either ductal carcinoma in 
situ (DCIS) or lobular carcinoma in situ (LCIS), or both. In the UK between 
2008-2010, the average proportion of all in situ carcinoma diagnosed as DCIS 
was 84.5%, while LCIS composed 9.3% of in situ lesions, with a small 
proportion of the cases (6.2%) unspecified (Cancer Research UK, 2014).  
 
 1.5.1.1 Lobular Carcinoma In Situ (LCIS) 	
LCIS is a non-invasive breast lesion arising from the lobules (Figure 1:4). The 
histological appearance is characterized by an intralobular epithelial 
proliferation of oval to round nuclei with indistinct cell borders and infrequent 
mitosis. Intracellular lumens are often present. No necrosis or 
microcalcifications are usually present. Loss of E-cadherin, which is also the 
molecular hallmark of Invasive lobular carcinoma, is frequent and explains the 
pattern of growth. LCIS is not usually detectable on mammograms and is 
typically incidental in biopsies performed for another reason, such as 
fibroadenoma (Vos, Cleton-Jansen et al. 1997, Lei, Sjoberg-Margolin et al. 
2002, van de Vijver 2005, Hussain and Cunnick 2011). 
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Figure 1:4 Lobular carcinoma in situ. Abnormal cells are arising in the lobules. 
(Image from www.cancer.gov). 
 
 
  1.5.1.2 Ductal Carcinoma In Situ (DCIS) 
 
DCIS is biologically heterogeneous, with variable pathological, molecular and 
clinical features. Historically it was detected when patients were diagnosed 
with Paget’s disease of the nipple or the finding of a palpable breast mass. 
After the introduction of mammography, the number of DCIS cases increased 
and it now accounts for approximately 20% of screen-detected breast cancers 
(Valenzuela and Julian 2007, Pinder 2010). The proliferative cells in DCIS 
expand the duct structures but do not invade through the basement 
membrane (Figure 1:5). It is usually associated with typical patterns of 
microcalcification.  
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Figure 1:5	Ductal carcinoma in situ. The abnormal cells are arising in the ducts 
(Image from www.cancer.gov). 
 
DCIS varies in microscopic appearance and the disease has been classified 
in a variety of ways. It is now classified into low, intermediate or high grade 
disease according to the nuclear grade, growth and the presence of central 
necrosis ( Figure 1:6).  
 
High grade DCIS is characterized by large pleomorphic cells with differences 
in shape and size, mitosis, coarse chromatin, prominent nucleoli and an 
absence of polarity (Brown and Pinder 2012). In low grade DCIS, the 
malignant cells are arranged in well-ordered patterns. They are more uniform 
and evenly-spaced with regular round nuclei centrally located with the 
cytoplasm. Cells in intermediate grade DCIS show moderate pleomorphism. 
They lack the uniformity of low grade lesions but do not show the 
pleomorphism of high grade disease with the occasional nucleoli often 
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Figure 1:6 DCIS cases are classified into low, intermediate or high grade according to their 
nuclear grade, growth and the presence of central necrosis. 
(Image modified from http://www.breastpathology.info/Sloane/dcis.htm). 	
DCIS can also be sub-categorized according to the architectural patterns of 
the lesion including: cribriform, solid, papillary, flat/clinging, micropapillary and 
apocrine types. This classification can provide some indication of the extent 
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Figure 1:7 DCIS can be classified according to the architectural patterns of the lesion (Image 
modified from http://www.breastpathology.info/Sloane/dcis.htm). (Cribriform, solid, papillary, 
micropapillary, flat, and solid with comedo-type necrosis, from left to right, top and bottom 
rows, respectively). 
 
In addition to the cytonuclear grade of DCIS, some recommend the Van Nuys 
Prognostic Index (VNPI) as a useful aid to classify DCIS patients in terms of 
likelihood of local recurrence. The index includes three factors associated with 
DCIS aggressiveness: nuclear grade (including presence or absence of 
comedo necrosis), tumour size and margin width. Each of these factors is 
scored one to three, and the sum total of values for the three parameters is 
taken as indication for local recurrence likelihood (Table 1-2) (Silverstein, 







Introduction                                                                                        Chapter-1                                                         
  21 
  Table 1-2 The Van Nuys prognostic index (VNPI). 	
Predictor Score1 Score2 Score3 
Size of DCIS 
(mm) 
 







  High grade, with 




>10 1-10 <1 
Table from (Gilleard, Goodman et al. 2008) 
 
Despite the value of the previous systems for classification, DCIS remains a 
challenge for the multidisciplinary team when choosing the intensity of 
recommended treatments, since clinical trials have failed to identify which 
women are at high or low risk of developing invasive cancer among DCIS 
patients (Burstein, Polyak et al. 2004, Okumura, Yamamoto et al. 2008, 
Kerlikowske, Molinaro et al. 2010, Pinder 2010). 
 
		1.5.2 Invasive breast carcinoma 	
In invasive carcinoma, tumour cells invade progressively beyond their pre-
existing ductal and lobular structures, breaching the myoepithelial layer and 
basement membrane, with invasion into the stroma. There are numerous 
different sub-types of invasive carcinomas but the majority are invasive ductal 
carcinomas (IDC) (now called no special type, NST), representing 75-80% of 
all cases in most series, although a lower proportion in some others 
(Suryadevara, Paruchuri et al. 2010, Bombonati and Sgroi 2011, Caldarella, 
Buzzoni et al. 2013) 
 
In NST cancers the tumour cells can be arranged in cords, irregular, or solid 
clusters. Glandular differentiation may be present as tubular structures with 
central lumina in tumour cell groups. Nuclei may be regular, uniform or highly 
pleomorphic with prominent nucleoli. In some NSTs foci of associated DCIS 
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may be present. The associated DCIS is often of high grade (Fisher, Gregorio 
et al. 1975, Lakhani 2012 ).  
 
Invasive lobular carcinomas (ILC) comprise 5-15% of cases (Caldarella, 
Buzzoni et al. 2013, Reed, Kutasovic et al. 2015). The infiltrating cells are 
arranged in single file pattern with a tendency to grow in a circumferential 
fashion around ducts and lobules. E-cadherin is typically negative in cases of 
ILC (Vos, Cleton-Jansen et al. 1997, Arpino, Bardou et al. 2004).  
 
Numerous other forms of invasive breast carcinoma are described, such as 
papillary, tubular, medullary, metaplastic and mucinous carcinomas but all are 
less frequent (0.1-4%) (Ellis, Galea et al. 1992,	Page 2003, Lakhani 2012). 
 
  1.6 Breast tumour prognosis 	
Until recently, the clinical behaviour of an invasive breast cancer, and its risk 
of recurrence after treatment, could only be predicted by the microscopic 
appearances. Prediction of behaviour depended mainly on morphologic 
characteristics of the tumour including histological grading, as well as the 
tumour size, lymph node status and the expression of a very limited set of 
biomarkers such as steroid hormone receptors oestrogen receptor (ER) and 
progesterone receptor (PR), expression of the Her2/neu oncogene and 
biomarkers for cell proliferation such as Ki-67 antigen (Desai, Kavanaugh et 
al. 2002). 
1.6.1 Histological grading of breast tumour 	
Bloom and Richardson (1957) used a simple system for tumour grading in 
breast cancer based on the histological appearance. Elston and Ellis (1991) 
significantly amended the grading system to form the Nottingham combined 
histological grade, which enhanced the reproducibility of scoring. Three 
histologic features (tubule formation, nuclear pleomorphism and mitotic 
frequency) are scored 1-3 and the scores are added up to a final score 
ranging from 3-9. Tumours are considered of grade 1 (well differentiated) if 
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they have a score of 3-5, grade 2 (moderately differentiated) tumours have a 
score of 6-7, and grade 3 (poorly differentiated) tumours have a score of 8 or 
9. Patients with grade 1 tumours have a better prognosis with an 85% chance 
of a 10 year survival compared to patients with grade 3 tumours who have 
less than a 45% survival at 10 years (Pinder, Ellis et al. 1995, Weigelt, Geyer 
et al. 2010). 
  
	1.6.2 TNM staging system (Tumour (size), Node, Metastases)  
																																																																		
The TNM staging system can provide important information about a patient’s 
prognosis and survival rate. It depends on tumour size, lymph node 
involvement and the presence or absence of distant metastases. Tumour size 
is an important factor for predicting patient’s long-term survival; patients with 
smaller tumours have a better long-term survival than patients with larger 
tumours size (Carter, Allen et al. 1989, Fitzgibbons, Page et al. 2000, 
Rampaul, Pinder et al. 2001). Lymph node involvement is also important in 
predicting patient 10-year survival rate, which is 75% for negative lymph node 
patients and 25-50% for positive lymph node patients (Galea, Blamey et al. 
1992, Rampaul, Pinder et al. 2001). 
 
		1.6.3 Nottingham Prognostic index (NPI)  	
The Nottingham Prognostic index (NPI) combines the three most important 
factors of prognostic relevance in invasive breast cancer to provide more 
information about the patient’s outcome. The index involves the addition of 
lymph node stage to the histological grade and 0.2x the tumour size in cm. 
The node stage has a score from 1-3, in which 1 indicates no lymph node 
involvement, 2 indicates three or less lymph node metastases while 3 
indicates 4 or more lymph node metastases. The NPI score represents a 
guide to the patient’s prognosis and can be used to select adjuvant therapy 
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		1.6.4 Predictive markers in breast cancer 	
As previously noted, there are limited predictive markers on which to 
determine which patients are likely to respond to specific treatments. These 
markers include steroid hormone receptors for oestrogen receptor (ER) and 
progesterone receptor (PR), and the expression of the Her2/neu oncogene. 
 
		1.6.4.1 Estrogen and Progesterone receptors (ER and PR) 	
ER and PR pathways play an important role in breast physiology and growth. 
The status of these two hormone receptors in an invasive breast cancer is 
also a predictive marker for response to hormone therapy and is assessed by 
immunohistochemistry (IHC) staining technique. ER acts as a hormone 
dependent transcriptional factor that regulates several genes including 
progesterone (PR), pS2, bcl2 apoptosis inhibitor and other growth related 
genes. ER mediates its function through two specific intracellular receptors 
ERα and ERβ, although ERα overexpression has more predictive significance 
than ERβ status in breast cancer patients (Esteva and Hortobagyi 2004, 
Morris and Carey 2007). Specifically, breast cancer patients with ER positive 
tumours are more likely to have a better response to anti-estrogen drugs such 
as Tamoxifen (Tamoxifen has the ability to bind the ligand-binding domain of 
the ER and block the potential stimulation for estrogen) and a better survival 
rate than patients with ER negative tumours (Osborne 1998, Esteva and 
Hortobagyi 2004, Morris and Carey 2007). 
 
PR, which is regulated by ER, is expressed as two isoforms (PR-A and PR-B) 
from a single gene. About 50% of ER positive breast tumours are also PR 
positive and the expression of PR and ER combined has a better prognostic 
and predictive value than ER alone in some series (Osborne 1998) . 
 
		1.6.4.2 HER2/neu receptors 	
HER2 plays an important role in cell growth, and it is a key prognostic factor in 
patients with an early stage of breast cancer. It is located on chromosome 
17q12 and encodes a 185-kDa tyrosine kinase glycoprotein (van de Vijver 
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2005). HER2 gene amplification is associated with several cancers and the 
overexpression of HER2 protein is seen in 40-60% of DCIS cases and in 10-
15% of infiltrating breast carcinomas (Gusterson, Machin et al. 1988, Allred, 
Clark et al. 1992, Millis, Bobrow et al. 1996, Leonard and Swain 2004, Lari 
and Kuerer 2011). HER2 does not have a known ligand and it is activated by 
homo-dimerization due to overexpression, or hetero-dimerization with one of 
the EGFR family members (Di Fiore, Pierce et al. 1987, Rubin and Yarden 
2001, Cho, Mason et al. 2003).  
 
HER2 is the preferred partner of all the EGFR family members, despite the 
fact that it has no known ligands. This is due to an intrinsically extended 
interaction loop rendering it constitutively available for dimerization (Eccles 
2011). The status of HER2 is determined by an IHC staining technique and/or 
in situ hybridization, either fluorescent or chromogenic (FISH or CISH). The 
density of IHC staining is used as an indicator of (up-regulated) protein 
presence and typically reflects gene amplification (Press, Slamon et al. 2002, 
Perez, Cortés et al. 2014). Stained tissues are scored 3+ if they demonstrate 
strong complete membrane staining in >10% of tumour cells and scored 2+ if 
they show weak to moderate staining in >10% of tumour cells requiring 
confirmation of HER2 status by an alternative method, usually ISH (Perez, 
Cortés et al. 2014). 
1.7 Molecular classification of breast cancer 
 
Despite the important information gained from the breast cancer pathology, 
grading and the status of HER2, ER/PR, there is still a need for more detailed 
information about individual breast cancers. Gene expression profiling by 
complementary DNA (cDNA) microarray technology allows for the analysis of 
thousands of genes at the same time. A greater understanding of the genetic 
alterations underlying breast cancer progression and development has been 
achieved by microarray technology. This understanding led to the molecular 
classification of breast cancer into intrinsic subgroups (Sorlie 2004).  
 
Introduction                                                                                        Chapter-1                                                         
  26 
Perou and colleagues, in 2000, examined the differences of gene expression 
in 65 breast tissue samples, malignant and normal. The expression pattern of 
the genes analysed by complementary DNA (cDNA) microarray was applied 
to classify tumours into different subtypes by measuring the expression of 
8,102 genes (Perou, Sorlie et al. 2000, Sørlie 2004). The study was able to 
divide breast cancer tumours into groups, namely ER positive and ER 
negative. The ER positive groups were further subdivided into luminal A and 
luminal B subtypes. The ER negative groups were subdivided into HER2 
overexpression, normal-like and basal subtypes (Sorlie, Perou et al. 2001). 
  
		1.7.1 Prediction of prognosis and response to treatment 	
cDNA microarray studies have been found to be useful in predicting the 
outcome of breast cancer patients, through assessment of genes that are 
involved with cell proliferation, apoptosis, angiogenesis, signal transduction 
and transcription factors (van de Vijver, He et al. 2002). There are at least five 
commercially available DNA microarray assays, which can be used to predict 
the breast cancer patient’s prognosis and likely response to therapy. These 
assays include the MammaPrint 70 gene signature, Oncotype Dx, MapQuant 
Dx, PAM50 breast cancer Intrinsic subtype classifier and Theros Breast 
cancer Index (van de Vijver, He et al. 2002, Paik, Shak et al. 2004, Parker, 
Mullins et al. 2009, Paik 2011) 
 
The MammaPrint 70 gene signature was the first commercially available 
microarray assay developed by Van't Veer et al, 2002. They used microarray 
technology to analyse primary breast tumours from 117 young patients. The 
profile developed was compared with prognosis in breast cancer. The authors 
were able to identify a combined signature of 70 genes that could predict 
recurrence of the disease and provide a strategy to select patients that would 
benefit from adjuvant therapy. They predicted the actual outcome of the 
disease for 65 of 78 lymph node negative patients. Forty-four patients 
categorized among as a good prognosis group remained free of disease for at 
least five years while 34 patients in the poor prognosis group developed 
distant metastasis within 5 years (Figure 1:8 a&b). To confirm the prognostic 
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classifier, the group selected a new group of 19 young lymph node negative 
breast cancer patients consisting of 7 patients who remained metastases free 
for at least five years and 12 patients who developed metastases within five 
years. They were able to predict the outcome of the disease by using the 70-
gene classifier with only 2 of 19 cases incorrectly classified (Figure1:8 c) (van 
't Veer, Dai et al. 2002).  
 
The Oncotype DX (21-gene recurrence score) is a clinically validated reverse 
transcription-PCR genomic test that predicts the likelihood of breast cancer 
recurrence in early stage, ER positive, HER2 negative breast cancer patients. 
The Oncotype DX assay investigates 21 genes in formalin fixed paraffin 
embedded samples. Theses genes were selected since they were strongly 
involved with distant recurrence in the 250 genes investigated. The 
recurrence score (RS) is calculated on a scale from 0-100 (low risk group RS 
<18; intermediate risk RS ≤18 <31; high risk group RS ≥ 31) and predicts the 
risk of 10 years distant recurrence (Paik, Shak et al. 2004, Sparano and Paik 
2008). In addition, the RS does not only quantify the risk of recurrence in node 
negative patients, it also predicts the benefits of using chemotherapy. Patients 
with low RS are treated with endocrine therapy alone while patients with high 
RS are treated with chemotherapy and endocrine therapy (Paik, Tang et al. 
2006, Paik 2011). Oncotype DX is considered now for routine clinical use as 
an adjunct to pathological and clinical information and has been incorporated 
into clinical guidelines in the USA and elsewhere (Cronin, Sangli et al. 2007, 
Paik 2011). 
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Figure 1:8  Disease outcome and the expression pattern of 70 genes.  a, from 78 
sporadic breast tumours a poor prognosis and good prognosis group are identified by using 
prognostic reporter genes. b, 70 prognostic marker genes expression data matrix from 
tumours of 78 breast cancer patients (left panel). Each row represents a tumour and each 
column a gene, whose name is labelled between b and c. Genes are ordered according to 
their correlation coefficient with the two prognostic groups. Tumours are ordered by the 
correlation to the average profile of the good prognosis group (middle panel). Solid line, 
prognostic classifier with optimal accuracy; dashed line, with optimized sensitivity. Patients 
have a good prognosis signature above the dashed line, and poor prognosis below the 
dashed line. The right panel show the metastatic state: white indicates patients who 
developed distant metastases within 5 years after the primary diagnosis; black indicates 
patients who continued to be disease-free for at least 5 years. c, Same as for b, but the 
expression data matrix is for tumours of 19 additional breast cancer patients using the same 
70 optimal prognostic marker genes. Thresholds in the classifier (solid and dashed line) are 
the same as b. Image from  (Perou, Sorlie et al. 2000). 
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		1.8 The Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) 
 
The METABRIC study is another example of a molecular profiling study in 
breast cancer aiming to classify breast tumours into subcategories based on 
molecular signatures to help determine optimal patient treatment (Curtis, 
Shah et al. 2012). This study presented a joint analysis of the genomic and 
transcriptomic profile of 2,000 primary breast cancer specimens with long 
term follow up. Through this study, breast cancer was reclassified into ten 
new categories called integrative clusters (IntClust) associated with distinct 
clinincal outcomes (Figure 1:9). The classification was based on the cis-acting 
and trans-acting copy number abberations (CNAs) that dominate gene 
expression. Cis-acting refers to a variant at a locus that has an impact on its 
own gene expression, while trans-acting refers to a variant that has an impact 
on other sites in the genome (Curtis, Shah et al. 2012). 
 
Among the identified subgroups was a new ER positive group (IntClust2) 
composed of 11q13/14 cis-acting luminal tumours. This subgroup was found 
to be associated with very poor prognosis suggesting that alternative 
therapies may be required to treat these patients. Another subgroup 
associated with poor prognosis was the IntClust5, which consists of HER2-
amplified tumours. Patients in this group were enrolled in this study before the 
addition of trastuzumab to the oncology treatment options, which could 
explain the poor overall survival. The subgroups IntClust3, IntClust4, IntClust7 
and IntClust8 were found to be associated with good prognosis, while the 
subgroups IntClust1, IntClust6, IntClust9 and IntClust10 were associated with 
intermediate prognosis (Curtis, Shah et al. 2012). 
. 
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Figure 1:9 The clinical outcome of the integrative subgroups.  
Kaplan–Meier plot of disease-specific survival (truncated at 15 years) for the integrative 
subgroups in the discovery cohort. For each cluster, the number of samples at risk is 




Genes identified through all such molecular approaches provide additional 
insight into breast cancer biology, potentially allowing clinicians to predict the 
likelihood of the tumour recurring or metastasizing. It also potentially allows 
oncologists to predict whether a tumour is likely to respond to a particular 
treatment (Curtis, Shah et al. 2012) as well the identification of new drug 
targets. 
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1.9 The cancer biomarker problem 	
Breast cancer patients may have the same pathological presentation and 
clinical pattern of disease but turn out to have different responses to treatment 
and overall survival rates. There are relatively few markers now widely used 
for the diagnosis, prognosis and prediction of effectiveness of treatment of 
breast cancer. There is certainly a belief that there are more accurate and 
specific markers yet to be identified. The lack of predictive factors is also 
relevant to DCIS where there is doubt as to the most appropriate treatment 
choice for each patient. Indeed there is a great need for new opportunities to 
prevent cancer progression through an improved understanding of the 
molecular events in the early stages of the disease, as well as better 
prediction of prognosis and of response to therapy for those with established 
invasive breast cancer (Ye, Qiu et al. 2004).  
 
Despite advances, the identification of genes associated with increasing 
metastases incidence has not brought great progress to the understanding of 
how these events occur; these gene expression profiles are signatures, they 
do not define mechanistic drivers. The function of the gene products, typically 
proteins, must be assessed to address this. Although genetic aberrations 
cause disease, the functional consequences are mediated through protein 
networks. 
 
1.10 Journey to the centre of the cell 	
1.10.1 The Hallmarks of Cancer. 	
As previously mentioned, breast cancer therapies can be either cytotoxic 
chemotherapy or hormonal therapy but not all patients have the same 
treatment response, suggesting that a reconsideration of the conceptual 
approach to treatment of breast cancer is required. In 2011, Hanahan & 
Weinberg provided a summary of the biological mechanisms that are 
Introduction                                                                                        Chapter-1                                                         
  32 
important for the growth and metastatic spread of cancer in which they 
proposed an updated set of hallmarks of cancer which include:  
Self-sufficiency in growth signals, insensitivity to antigrowth signals, avoiding 
apoptosis, infinite proliferative capacity, angiogenesis, tissue invasion, 
escaping immune destruction, genome instability, promoting inflammation and 




Figure 1:10	 The acquired capabilities that govern the behaviour of tumour cells proposed by 
Hanahan & Weinberg in 2011 (picture taken from www.cell.com) 	
These properties provide a description of what is needed for tumours to 
develop, survive and disseminate, including an energy supply (oxygen, 
nutrients, etc), suppression of immune elimination and avoidance of 
apoptosis. The hallmarks of cancer provide a framework for identifying 
biomarkers that might be beneficial in treating breast cancer patients. In 
relation to this thesis, an acquired capability for self-sufficiency in growth 
signals is discussed in further detail.  
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  1.10.1.1 Self sufficiency in growth signals 
                                                        
A most important trait of cancer cells is their ability to maintain chronic 
proliferation. Normal tissues have the ability to maintain their architecture and 
function by carefully controlling the release and production of growth signals 
that regulate proliferation. Typically these endogenous signals are transmitted 
into the cells by trans-membrane receptors that bind to different types of 
signalling molecules and, only in case of growth signal stimulation, cells can 
move from an inactive state to an active proliferative state (Aaronson 1991, 
Hanahan and Weinberg 2000). However, cancer cells have the ability to 
generate continuous growth signalling independent of their normal tissue 
microenvironment, allowing them to proliferate uncontrollably. These 
transformed cells use three common molecular strategies to obtain their own 
growth signalling, including alteration of extracellular growth signals, of 
transcellular transducers of those signals, or of intracellular circuits that 
translate those signals into action (Hanahan and Weinberg 2000). 
 
Many cancer cells have the ability to produce growth factor ligands 
themselves, to which they can respond via the expression of cognate 
receptors, resulting in autocrine proliferative stimulation of growth factors from 
other cells within the tissue. As an example, the production of tumour growth 
factor α (TGFα) in sarcomas and the production of PDGF (platelet-derived 
growth factor) in Glioblastomas are two illustrative examples (Sporn and 
Roberts 1985, Hanahan and Weinberg 2000).  
 
The cell surface receptors that transduce growth stimulatory signals inside the 
cell are sometimes targets of deregulation during tumour development; for 
example, growth factor receptors are overexpressed in many tumours such as 
Epidermal Growth Factor Receptor (EGFR), which can be over-expressed in 
different tumours such as breast and stomach cancer (Nicholson, Gee et al. 
2001, Hynes and Lane 2005). Similarly, HER2 can be also overexpressed in 
stomach and breast carcinomas (Witton, Reeves et al. 2003, Gravalos and 
Jimeno 2008). The overexpression of these receptors may intrinsically trigger 
growth signals, or may allow the cell to become hyper-responsive to the 
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surrounding levels of growth factors that would not normally trigger 
proliferation (Yarden and Sliwkowski 2001, Hanahan and Weinberg 2011).  
 
Another example of the cancer cell strategy to maintain growth signals is the 
alteration in the downstream signalling pathway. For example, Ras proteins, 
which play a key role in cell proliferation by the activation of a cascade of 
kinases, are present in altered forms in 30% of human tumours, allowing them 
to potentially release proliferative signals without being stimulated by their 
upstream regulators (Hanahan and Weinberg 2000, Fernández-Medarde and 
Santos 2011, Hanahan and Weinberg 2011). 
 
1.11 The role of Epidermal Growth Factor Receptor 
Family (EGFRs) in human cancer 	
As noted, one of the hallmarks of cancer cells is their ability to generate 
continuous growth signalling allowing them to proliferate uncontrollably; this is 
frequently due to the high expression level of growth factors, the up-regulation 
of their receptors or the acquisition of receptor mutations (Marmor, Skaria et 
al. 2004, Normanno, De Luca et al. 2006). The family of Epidermal Growth 
Factor Receptors (EGFRs) or HER receptors are among the best-studied 
growth factor receptors that are found to be up-regulated or altered in human 
cancer (Ciardiello and Tortora 2001, Burgess 2008, Wieduwilt and Moasser 
2008). The EGFR pathway contributes to a number of important processes in 
cancer development, including cell proliferation, angiogenesis, metastasis and 
anti-apoptosis (Ciardiello and Tortora 2001).  
 
		1.11.1 EGFR family structure and activation 	
The EGFR family (known also as ErbB tyrosine kinase receptors) are 
expressed on the surface of normal cells and consist of four receptors: EGFR 
(HER1/ErbB), ErbB2 (HER2/neu), ErbB3 (HER3) and ErbB4 (HER4), named 
ErbB because of their homology to the erythroblastoma viral gene product v-
erbB (Downward, Yarden et al. 1984). These receptors are single chain 
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transmembrane glycoproteins consisting of an extracellular domain, a single 
hydrophobic trans-membrane domain, a short juxtamembrane section, a 
tyrosine kinase domain and a tyrosine containing C terminal tail which carries 
several tyrosine auto-phosphorylation sites (Figure 1:11). The extracellular 
domain is composed of four subdomains (I-IV): subdomains I and III (also 
called L1 and L2) which have a beta helical fold and are important for ligand 
binding, and cysteine rich subdomains II and IV (also called CR1 and CR2) 
(Normanno, De Luca et al. 2006, Hynes and Watson 2010). 
 
The EGFR family exists as inactive/low activity monomers. Dimerization 
between two identical receptors (homo-dimerization) or between different 
receptors within the family (hetero-dimerization) occurs either due to ligand 
binding or receptor overexpression (Mendelsohn and Baselga 2000). The 
dimerization leads to the phosphorylation of tyrosine kinase located in the C 
terminal tail. These phosphorylated residues serve as a binding site for 
proteins containing phosphotyrosine recognition domains such as Src 
homology 2 (SH2) and phosphotyrosine binding (PTB) domains (Normanno, 
De Luca et al. 2006, Hynes and Watson 2010). 
 
The EGFR family ligands are divided into three groups based on their 
receptor specificities. The first group, which binds EGFR, includes EGF, 
transforming growth factor (TGF)-α, amphiregulin (AR) and epigen (EPG). 
The second group, which binds both EGFR and HER4, includes betacellulin 
(BTC), heparin binding EGF (HB-EGF) and epiregulin (EPR). The third group, 
the neuregulins (NRGs) bind HER3 and HER4 (Figure 1:11) (Riese, van Raaij 
et al. 1995, Olayioye, Neve et al. 2000, Mass 2004, Normanno, De Luca et al. 
2006, Burgess 2008). 
 
In the absence of a bound ligand, the EGFR receptor monomer is held in a 
closed conformation by an intramolecular tether formed by loops in 
subdomains I and III. Upon ligand binding, the intramolecular tether is broken, 
and the receptor is opened into an extended conformation, which interacts 
with another monomer, forming a back-to-back dimer (Eccles 2011, Tynan, 
Roberts et al. 2011). However, the HER2 extracellular domain differs 
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significantly from that of other EGFR family in which domains I and III are very 
close and this interaction makes ligand binding impossible, explaining why 
HER2 lacks ligand binding (Normanno, De Luca et al. 2006). 
 
Each member of the EGFR family has a unique characteristic. EGFR binds 
ligands and its kinase is activated by asymmetric interactions with other family 
member kinase domains: EGFR, HER2, HER3 and HER4 (Burgess 2008). 
HER2 lacks ligand binding but is the preferred partner of all the EGFR family 
members due to an intrinsically extended extracellular interaction loop, 
rendering it constitutively available for dimerization (Normanno, De Luca et al. 
2006). HER3 has an essentially inactive kinase domain (it is classified as 
pseudokinase); it confers activation on the kinase activities of other family 
members, usually HER2 through characteristic asymmetric interactions. 
Moreover, the HER2/HER3 heterodimer is the most potent signalling module 
in terms of cell proliferation and in vitro transformation (Citri, Skaria et al. 
2003, Lee-Hoeflich, Crocker et al. 2008). The signalling potency of the 
HER2/HER3 heterodimers derives from the fact that this dimer has the ability 
to signal efficiently through the Ras/Raff mitogen-activated protein kinase 
(MAPK) pathway for proliferation and through the PI3K/Akt pathway for 
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Figure 1:11 ErbB / HER receptor family. The HER receptor family consists of four closely 
related type 1 transmembrane tyrosine kinase receptors: EGFR, HER2, HER3, and HER4. 
EGFR and HER4 have known ligands and active tyrosine kinase domains, HER3 lacks 
tyrosine kinase activity but binds to several heregulins as ligands. However, HER2 cannot 
bind ligands but possesses an active tyrosine kinase domain. This receptor exists in the 
active conformation state, so is constitutively available for dimerization. Ligand binding to 
HER receptors induces the formation of receptor homo- and heterodimers and activation of 
the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues. These 
phosphorylated residues serve as docking sites for a range of proteins, the recruitment of 
which leads to the activation of intracellular signaling pathways. (red and green arrows 
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 1.11.2 EGFR family downstream signaling 	
The EGFR family signalling pathway involves a highly complex and interactive 
multi-layered network. Signals are initiated at the cell surface and the resulting 
activation and dimerization of the receptors transmits and amplifies the signal 
through a cytoplasmic signal-processing layer through complex system of 
enzymes, proteins and small molecule secondary messengers (Yarden and 
Sliwkowski 2001). The signal transduction process terminates in the nucleus, 
where transcriptional control i.e. cell (re)programming is modified, so 
generating effects on key cellular regulatory processes that promote division 
(Mass 2004). 
 
Signal transduction pathways are initiated upon ligand binding to the receptor, 
which leads to the phosphorylation of the tyrosine kinase within the 
cytoplasmic domains (Marmor, Skaria et al. 2004). These phosphorylated 
residues recruit down-stream scaffolds and signalling proteins such as Grb2, 
Grb7, Shc, Nck, PLCγ, the intracellular kinases Src (pTK) and PI3K (Lipid 
Kinase), the protein tyrosine phosphatases SHP1 and SHP2 and the Cbl E3 
ubuquitin ligase (Figure 1:12) (Hackel, Zwick et al. 1999, Yaffe 2002, 
Schlessinger and Lemmon 2003, Bazley and Gullick 2005). The four 
receptors have specific patterns of binding partners, although each may be 
recruited to more than one site, with different affinities, as shown by 
systematic profiling of phosphotyrosine interaction site. For example, Grb2 or 
PI3K binding to HER2 is influenced by the mode of activation and the 
dimerization partner (Schulze, Deng et al. 2005).  
 
The ras/raf/MEK/MAPK pathway is activated by all EGFR receptors through 
either Grb2 or Shc adaptor proteins (Figure 1:12)  (Carpenter 2003, Marmor, 
Skaria et al. 2004). They also activate PI3K by recruitment through the p85 
regulatory subunit to the activated receptors (Soltoff, Carraway et al. 1994, 
Lapin, Shirdel et al. 2014). STAT5 has been identified as a direct binding 
partner to EGFR and HER4, and this interaction is essential in the breast 
during lactation (Olayioye, Beuvink et al. 1999, Carpenter 2003, Schulze, 
Deng et al. 2005). Moreover, there are substrates that can only bind to one 
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member of the family; for instance, Cbl, phospholipase PLCγ and Eps15 bind 
only to EGFR (Normanno, De Luca et al. 2006). Interestingly, Eps15 
facilitates clathrin-coated pits endocytosis of EGFR by binding to the clatherin 
adaptor protein complex AP-2 (Torrisi, Lotti et al. 1999, Tomas, Futter et al. 
2014). Furthermore, the EGFR family receptors activate different transcription 
factors such as c-fos, c-myc, STAT, c-Jun, NF-kB, zinc finger transcription 
factor and Ets family members (Biswas, Cruz et al. 2000).  
 
The duration of the EGFR family signaling can be affected by various factors 
such as the composition of the receptor complex, the identity of the ligand and 
specific structural determinants of the receptors (Normanno, De Luca et al. 
2006). Ligands can also affect signaling, for example, the binding between 
EGF and EGFR is stable to the mildly acidic pH of early and late endosomes 
and results in lysosomal degradation (Alwan, van Zoelen et al. 2003). On the 
contrary, the binding between TGF-α and NRG-1 with their respective 
receptors is pH sensitive, resulting in dissociation in the endosome and 
recycling of the receptor to the cell membrane (Olayioye, Neve et al. 2000, 
Romanelli and Wood 2008).   
 
EGFR family receptor transactivation is another mechanism that induces the 
receptors tyrosine phosphorylation, and subsequent stimulation, of 
intracellular signaling pathways. For example, cytokines, such as prolactin 
and growth hormone can activate EGFR receptors indirectly through Janus 
tyrosine kinase 2 (Yamauchi, Ueki et al. 1997).  
 
In summary, EGFR family receptors activate major downstream signaling 
pathways such as Ras-Raf-MAP-Kinase and PI3K/AKT pathways, which 
regulate key cellular processes such as proliferation and apoptosis. 
Dysregulation, or disruption, in any or all-downstream processes may result in 
cell transformation and malignancy (Figure 1:12).  
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Figure 1:12. EGFR family downstream signaling. The EGFR family receptors activate 
major downstream signaling pathways such as Raps-Raf-MAP-Kinase and PI3K/AKT 
pathways, which regulate key cellular processes such as proliferation and apoptosis. 
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1.11.3 Down-regulation of signaling receptors 	
Endocytic down-regulation of signalling receptors has been considered a way 
of attenuating receptor signalling. However, evidence shows that some 
receptors, including EGFR, may continue their signaling activity from the 
endocytic compartment (Sorkin and von Zastrow 2009, Ménard, Parker et al. 
2014). Thus, endocytosis of the EGFR family receptors is not only a means of 
turning off activated receptors, it can also be a regulatory mechanism altering 
the signaling outcome (Roepstorff, Grøvdal et al. 2008).  
 
Regarding receptor down-regulation, the mechanism of EGFR endocytosis 
and trafficking has been the most studied and hence is best understood 
model (Tomas, Futter et al. 2014). Activated EGFR complexes are relocated 
to clathrin-coated pits on the plasma membrane during signal termination at 
the plasma membrane. These pits give rise to clathrin-coated endocytic 
vesicles which then de-coat after they have been released from the plasma 
membrane to form early endosomes (Roepstorff, Grøvdal et al. 2008). Free 
EGFRs from the early endosomes recycle back to the cell surface, while 
ligand-bound receptors undergo receptor kinase-dependent sorting into the 
internal vesicles of the multivesicular bodies (MVBs) (Katzmann, Odorizzi et 
al. 2002). The maturation to late endosomes from early endosomes is 
accompanied by accumulation of EGF-EGFR complexes in the internal 
vesicles of MVBs (Oksvold, Skarpen et al. 2001). This results in sequestration 
of the cytoplasmic domain, thus barring it from interacting with cytoplasmic 
target molecules. Afterwards, the late endosome fuses with pre-existing 
lysosomes leading to lysosomal degradation of ligand-receptor complexes by 
the lysosomal proteases (Futter, Pearse et al. 1996). Due to the action of the 
vacuolar ATPase, the pH of the lumen decreases along the endocytic route 
(Alexander 1998, Alwan, van Zoelen et al. 2003). However, due to its 
resistance to mildly acidic pH the EGF-EGFR complex remains along the 
endocytic route and they are ultimately both degraded upon reaching the 
lysosomes by the lysosomal proteases (Alexander 1998).  
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An essential part of the down-regulation of EGFR is ligand-induced 
polyubiquitination (Levkowitz, Waterman et al., Galcheva-Gargova, Theroux 
et al. 1995). This process requires the ATP-dependent activation and covalent 
binding of the ubiquitin molecule by the ubiquitin-activating enzyme 
(designated E1). Afterwards, ubiquitin is transferred to an E2 ubiquitin-
conjugating enzyme. E2 enzymes ubiquitinate the target substrate proteins in 
concert with either E3 ubiquitin ligase enzymes or with E3 RING finger 
adapter proteins. This leads to the covalent attachment of ubiquitin molecules 
to a lysine residue on a substrate protein. This is often repeated, resulting in 
multiple attachments of ubiquitin molecules to either a different lysine residue 
on a substrate protein or to a lysine residue on previously attached ubiquitin 
(Weissman 2001, Alwan, van Zoelen et al. 2003). 
 
EGFR ubiquitination is mostly dependent on the activity of Cbl adapter 
proteins (Meisner and Czech 1995, Mohapatra, Ahmad et al. 2013). Cbl-b and 
c-Cbl are members of the Cbl adapter family that constitute an important part 
of the ubiquitination machinery and in response to EGFR activation both 
undergo tyrosine phosphorylation (Meisner, Daga et al. 1997, de Melker, van 
der Horst et al. 2004, Mohapatra, Ahmad et al. 2013).  Activated EGFRs 
negative regulation requires an intact SH2 variant N-terminal region, through 
which Cbl interacts with phosphotyrosine 1045 in the C-terminal tail of the 
EGFR, and intact linker and RING finger domains to which ubiquitin-
conjugating enzymes (E2s) bind (Levkowitz, Waterman et al., Yokouchi, 
Kondo et al. 1999, Zheng, Wang et al. 2000). The Cbl proteins dual binding 
property facilitates recruitment of the ubiquitination machinery to activated 
EGFRs, which results in polyubiquitination of EGFR (Alwan, van Zoelen et al. 
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1.11.4 Role of HER receptors in normal tissue development 
 
The EGFR family plays an important role in the control of different cellular 
processes during embryonic development and in the regulation of many 
metabolic and physiologic processes in different tissues and organs (Casalini, 
Iorio et al. 2004). Studies in knockout animal models have demonstrated the 
importance of the EGFR family in the development of normal tissue 
(Normanno, De Luca et al. 2006). Genetically engineered mice with mutations 
in genes that encode HER receptors develop failure in different organs, 
leading to embryonic or perinatal death (Table 1-3) (Normanno, De Luca et al. 
2006). EGFR mutations cause developmental defects in the epithelial 
structures of the skin, lung, pancreas, gastrointestinal tract and in the central 
nervous system (Miettinen, Berger et al. 1995, Sibilia and Wagner 1995, 
Threadgill, Dlugosz et al. 1995). HER2 knockout mice have abnormal 
oligodendrocyte development and myelin formation. HER2, HER3 and HER4-
deficient mice show alterations in cardiac and neural structures that cause 
lethality (Lee, Simon et al. 1995, Sibilia and Wagner 1995, Erickson, O'Shea 
et al. 1997). 
 	
  Table 1-3. Mice with HER receptor mutations develop multiorgan failure. 	
Mutation target Localisation of defects 
EGFR Epidermis, mammary gland, lung, pancreas, intestine, 
central nervous system 
HER2 Mammary gland, heart, central nervous system 
 
HER3 Heart, central nervous system 
 
HER4 Mammary gland, heart, central nervous system 
 
Table from (Normanno, De Luca et al. 2006) 
			
Introduction                                                                                        Chapter-1                                                         
  44 
1.11.5 Role of HER receptors in normal human breast 
development 
 
The EGFR family receptors and their ligands are expressed in the mammary 
glands and play non-oncogenic roles during normal breast development, 
maturation and involution (Wiesen, Young et al. 1999, Eccles 2011). 
Mammary gland development begins during embryogenesis, but is not fully 
developed until the beginning of lactation. Most mammary gland development 
occurs during puberty, stimulated by steroid hormones. During puberty, 
estrogen and estrogen receptor α (ERα) induce elongation and branching of 
the mammary ducts to extend throughout the fatty mesenchyme. 
Progesterone plays a key role in the adult (Stern 2003, Eccles 2011).  
 
EGFR receptors also have a major contribution to breast development during 
puberty, pregnancy and lactation, when the steroid hormones up-regulate the 
production of many growth factors, including the HER family (Eccles 2011). 
During puberty the growth of mammary epithelium and ductal differentiation 
are stimulated by EGFR and TGFα (Snedeker, Brown et al. 1991). During 
pregnancy and lactation, the second wave of HER receptors activation 
occurs. HER2 is required for lobular differentiation and milk production, in 
association with its partners and in response to neuregulins (Sebastian, 
Richards et al. 1998). HER3 also plays a key role in regulating 
morphogenesis of mammary epithelium. HER4 is essential for lobular 
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1.11.6 The role of HER receptors in cancer development and 
targeted therapies 	
The EGFR family and their ligands play a key role in the pathogenesis of 
human carcinomas.   
 
EGFR and its cognate ligands are found to be overexpressed or mutated in 
different forms of cancer such as non-small cell lung cancer (NSCLC), breast 
cancer, gliomas, colorectal, prostate, gastric, oesophageal, pancreatic and 
ovarian cancer (Ciardiello and Tortora 2001).  
 
The most common EGFR mutant found in human cancer is EGFRvIII 
(Hatanpaa, Burma et al. 2010). Mutant EGFRvIII is often amplified in lung 
cancer, resulting in overexpression of EGFRvIII in tumour cells (Voldborg, 
Damstrup et al. 1997, Ji, Zhao et al. 2006, Gan, Cvrljevic et al. 2013). The 
EGFRvIII is a truncated EGFR that is not capable of ligand binding due to 
deletion of exons 2 and 7 and loss of residues 6 to 276 in the extracellular 
domain. However, it has a constitutively activated tyrosine kinase domain, 
which stimulate cell proliferation without ligand binding (Knoop, Bentzen et al. 
2001, Biernat, Huang et al. 2004).  
 
A high expression level of EGFR has been associated with advanced tumour 
stage as well as resistance to both hormonal therapy and chemotherapeutic 
agents and poor prognosis in some tumours such as breast and ovarian 
cancer (Nicholson, Gee et al. 2001, Arteaga 2002). In one study of 155 breast 
cancer patients, pre-treatment EGFR expression level predicted a lower 
response rate to tamoxifen. However, other studies in ER positive breast 
cancer patients have not support the predictive value of EGFR status for 
tamoxifen response (Newby, Johnston et al. 1997, Knoop, Bentzen et al. 
2001).  
 
Due to the importance of EGFR signaling pathway in cancer progression, 
EGFR has become an attractive target for developing new strategies for 
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cancer therapeutics. Several anti-EGFR therapies were developed in the late 
1990s that inhibit EGFR functions in cancer, including monoclonal antibodies 
such as cetuximab and panitumumab, as well as tyrosine kinase inhibitors 
(TKIs) such as gefitinib and erlotininb (Huang and Harari 1999, Gajadhar, 
Bogdanovic et al. 2012, Seshacharyulu, Ponnusamy et al. 2012). Anti-EGFR 
monoclonal antibodies compete for receptor binding by binding the 
extracellular domain of the EGFR in its inactive state and blocking the ligand-
binding region and thus blocking ligand-induced EGFR tyrosine activation 
(Martinelli, De Palma et al. 2009). Anti-EGFR tyrosine kinase inhibitors bind to 
the intracellular catalytic domain of EGFR tyrosine kinase, competing with 
adenosine 5’ triphosphate and thereby inhibiting EGFR autophosphorylation 
and downstream signaling (Herbst 2004). Moreover, EGFR tyrosine kinase 
inhibitors can block different growth factor receptor tyrosine kinases, including 
other members of the EGFR family and also vascular endothelial growth 
factor receptor (Martinelli, De Palma et al. 2009). Conversely, anti-EGFR 
monoclonal antibodies recognise EGFR exclusively and are thus highly 
selective to EGFR. However, there is evidence of acquired resistance to 
EGFR inhibitors, limiting the use of these drugs in cancer therapy. This 
resistance could be due to over-expression of other tyrosine kinase receptors 
or constitutive activation of downstream mediators (Martinelli, De Palma et al. 
2009).  
 
HER2 expression is an important predictive and prognostic marker in breast 
cancer, as described above. HER2 overexpression is found in various human 
cancers such as breast, gastric, ovarian, colon and prostate cancer (Iqbal and 
Iqbal 2014, Lee, Park et al. 2014). Overexpression of HER2 is found in almost 
15-30% of invasive breast cancers (depending on stage of presentation) and 
is almost invariably associated with gene amplification (Burstein 2005, 
Moelans, de Weger et al. 2010). Breast cancers can exceptionally have up to 
25-50 copies of the HER2 gene, and up to a 40-100 fold increase in HER2 
protein (Kallioniemi, Kallioniemi et al. 1992). p95 is an aberrant form of HER2 
lacking the extracellular domain found in some breast cancers. p95 is 
constitutively active and causes resistance to anti-HER2 targeted therapies  
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that require the extracellular domain of HER2 for binding (Molina, Sáez et al. 
2002, Scaltriti, Rojo et al. 2007).  
 
HER2 gene amplification has been found to be associated with more 
aggressive tumour phenotype, an increased resistance to endocrine therapy 
and shorter disease free and overall survival (Seshadri, Firgaira et al. 1993, 
Carr, Havstad et al. 2000). Evidence suggests that HER2 amplification is an 
early event in breast tumour genesis, as up to 50% of DCIS shows HER2 
gene amplification (Park, Han et al. 2006). Breast cancers with HER2 gene 
amplification have increased sensitivity to certain cytotoxic chemotherapeutic 
agents in some series and resistance to certain hormonal agents and 
increased tendency to metastasize to the brain (Gabos, Sinha et al. 2006). 
 
The introduction of HER2 directed therapies such as the anti-HER2 
monoclonal antibody trastuzumab (Herceptin), which was approved by FDA in 
1998, has dramatically influenced the outcome of patients with HER2 positive 
breast cancer and latterly gastric/gastroesophageal cancers (Lewis Phillips, Li 
et al. 2008, Nahta 2012). Trastuzumab is a monoclonal antibody that binds to 
the extracellular subdomain IV of the HER2 receptor (Carter, Presta et al. 
1992, Vu and Claret 2012). It is approved as part of an adjuvant treatment 
regimen for breast cancer patients with HER2 overexpression and/or gene 
amplification (Hudis 2007). Clinical trials have demonstrated that the inclusion 
of trastuzumab to the regimen of patients with early invasive HER2 positive 
breast cancer produces a 50% improvement in disease free survival and a 
33% improvement in overall survival irrespective of the chemotherapy 
regimen or sequence of trastuzumab delivery (Piccart-Gebhart, Procter et al. 
2005, Romond, Perez et al. 2005, Joensuu, Kellokumpu-Lehtinen et al. 2006). 
 
Lapatinib is a tyrosine kinase inhibitor, directed against HER2 and EGFR. 
Lapatininb, unlike trastuzumab, binds to the intracellular domain of the 
tyrosine kinase receptor, allowing for complete blockage of the 
autophosphorylation reaction and a complete stop to the downstream 
cascade of events (Medina and Goodin 2008, Kim, Yoon et al. 2009). It is 
approved for the treatment of HER2 positive metastatic breast cancer patients 
Introduction                                                                                        Chapter-1                                                         
  48 
who have received prior therapy including trastuzumab. The risk of disease 
progression was reduced to 51% when lapatininb was used in combination 
with chemotherapeutic drugs in one series (Geyer, Forster et al. 2006).  
 
HER3 is a unique member of the EGFR family, it lacks intracellular kinase 
activity, and cannot form a homo-dimer but can still hetero-dimerize with other 
EGFR family members, mostly HER2 (Berger, Mendrola et al. 2004). 
However, weak activity of the HER3 tyrosine kinase has been reported (Shi, 
Telesco et al. 2010). Moreover, as an obligate partner of HER2, HER3 plays 
an important role in HER2 transforming and accelerating progression in 
human cancers (Jiang, Saba et al. 2012). In vivo studies have shown that 
HER3/HER2 combination results in more aggressive tumour growth and 
induced a higher level of VEGF than other EGFR family combinations. 
Therefore, the HER2/HER3 hetero-dimer is considered the most potent HER 
pairing as an oncogenic unit (Holbro, Beerli et al. 2003, Lee-Hoeflich, Crocker 
et al. 2008). Moreover, preferential HER3 phosphorylation, not EGFR, is 
observed in HER2-amplified breast cancers. However, HER3 appears to be 
the preferred EGFR dimerization partner in melanoma and pancreatic cancer 
(Alimandi, Romano et al. 1995). Indeed HER3 overexpression is reported in  a 
range of malignancies such as colorectal carcinoma, squamous cell 
carcinoma of the head and neck (SCCHN), and gastric, ovarian, colon, 
prostate and bladder cancers (Shi, Telesco et al. 2010). HER3 
overexpression is also found in breast cancer and is associated with 
metastasis and local recurrence risk (Lemoine, Barnes et al. 1992, Quinn, 
Ostrowski et al. 1994, Travis, Pinder et al. 1996). 
 
In addition, HER3 plays a key role in EGFR family targeted therapy drug 
resistance. Lengthy exposure to the EGFR inhibitors gefitinib or erlotinib or 
the HER2 inhibitor AG-825 in HER2 positive breast cancer cells leads to the 
up-regulation of HER3 and Akt phosphorylation (Engelman, Zejnullahu et al. 
2007). Overexpression of the HER3 ligand heregulin is also a possible 
mechanism for therapy resistance in colorectal cancer patients. Elevated 
NRG1 and activated HER3 are strongly associated with lapatinib sensitivity. 
The above resistance-promoting function could be due to an increase 
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activation level of HER3 rather than of total HER3 protein expression (Wilson, 
Lee et al. 2011, Yonesaka, Zejnullahu et al. 2011). HER3 inhibitors (mostly 
targeting the receptor extracellular domain) have been developed and a 
number of them are in early clinical trials (Jiang, Saba et al. 2012). Recently a 
kinase domain directed inhibitor has also been described which can confer 
degradation of the receptor (Xie, Lim et al. 2014). 
 
 
HER4 is activated by hetero-dimerization or ligand binding to betacellulin, 
epiregulin and neuregulins. Although the structure and mechanism of HER4 
are similar to those of other EGFR family, it remains unclear what precise 
roles HER4 plays in the development of human tumours. However, HER4 
mutation has been reported to be associated with various cancers such as 
breast, lung, colorectal and gastric carcinomas (Carpenter 2003). HER4 
overexpression has also been also found in 66% of medulloblastomas, where 
it is reportedly associated with poor prognosis (Carpenter 2003, Soung, Lee et 
al. 2006, Eccles 2011).  In breast cancer, HER4 expression has been 
reported to be associated with good prognosis in patients with luminal A 
subtype cancers (Carpenter 2003, Soung, Lee et al. 2006). It is also 
associated with ER positive breast cancer and therefore has been predicted 
to be oestrogen regulated.  
 
In summary, the EGFR receptor family are up-regulated in different forms of 
cancer. Furthermore, aberrant activation of signaling pathways drives many of 
the fundamental biological processes that accompany tumour initiation and 
progression. Additionally, aberrant dimerization and phosphorylation can be 
independent of receptor expression level. Therefore, methods which directly 
query signaling pathway activation via, for example, phosphorylation assays 
in breast cancers, are expected to provide important insights into the 
molecular ‘‘logic’’ that distinguishes cancer from normal tissues and potentially 
to have an impact on personalised intervention strategies. 
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 1.12 Proteomics   
   
Despite advances in the identification of genes associated with prognosis of 
patients with invasive breast cancer this has brought only a limited 
understanding of how these events contribute to the process. Ideally the 
function of the gene product, i.e. the protein, must also be assessed. Although 
the genetic aberration causes the disease, the functional consequences are 
mediated through protein networks. 
 
Proteins are the main functional output of genes and it is crucial to have a 
better understanding of the regulation and coordination of the 23,000 proteins 
(and their many splice and modification variants) encoded in the human 
genome. Proteomics allows the direct examination of the molecular pathways 
of cells including protein expression, post-translational modification and 
protein-protein complexes, which can be altered in many diseases such as 
cancer.  
Immunohistochemistry (IHC) techniques are well established for the 
assessment of biomarkers in biological samples. However, the reliable 
assessment of these biomarkers has proved challenging. IHC is not well 
controlled and it is semi-quantifiable and frequently lacks the specificity 
required for more challenging proteomic readouts. For example, IHC is limited 
to detecting individual proteins and cannot be used for analysis of protein 
complex interactions. There is a need to develop a simple technology that 
reports, with high specificity, not simply on the concentrations of proteins in 
patient’s samples, but also on their cellular distribution, partner associations 
and their post-translational modification (e.g. phosphorylation), reporting 
protein content, activity and location that can be applied routinely in research 
laboratories as well as clinical settings. The hunt for diagnostic and prognostic 
functional protein biomarkers has introduced some methods which can be 
used for the examination of protein expression, including mass spectroscopy 
(MS) and coincidence detection by fluorescent resonance energy transfer 
(FRET). These can yield information on post-translational modification of 
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proteins and thus on their functional states. However, they are limited by 
processing demands, sensitivity issues and both require non-routine 
equipment making them difficult to implement. Distinct approaches and new 
methods are needed to assess proteome functions in tissue samples. 
 
1.13 Hypothesis and Aims of the study 	
The hypothesis for this study is that aberrant dimerization and 
phosphorylation of EGFR family in breast cancer can be independent of 
receptor expression level. The proximity ligation assay (PLA) and coincidence 
biodetector technology are two methods which can directly query signalling 
pathway activation via phosphorylation assays in breast cancer biopsies and 
also assess complex formation. These methods are expected to provide 
important insights into the molecular ‘‘logic’’ that distinguishes cancer and 
normal tissues and to have an important impact on personalized intervention 
strategies. To investigate this hypothesis, the specific aims of this study are: 
 
1- To optimize and use the novel technologies, in part developed by our 
laboratory, which can detect the states of proteins in fixed tumour 
samples. 
 
2- To use these technologies to investigate the molecular events in DCIS 
and invasive breast cancer. 
 
3- To detect EGFR family protein expression, co-expression and 
activation states in a series of breast cancers. 
 
4- To assess how these states, relate to histological features of the 
cancers and to patient outcomes. [Both a series of invasive breast 
carcinomas with long-term follow-up (which will allow analysis of 
prognosis in this disease) and of DCIS are to be assessed.] 
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2.1 Materials 	
2.1.1 Tissue Microarrays (TMAs) 
 
 
Patient’s materials (Invasive and DCIS breast cases):  
 
Consecutive TMAs (cTMAs) containing a cohort of 293 invasive breast 
carcinomas (0.6mm cores) and three TMAs containing 37 pure DCIS cases 
(2mm cores) were used in this study (described in Chapters 5 and 6). The 
TMA cases with their clinical-histopathological data were collected from Guy’s 
and St Thomas’ (King’s Health Partner’s) Breast Cancer Biobank archive 
constructed previously by Mr. John Brown. There was ethical approval for the 
use of all patients’ tissue and their corresponding data. 
 
Control TMA for proximity ligation assay (PLA) optimization: 
 
One additional TMA block containing 12 cores (2mm2) was constructed for the 
purpose of PLA optimization by Mr. John Brown from Guy’s and St Thomas’ 
(King’s Health Partner’s) Breast Cancer Biobank. This TMA contained nine 
2mm cores from cases of formalin fixed paraffin embedded invasive breast 
carcinoma. A43l xenograft tumour model was included as a positive control, 
one normal breast tissue core and extra cores for orientation (described in 
Chapter 4). 		




Cell lines used in this study were selected as they express different levels of 
EGFR, HER2 and HER3 (Table 2-1). Cell lines were cultured either in 
Dulbecco’s modified eagle’s medium (DMEM) with phenol red and L-
Glutamine (Catalogue No-31966074, GIBCO, Life Technologies) or Memorial 
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Institute (RPMI-1640) with phenol red and L-Glutamine (Catalogue No -
21875034, GIBCO, Life Technologies) according to the manufacturer’s 
recommendations. Cell lines were not cultured beyond twenty passages. 
 
Cell lines were screened with western blot analysis for HER receptor 
expression.	
Table 2-1 Cell lines used in this study. 
Cell line 
 






Human epidermoid carcinoma cell line 
derived from an 85 year old female 
(Abcam). 
 







Human breast adenocarcinoma cell 
line derived from a pleural effusion of 
a 54 year old female patient with an 
infiltrating ductal carcinoma of the 
breast (Abcam). 
 







Human breast adenocarcinoma cell 
line derived from 61 year old female 
with grade 3 invasive ductal 
carcinoma (Supplied by Prof. Tony Ng, 
King’s College London). 
 







Human breast adenocarcinoma cancer 
cell line derived from a pleural 
effusion of 51 year old breast cancer 
patient (Supplied by Dr. Claire Wells, 
King’s College London). 
 







Human breast adenocarcinoma cancer 
cell line derived from the pleural 
effusion of 69 year old breast cancer 
patient (Supplied by Dr. Claire Wells, 
King’s College London). 
 








Human adenocarcinoma cell line 
derived from 31 years old patient with 
cervical cancer (Abcam). 
 
 
Medium expression  






Human breast adenocarcinoma cancer 
cell line derived from a pleural 
effusion of 45 year old breast cancer 
patient  (Abcam). 
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Other materials used for cell culture:  
 
• Dulbecco’s modified eagle’s medium (DMEM) without phenol red and 
L-Glutamine (Catalogue No. 31053028, GIBCO, Life Technologies) 
• Roswell Park Memorial Institute (RPMI 1640) without phenol red and 
with L Glutamine (Catalogue No. 11835030, GIBCO, Life 
Technologies) 
• Fetal Bovine Serum (Catalogue No. A15-101, PAA Laboratories),  
• Trypsin/EDTA Solution (10x) 0.5%/0.2% in (10x) PBS without Ca2+, 
Mg2+ (Catalogue No. L2153, Source BioScience LifeSciences) 
• Dulbecco's PBS (DPBS) (1x) without Ca2+, Mg2+ (Catalogue No -H15-
002, PAA Laboratories) 
• Dulbecco's PBS (DPBS) (1x) with Ca2+, Mg2+ (Catalogue No. H15-001, 
PAA Laboratories) 
• DMSO (Catalogue No. 41639-100 ML,Sigma) 




The growth factors used for the in vitro experiments were:  
• Untagged Human epidermal growth factor (EGF) obtained from 
Peprotech (Catalogue No. AF-100-15-100)  
• Recombinant Human Heregulinβ-1 (Catalogue No. AF-100-03-100). 			
2.1.3 Antibodies 
 
Several primary antibodies against total EGFR, HER2 and HER3 and 
phosphorylated forms of EGFR, HER2 and HER3 were chosen for this study. 
The specificity of all the primary antibodies was validated first by western blot 
analysis and standard Immunofluorescence (IF), described in the methods 
section. The full characteristics of all the primary antibodies used in this 
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project are shown in Table 2-2. Table 2-3 shows the list of the secondary 
antibodies used in this study.   
 
















Representing residue 985 












Raised against the 
Cytoplasmic domains of 
the EGFR 










Detects endogenous EGF 
receptor only when 












Detects endogenous levels 












Detects endogenous HER2 
receptor when 












Raised against the epitope 













Detect endogenous level of 
total HER3 











receptor when only 












Detects the C-terminal 











Recognizes an epitope 
located at the C-terminal of 
α-tubulin 
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Table 2-3 List of secondary antibodies. 
	















Reacts with rabbit 
























Antibody IgG (H+L) 
Labeled with green 




Reacts with IgG heavy 
chains and all classes of 











Antibody IgG (H+L) 
Labeled with green 
fluorescent Alexa Fluor 
488 dye 
 
Reacts with IgG heavy 
chains and all classes of 
immunoglobulin light chains 
from rabbit 
																					
Materials & Methods                                                                           Chapter-2                                                        
  58 
2.1.4 Proximity Ligation Assays (PLAs) Reagents 
 
The Duolink Proximity Ligation Assay reagents used in this study were 
purchased from Sigma and are listed in the following Table. 
 
Table 2-4   List of PLA assay reagents. 	
Reagent Description Catalogue number 
 





Affinity purified Donkey 











Affinity purified Donkey 











Affinity purified Donkey 






Duolink In situ PLA 
Anti-mouse plus 
 
Affinity purified Donkey 








λex 554 nm 
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2.1.5 Biodetectors Cloning and Purification 	
The Multisite Gateway Three Fragment Vector Construction Kit from 
Invitrogen (Catalogue No> 12537-023) was used for biodetector cloning and 
purification.  	
Other materials include:  
• Competent cells, PL21 (DE3) Gro EL/ES and DH5α cells from New 
England Biolabs (Catalogue No.C2987, NEB5-alpha) 
• The Bug Buster Protein Extraction Reagent from Novagen (Catalogue 
No. 70923) 
• The DNA purification system was from Promega (Catalogue No. 
A1123)  
• Isopropyl-βD-thiogalactoside (IPTG) from Sigma (Catalogue No. 
I6758).  
 




2.1.6 Western blot 	
Western loading and transfer buffers preparation: 
 
5X Tris Glycine Electrophoresis buffer: 
• 15.1 g of Tris base 
• 94 g of glycine 
• 25 ml of 20% SDS 
• DH2O 
 
5X Tris Glycine transfer buffer 
• 11.6 g of Tris base 
• 5.9 g of glycine 
• 3.75 ml of 20% SDS 
• DH2O 
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Blocking solutions used for western blots: 
 
5% BSA in TBS (2.5 g of BSA) (Catalogue No. 05482-25G, Sigma) + 50 ml 
TBS) and 3% BSA in TBS (1.5 g of BSA+ 50 ml TBS). TBS (25mM Tris pH 




M-PER lysis buffer comprised:  
• 5 ml M-PER (Catalogue No. 78501, Thermo Scientific) 
• Complete Mini-EDTA-free (Catalogue No. 04693159001, Roche) 
• PhosStop (Catalogue No. 04906837001, Roche) 
• 1mM EDTA pH8.0 (Catalogue No. AM97595, Ambion) 
• 150mM NaCl (Catalogue No.  AM9260G, Ambion) 
 
10% and 12% electrophoresis gels were used in this project; the preparation 
of these gels is described in Table 2-5. 
 
Table 2-5 Preparation of gels used in Western Blot. 	
Reagents 10% (ml) 
 
12%(ml) 
 Resolving Stacking Resolving Stacking 
H2O 4 2.1 6.6 3.4 
30% acrylamide mix 3.3 0.5 8.0 0.83 
1.5M Tris (pH 8.8) 2.5 0.38 5.0 0.63 
10% SDS 0.1 0.03 0.2 0.05 
10% APS 0.1 0.03 0.2 0.05 
TEMED 0.004 0.003 0.008 0.005 
 
Other materials and Equipment: 
 
• Precision Plus Protein Dual marker (Catalogue No. 1610374 Bio-Rad 
laboratories) 
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• EZBLUE gel staining solution (Catalogue No. G1041, Sigma) 
• 10% ammonium per-sulphate (Catalogue No. 17837-100ML, Sigma) 
• TEMED (Catalogue No. T7024-100ML, Sigma)  
• 30% (w/v) acrylamide/bis-acrylamide solutions (Catalogue No. A3574-
100ML, Sigma) 
• Sodium dodecyl Sulphate (SDS) (Catalogue No. L3771, Sigma) 
• Chemiluminescence Detection (ECL) (Catalogue No. 11556345, Fisher 
Scientific) 
• Dimethyl Sulphoxide (DMSO) (Catalogue No. 41639-100ML, Sigma) 
• Streptavidin magnetic beads (Catalogue No. S1420S, New England 
Biolab) 
• Transfer membrane Immobilon Polyvinylidene Difluoride (PVDF), 
(Catalogue No. IPFL00010, Millipore)  
• Tween-20 (Catalogue No. P1379, Sigma). 
The Nano drop (ND-100, Spectrophotometer) was employed to measure 
protein concentrations. 
 
2.1.7 Enzyme-linked immunosorbent assay (ELISA) 	
Peptides used for ELISA were: biotin-Eahx-DVVDADEYLIPQ-CONH (Bio-
EGFR-Fa4) and biotin-Eahx-SRKHDSIKDDSEDLKPVIDG-NH2 (Biotinylated-




3,3’,5,5’ tetramethylbenzidine (TMB) (Catalogue No. PI-34021, Thermo 
scientific). ELISA 96 well microtiter plates (ImmuIon 2HB, Nunc) and 
Multiskan EX plate reader (Thermo electron corporation). 
 
2.1.8 Haematoxylin and Eosin (H&E) staining 
	
The reagents used for the standard H&E staining were:  
• Haematoxylin (Catalogue No. HHs16, Sigma)  
• Eosin (Catalogue No-E449, Sigma) 
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• Xylene (Catalogue No. 534056-4L, Sigma) 
• Ethanol Absolute (Catalogue No. 20816.367, VWR International) 
• DPX mounting media (Catalogue No. 44581, Sigma) 
 
2.1.9 Xenograft Tumor models. 	
Female CD-1 Fox nu/nu mouse (5-6 weeks old; CRL) were used to generate 
xenograft tumour models kindly provided by Professor Tony Ng’s group, 




 Images were captured at 40x and 60x using A1R Nikon Confocal Microscopy 
(Nikon Imaging Center). TMA Images were taken at 40x to a resolution of 
0.181 μm/pixel with an Ariol SL-50 automated slide scanner (Leica 




2.2.1 Cell culture 	
Cell lines were cultured in either Dulbecco’s modified Eagle’s medium 
(DMEM) or Roswell Park Memorial Institute medium (RPMI), according to the 
supplier’s recommendations and kept in a humidified chamber at 37% in 5% 
CO2. To maintain exponential growth, cells were regularly passaged when 
cultures had grown to 80-90% confluence. 
 
 Passaging Cells 
 
Cell lines were grown until they were semi-confluent (80-90%). The medium 
was then aspirated and cells washed twice with PBS. Trypsin was added and 
incubated for 3 minutes at 37°C. To encourage greater detachment of cells, 
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the flasks were gently tapped, medium was added to the flask to terminate 
trypsin activity and the contents were transferred into 15 ml Falcon tubes and 
centrifuged at 1000 rpm for 4 minutes with an Eppendorf centrifuge. The 
supernatant was removed and the cell pellet was re-suspended in 5 ml of 
fresh growth media for subsequent culture.  
 
Preservation and storage of cells 
 
All cell lines were stored in liquid nitrogen (-196°C) as described in the 
American Type Culture Collection (ATCC) guidelines. For storage, cell pellets 
were re-suspended in freezing medium (the appropriate cell line culture 
medium with Fetal Bovine Serum (FBS) and phenol red with 5% DMSO). 
Cells (1ml) were put in a Cryotube and stored at -80C overnight before being 
placed in liquid nitrogen. 
 		




Proteins were extracted from cells, post harvesting using M-PER lysis buffer 
(Thermo Scientific). At first, cells were plated in 10mm dishes (3,000,000 
cells/plate) in 10 ml of appropriate media and left overnight to adhere. After 
washing twice with PBS, cells were serum-starved overnight by adding 
medium without Fetal Bovine Serum (FBS) and phenol red at 37°C 5% CO2. 
After washing the cells twice with cold PBS without Ca2+ & Mg2+ (PBS -/-, 
PAA) (10ml/plate), cells were either left un-stimulated or stimulated with the 
appropriate ligand, (100nM in cold medium without FBS). Cells were then 
scraped and added to a 1.5 eppendorf tube, spun down at 200 g (1,200rpm) 
for 5 minutes at 4°C and the supernatant removed. Cell pellets were re-
suspended in M-PER lysis buffer according to the manufacturer’s 
recommendation with the addition of 150 mM NaCl. After shaking the mixture 
gently for 10 minutes, the cell debris was removed by centrifugation at 
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14,000xg for 15 minutes and the cells were transferred to a new tube for 
analysis (Figure 2:1). Protein concentrations were determined using the 
NanoDrop (ND-100, Spectrophotometer). The samples were then mixed with 
SDS PAGE buffer containing 1mM DTT, denatured at 90°C for 2 minutes and 
loaded into 10% polyacrylamide gel. The gel was run at 100V for 30minutes 




Figure 2:1 Cell lysate preparation. Proteins were extracted from cells post harvesting using 
M-PER lysis buffer, cell debris was removed by centrifugation and cells containing proteins 
were transferred to a new tube for analysis (Image from http://www.novusbio.com). 
 
Transfer of Protein to PVDF membrane 
 
Prior to transfer, the PVDF membrane was “wetted” by placing it in methanol 
for one minute, rinsed in distilled water and kept in transfer buffer until use. 
For the transfer, the membrane was placed on a plastic grid on top of a wet 
sponge and filter paper, the gel was carefully placed on top of the membrane 
and another filter paper and wet sponge were placed on top of the gel. All air 
bubbles were removed, the plastic grid was placed in the western blot 
chamber and the transfer was performed at 100V for two hours.  
 
After transfer, the membrane was blocked with TBS, 3%BSA overnight at 4°C 
to avoid unspecific binding of the primary antibody and thus to reduce 
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background staining. The membrane then was incubated for one hour with the 
primary antibody targeting the protein of interest diluted in TBS, 1% BSA. 
After washing three times with TBS, 0.1% Tween-20 the membrane was 
incubated for half an hour with the secondary antibody diluted 1: 15,000 in 
TBS, 1%BSA, 0.1% Tween-20. Substrate Chemiluminescent (ECL) detection 
system kit (Thermo scientific) reagents A and B were mixed in equal amount, 
added to the membrane and incubated for 1 minute. Excess liquid was 
removed and the membrane was exposed to X-ray film for different times 
depending on the intensity of the band and the film developed using a medical 
film processor (SRX-101A, Konica Minolta). 
   
Stripping of the membrane 
 
To dissociate the bound antibodies previously used from the membrane for 
subsequent usage, membranes were incubated with stripping buffer (25mM 
glycine pH2.0, 2% SDS) for 10 minutes and left at room temperature with 
gentle shaking. After rinsing twice with PBS, 0.1% Tween-20 for 5 minutes, 
successful stripping was checked using the ECL detection method as 
described above. 
 
2.2.3 Cloning of the Protein-G biodetector and protein 
purification 
 
Cloning of the Bio-detector. 	
The MultiSite Gateway Technology was used to clone and assemble the 
biodetectors. The technology is a universal cloning method that provides a 
rapid and highly efficient way to transfer heterologous DNA sequences into 
multiple vector systems for functional analysis and protein expression. The 
technology uses site-specific recombinational cloning to allow simultaneous 
cloning of multiple DNA fragments in a defined order and orientation (Hartley, 
Temple et al. 2000).  
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The Multisite Gateway Three Fragment Vector Construction Kit (Invitrogen) 
was used to clone the modules of the biodetector and to assemble it. The 
pENTRY clones were generated by standard donor vectors following 
manufacturer’s instructions. Three DNA segments were cloned directionally 
and in a specific order into a destination vector (pDEST) containing the 
recombinant cassette attR4-attR3. At first, the PCR products of the fusion 
constructs were recombined into pDONOR vectors to generate pENTRY 
clones and then sub-cloned in frame by LR recombination into the in-house 
modified destination vector p-GEX-4T1 (GE, Healthcare). The p-GEX-4T1 
expression vector was modified inserting the recombinant cassette attR4-
attR3 into the vector to convert pGEX-4T1 into a Multisite Gateway 
destination vector (pGEX-4T1-DEST-attR4-attR3). The attR4-attR3 cassette 
was cloned into pGEX-4T1by PCR and restriction enzyme digestion together 
with the ccdB and chloramphenicol resistance genes, as it is in the original 
pDEST-R4-R3 cassette of the Multisite Gateway three-fragment vector 
construction kit. Therefore, the pGEX-4T1 vector expresses the Glutathione 
S-transferase (GST) gene in frame with any of the three modules of choice 
allowing expression and affinity purification from E.coli. Furthermore, RXR 
and RAR detection modules had been generated with an HRV 3C protease 
cleavage site at their N-terminal ends to obtain vector free purification.   
 
Transformation 	
In a 1.5ml micro centrifuge tube, 1µl of the pENTRY clones (10fmoll/µl, 
supplied by Dr. Perani, King’s College London) were recombined with 300ng 
of the destination vector (p-GEX-4T1-DEST-attR4-attR3). LR clonase II 
enzyme were added, mixed and kept at room temperature (RT) overnight.  
Proteinase-K (2μg/μl in,10 mM Tris-HCl, pH 7.5, 20 mM CaCl2, 50% glycerol) 
was added to terminate the reaction and incubated at 37° C for 10 minutes. 
The recombinant DNA was added to DH5α cells (NEB5-alpha New England 
Biolabs), kept for 2 minutes on ice then for 45 seconds in a 42° C water bath. 
The cells were quickly placed on ice for 2 minutes, 300 µl of Lysogeny 
broth (LB) medium was added to the cells and cultures kept in a shaking 
incubator at 37° C for one hour. The whole culture was spread on an LB agar 
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plate containing the appropriate antibiotic and left overnight at 37° C for the 
colonies to grow. Preparation of the DNA was done using DNA purification 
system from Promega. The DNA was sent to Eurofin for sequencing using 
PGex-forward and reverse primers.    	
Protein expression and purification. 
 
PL21 (DE3) Gro EL/ES bacteria cells were transformed with pGEX vectors 
encoding the GST tagged Protein-G domains following the previous 
procedure for transformation into DH5α cells (see above). A starter culture 
was prepared by adding one colony in 60ml LB broth containing the following 
antibiotic for selection carbinicillin 60µg/ml, chloramphenicol 34µg/ml with the 
addition of ZnCl2 (50µM). The starter culture was kept in a shaking incubator 
overnight at 37°C. The starter culture (6 ml) was inoculated in 600ml LB Broth 
(dilution 1:100) containing the same antibiotics as the starter culture. The cells 
were then grown in a shaking incubator at 37°C until the absorbance reached 
0.4-0.5 Optical Density (OD). The culture was induced with 0.8mM isopropyl-
βD-thiogalactoside (IPTG) and kept in the shaking incubator for 2 hours at 22 
°C to express the protein.   
 
The bacteria were harvested by centrifugation at 3000g for 15 minutes at 4°C 
using a RC5C centrifuge (Sorvall Instruments) and cell pellets were collected 
and stored at -80°C. The cell pellets were re-suspended in 40ml of Bug 
Buster Master Mix (Novagen) according to the manufacturer’s instructions. 
The cell suspension was kept on a shaking platform for 10 minutes. The 
soluble proteins were separated from the insoluble proteins by centrifugation 
at 27,000g using a G25 incubator shaker (New Bruswick Scientific). The 
purification of the protein was carried out using immobilized glutathione beads 
in which 1ml of GST bead (50% slurry) (Thermo Scientific) was added to the 
lysates and incubated at room temperature for 30 minutes. The beads were 
centrifuged for one minute at 700g at RT. The GST beads were washed five 
times with Tris (pH7.6), 1mM Dithiothreitol (DTT), 100mM NaCl.  3C protease 
(70 µg/ml) was added to the GST beads and incubated at 4°C for three hours 
to cleave the protein. The cleaved proteins were collected with centrifugation 
at 1,000 g for 1 minute. Protein concentration for each eluted fraction was 
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measured using a NanoDrop (ND-100, Spectrophotometer). The fractions 
containing proteins were then pooled and dialysed at 4°C overnight against 
Tris pH 7.6, 100mM NaCl, 50% ethyleneglycol, 1 mM DTT. The samples were 
aliquoted, snap frozen in liquid N2 and stored at -80°C. 
 
SDS PAGE. 	
Samples collected during the purification to monitor the process were 
separated on 12% polyacrylamide gels. Molecular weight markers were 
loaded for the determination of the detected proteins size (Laemmli 1970). 
 
Gel-electrophoresis was performed to investigate the size and concentration 
of proteins. The polyacrylamide gels (12%) were run in running buffer (25mM 
Tris, 250mM Glycine, 0.1% SDS). To estimate the molecular weight, 10μl of a 
molecular weight marker (Precision Plus Protein Dual Color – Bio-Rad) were 
loaded together with the protein samples. To estimate protein concentration a 
serial dilution of BSA ranging from 5µg to 0.255µg was made. The gel was 
run at 120V for approximately 2 hours using a Novex Mini-Cell apparatus 
(Invitrogen) and a HC PowerPac (Bio-Rad). The gel was then stained with 
EZBlue Gel Staining Reagent (Sigma) for one hour and de-stained in dH2O 
overnight. 
 
2.2.4 Enzyme-Linked Immunosorbent Assay (ELISA). 
 
The ELISA technique is widely used as a diagnostic and analytical tool in 
medicine and biomedical research due to the high sensitivity and specificity of 
this method compared to other immunoassays methods (Gan and Patel 
2013). Designed ELISAs were used here to test the functionality of the 






Materials & Methods                                                                           Chapter-2                                                        
  69 
Testing protein fusion functionality by ELISA 
 
Wells were coated with the desired antibodies diluted 1:100 in 100mM sodium 
carbonate/bicarbonate pH 9.6 (antibody final concentration 10ng/µl, 50µl/well) 
and incubated at RT on a shaker for two hours. To avoid unspecific binding, 
wells were then incubated with 3% Bovine Serum Albumin (BSA; Sigma) in 
SSC 0.8x pH 7.0 overnight at 4°C. Protein fusions were added and incubated 
for one hour, followed by washing and then biotinylated (BIO)-PrA-DR5 
(5pmol/well) diluted in 1% BSA in SSC 0.8x pH 7.6 (50µl/well) added for one 
hour at RT. After washing, streptavidin-horseradish peroxidase (10ng/µl; 
Streptavidin-HRP, Calbiochem) was added diluted in 1% BSA in SSC 0.8x pH 
7.6 and incubated for 30 minutes at RT. Finally, 3,3’,5,5’ tetramethylbenzidine 
(TMB, Thermo scientific) substrate was added for 10 minutes and the reaction 
was blocked with 2 M H2SO4. Optical density (O.D.) was read with a Multiskan 
EX plate reader (Thermo Electron Corporation) at the wavelength of 450 nm. 
Figure 2:2 shows a schematic illustration of designed ELISA assay to test the 
functionality of the biodetectors. 
 
 
Figure 2:2 Schematic Illustration of designed ELISA assay used to test the 
functionality of the biodetectors. The wells were coated with the desired antibodies diluted 
1:100 in 100mM Carbonate/Bicarbonate buffer pH9.6) (50µl/well), blocked overnight with 3% 
BSA in SSC 0.8x pH 7.0. After the addition of the domains, the wells were washed to remove 
the unbound reagents. Biotinylated DR5 was added (5 pmol/well. dilution 1:1,000). The signal 
was generated using Streptavidin HRP conjugated, TMB substrate was then added and 
absorbance was measured at 450nm.	
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2.2.5 Pull down Assay. 
 
The pull down assay is an in vitro method used to determine a physical 
interaction between two or more proteins. The assay is useful for both 
confirming the functionality of proteins or the existence of a protein-protein 
interaction (Schechtman, Mochly-Rosen et al. 2003). A pull down assay was 
used here to assess the functionality of ProteinG constructs using streptavidin 
magnetic beads to capture and pull down the protein of interest. At first, 
streptavidin magnetic beads (4mg/ml in phosphate buffer pH7.4) (New 
England Biolab) were washed with SSC 0.8x pH7.6 and incubated for half an 
hour with 3% BSA in SSC 0.8x pH7.6 to block any unspecific binding. Bio-F4 
epitope (0.33µl/500 µl of 3% BSA in SSC 0.8x pH 7.6, Peptide stock=1mg/ml) 
was then added to the beads and incubated for another half an hour. After 
washing two times with SSC 0.8x pH7.6, F4 antibody was added and 
incubated for one hour (11.25µl/500 µl of 3% BSA in SSC 0.8x pH 7.6, stock 
1.2mg/ml). ProteinG fusion (RAR-15nm-ProteinG, 27.2pmols in 500µl, 14µl 
/500ul) was added and incubated at 4°C overnight after washing two times 
with SSC 0.8x pH7.6. To ensure interpretability of results, multiple conditions 
were tested in parallel with the appropriate positive and negative controls 
(Table 2-6). The samples were then mixed with SDS PAGE buffer containing 
1mM DTT, denatured at 90°C for 2 minutes and loaded into 12% 
polyacrylamide gel. The gel was run at 100V for 30minutes and then at 120 V 
until the dye front reached the end of the gel. 
 
The RAR-15nm-ProteinG module was detected by western blot analysis, as 
described above, using α-EE antibody, which binds the EE-tag expressed on 
the C terminus of the ProteinG module.  Figure 2:3 shows a schematic 
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Table 2-6 The multiple conditions tested in parallel with the appropriate 
positive and negative controls in the pull down assay. 	








7 µl RAR-15nm-protein G+ 7µl of 
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Figure 2:3  Illustration of the pull down assay. The functionality of ProteinG constructs 
was assessed using streptavidin magnetic beads to capture and pull down the protein of 
interest. 
 
2.2.6 Preparation of fixed cells 
 
Fixed cells were prepared for the purpose of performing various experiments, 
including testing the biodetectors functionality and proximity ligation assays 
(PLAs) in different cell lines. 13mm coverslips were sterilized with 70% 
ethanol before placing one coverslip in each well of a 24 well plate (VWR 
international). Cells were plated at a density of 2x105/well then left to adhere 
overnight at 37% in 5% CO2. As the cells attached they were washed twice 
with PBS without Ca2+ and Mg2+ (PBS -/-, PAA), serum starved by adding 
their appropriate medium without fetal bovine serum (FBS) and phenol red 
and incubated overnight at 37°C in 5% CO2. They were then washed twice 
with cold PBS-/-. Cells were left un-stimulated or stimulated with a growth 
factor either with untagged human epidermal growth factor (EGF, Peprotech) 
or recombinant human heregulinβ-1 (Peprotech), according to the experiment, 
diluted in their appropriate medium without FBS and phenol red (100nM final 
concentration) and kept for one hour at 4°C. Cells were then washed twice 
with cold PBS-/- and incubated at 37°C 5% CO2. Pre-equilibrated medium 
without FBS and phenol red was added to the cells either for 10 minutes or 30 
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minutes as indicated in the text or legends. Cells were then washed with cold 
PBS-/- twice, fixed in 4% paraformaldehyde (Alfa Aesar) for 20 minutes at 
room temperature. After washing three times with PBS with Ca2+ and Mg 2+ 
(PBS+/+, PAA), cells were stored in IFF medium (1% BSA, 2% FBS in PBS) 
(200 µl/well) and kept at 4°C.  
 
2.2.7 Testing the Biodetectors in fixed cells. 
 
Fixed cells were permeabilised in 0.2% Triton X-100 in PBS+/+ for 10 
minutes, washed three times with PBS +/+ and blocked with 3% BSA in PBS 
overnight at 4°C. After washing three times with PBS, cells were incubated 
with the primary antibody for one hour (e.g. α-phosphotyrosine Y1068 [Cell 
Signalling] diluted in 1:100 1% BSA in PBS). Following three washes with 
PBS, 0.1% Tween-20, cells were incubated with protein G domains diluted in 
1% BSA in PBS for one hour. Cells were then washed three times with PBS, 
0.1% Tween-20 then incubated with a detection antibody anti-Glu tag (CRUK) 
diluted in 1% BSA in PBS, 0.1%Tween-20. A secondary antibody anti-mouse 
AlexaFluor 488 (2mg/ml) (Life Technologies) was added diluted 1:1000 in 1% 
BSA in PBS, 0.1% Tween-20 and incubated for half an hour. Cells were 
mounted on a glass slide using Duolink in situ mounting medium with DAPI 
(Sigma). All incubations were done at room temperature in a humidity 
chamber. 
 
2.2.8 Total Internal Reflection Fluorescence (TIRF).  	
Cells were serum starved and stimulated with Epidermal Growth Factor (EGF) 
at 4ºC before fixation. The cells were incubated with α-EGFR primary 
antibody, followed by the addition of the biodetector reagents (RXR-E3-
ProteinG+RAR-G/S-PLCy). Then Cy3 labeled DR5 (3,8pmols/well) at dilution 
1:1000 was added. After incubation at RT for 1 hour the wells were washed 3 
times with 0.8x SSC pH 7 plus 0.1% Tween. The chambers were imaged 
using an objective-type based Total Internal Reflection Fluorescence (TIRF) 
microscope, (Nikon Eclipse Ti). The fluorophores Cy3 and Atto647N were 
excited with a 527nm (Laser 2000) and 642nm (Vortrand Laser Technology) 
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respectively. The fluorescence emission was spectrally separated in two 
channels and detected using EMCCD (Photometrics EVOLVE). 
2.2.9 Preparation of paraffin embedded cell pellets. 
 
Paraffin embedded cell pellets were prepared from two different cell lines, 
A431 and T47D, for PLA assay optimisation. Cells were left to grow to 70% 
confluence in a T175cm2 flask. Medium was removed by aspiration and cells 
were washed twice with 25ml PBS-/- and serum starved in their appropriate 
medium without FBS overnight at 37% in 5% CO2. Cells were then placed on 
ice and after removing the medium by aspiration, they were washed twice with 
cold PBS-/- and stimulated with EGF as described above, followed by 10 
minutes, or 30 minutes CHASE, or left un-stimulated. Following washing twice 
with 25ml cold PBS-/-, 10 ml of cold PBS -/- was added and cells were 
scraped and transferred to 50ml falcon tube, then harvested by centrifugation 
at 1,000rpm (200g) for 10 minutes at 4°C, they fixed in 4% paraformaldehyde 
for one hour at room temperature and processed by histopathology processor 
(Thermo Shandon) and embedded as paraffin blocks. 
 
2.2.10 Preparation of A431 and HCC1954 xenograft Tumour 
Models. 
 
In order to study human cancer, several murine models have been developed 
to investigate the factors involved in malignant transformation, invasion and 
metastasis, as well as to examine response to therapy. The human tumour 
xenograft is one of the most widely used models. In this model, human tumour 
cells are transplanted, either under the skin or into the organ type in which the 
tumor originated, into immunocompromised mice that do not reject human 
cells (Richmond and Su 2008). For the purpose of this study xenograft tumour 
models were prepared from A431 and HCC1954 cell lines that express high 
levels of EGFR and HER2 respectively. 
 
A431 and HCC1954 cell lines were cultured in their appropriate medium and 
kept at 37% in 5% CO2 and grown until they were near confluent (80-90%). 
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The medium was then aspirated and cells washed twice with PBS-/-. Cells 
were trypsinized for 3 minutes at 37°C. Fresh medium was added to the flask, 
the contents were transferred into 15 ml Falcon tube and centrifuged at 1000 
rpm for 4 minutes. The cell pellet was re-suspended in fresh medium and 
centrifuged again at 1000 rpm for 4 minutes. Cells were then counted using a 
Casey cell counter (Innovatis). 1.5 million of A431 and HCC1954 cells were 
re-suspended in 50µl sterile PBS-/- and injected subcutaneously into three 
female CD-1 Fox nu/nu mice (5-6 weeks old; CRL). The mice received two 
injections between the 4th and 5th nipple on either side. Tumour-bearing mice 
were kept for up to 3 weeks. Tumour volume was calculated using the formula    
v = l x (w)2/2, where v = volume, l = length and w = width of tumour. After 
three weeks, tumours were harvested, fixed in 10% buffered formalin 
overnight, processed by histopathology processor and embedded as paraffin 




Figure 2:4 lllustration of xenograft tumour model preparation. Cell lines were injected 
into female CD-1 Fox nu/nu mice. Tumours were harvested after three weeks, fixed in 10% 
buffered formalin overnight, processed by histopathology processor and embedded as 
paraffin blocks. (Image modified from http://ior.iosi.ch).  	
 
2.2.11 Tissue Microarrays (TMAs).  
 
The construction of control TMA for PLA optimization. 
 
The control TMA was constructed by Mr John Brown (Guy’s and St. Thomas 
Hospital / King’s Health Partner’s Biobank) containing 12 cores (each 2mm 
Materials & Methods                                                                           Chapter-2                                                        
  76 
diameter). Nine cases of invasive breast carcinoma with known status of 
EGFR and HER2, a positive control from the A43l xenograft tumour model, 
normal breast tissue and extra section for orientation. Paraffin embedded 
tumour tissue blocks from breast cancer cases with high expression of EGFR 
and HER2 were retrieved from the archive with the matching haematoxylin 
and eosin (H&E) slides. The area of interest on the H&E section was marked 
and matched to its approximate position in the donor block. Using manual 
arrayers (Beecher Instrument), a 2mm core of wax was removed from the 
recipient block using a stylet, before taken 2mm core from the donor block 
and place the donor in the hole using a second stylet (Figure 2-5). 
 
TMAs of invasive and DCIS cases. 
All the TMAs containing invasive breast cancer (0.6mm cores) and TMAs 
containing pure DCIS cases (2mm cores) used in this study were constructed 






Figure 2:5 TMA construction. Tissue cores obtained from donor paraffin block and arrayed 
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3 µm sections were dewaxed by immersing in xylene twice for 7 minutes each 
and rehydrated in 99% ethanol twice for 5 minutes then in 70% ethanol once 
for 5 minutes and with a final rinse in water. The slides were stained in 
Mayer’s haematoxylin (Sigma) for 10 minutes, rinsed in water, differentiated 
for 3 seconds in 1% acid alcohol, and to remove excess stain, slides were 
washed in running tap water for 10 minutes. Then slides were stained with 
eosin (Sigma) for 10 seconds and rinsed in water. Slides were rehydrated and 
cleared in three changes of ethanol and two changes of xylene respectively 
then mounted with DPX (Sigma). 
 
 
2.2.13 Immunohistochemistry (IHC) staining 
 
Antigen retrieval & IHC 
 
Dewaxing and antigen retrieval was performed by heat induced antigen 
retrieval using either MenaPath Access retrieval unit (Dako) according to the 
manufacturer’s instructions or a BenchMark ULTRA® (Ventana Medical 
Systems, Inc, Tucson, AZ) automated staining system.  
 
In Ventana Medical Systems, the tissue sections were deparaffinized at 72°C 
with EZ Prep (Ventana). For antigen retrieval, sections were heat pretreated 
in Cell Conditioning 1 (CC1: Ventana) at 95°C for 8 minutes. 
 
The HER2 protein status in breast cancer patients’ samples was determined 
by IHC using the pathway anti-HER2/neu(4B5) rabbit monoclonal antibody 
using the Ventana Ultraview DAB detection kit in the fully automated platform 
BenchMark ULTRA®, Then anti-HER-2/neu antibody (4B5) was incubated for 
16 minutes at 36°C. Antigen detection was performed using DAB Universal 
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Detection Kit Ultraview. Sections were counterstained with haematoxylin II for 
8 minutes and "Bluing Reagent" for 4 minutes more.  
 
HER1 protein status in breast cancer samples was also determined by IHC 
using the Ventana BenchMark ULTRA®. The anti-EGFR primary antibody 
(NCL-L-EGFR-384, Leica biosystems) was applied manually and incubated 
for 32 minutes at 36°C. Antigen detection was performed using DAB 
Universal Detection Kit Ultraview. Sections were counterstained with 
haematoxylin II for 8 minutes and "Bluing Reagent" for 4 minutes more.  
 	
2.2.14 Primary antibody validation 
Several primary antibodies against total EGFR, HER2 and HER3 and 
phosphorylated forms of EGFR, HER2 and HER3 were used in this study. All 
the primary antibodies were validated first for their specificity by western blot 
analysis as described before and standard Immunofluorescence (IF) in cell 
lines.   	
Validation of primary antibodies by IF in cell lines  	
Fixed cells were permeabilised in 0.2% Triton X-100 in PBS+/+ for 10 
minutes, washed three times with PBS +/+ and blocked with 3% BSA in PBS 
overnight at 4°C. After washing three times with PBS, cells were incubated 
with the primary antibody for one hour (e.g. α-EGFR mouse antibody) diluted 
in 1:100 1% BSA in PBS). Following three washes with PBS, 0.1% Tween-20, 
cells were incubated with the secondary antibody anti-mouse AlexaFluor 488 
(2mg/ml) diluted 1:1000 in 1% BSA in PBS, 0.1% Tween-20 and incubated for 
half an hour. Cells were mounted on a glass slide using Duolink in situ 
mounting medium with DAPI (Sigma). All incubations were done at room 
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2.2.15 Proximity Ligation Assays (PLAs). 
 
The PLA assays were used to study the expression, phosphorylation and 
dimerization of the HER1, HER2 and HER3 proteins in breast cancer patients. 
Figure 2:6 illustrates the final designed assays used to detect the EGFR 
family on paraffin embedded patient’s samples. The PLA assays were carried 
out using the Duo link II reagent kit (DUOLINK, Sigma) according to the 
manufacturer‘s instructions. 

































Figure 2:6. Illustration of the designed PLA assays. The assays were used to evaluate 9 
different biomarkers representing HER1, HER2 and HER3 expression, phosphorylation and 
complex formation in breast cancer patients (DUOLINK, Sigma). 
 
PLA assays in fixed cells 
 
Fixed cells were first washed twice with PBS, then permeabilized with 0.1% 
Triton X-100 (Fisher Scientific) in PBS for 10 minutes. After washing twice 
with PBS, cells were blocked with Duolink blocking agent at 37°C for half an 
hour. Cells were then incubated for one hour with the primary antibody diluted 
in antibody diluent from Duolink at room temperature, PLA plus and minus 
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probes (containing the secondary antibodies conjugated with 
oligonucleotides) were added and incubated for one hour at 37°C. Further 
oligonucleotides were added, allowed to hybridize to the PLA probes, the two 
oligonucleotides are then joined by ligase to form a closed circle. The DNA 
was amplified by polymerase (rolling circle amplification, RCA) and detection 
was carried out using the Duolink detection reagent orange, resulting in red 
fluorescence signals. The slides were mounted with Duolink in situ mounting 
medium with DAPI (Duolink, Sigma). 
 
PLA assays in paraffin embedded sections. 
 
Slides were freshly cut 3µm in depth and kept overnight at 37°C. Before 
staining, the slides were kept in the oven at 60°C for one hour. After antigen 
retrieval using the Ventana BenchMark ULTRA®, slides were stained with the 
Duolink kit as described above. 
 
2.2.16 Image Analysis and scoring 
 
Images were taken at 40x to a resolution of 0.181 μm/pixel with an Ariol SL-
50 automated slide scanner (Leica Biosystems) or captured by A1R confocal 
microscopy (Nikon imaging Center) using a 40x or 60x objective for the PLA 
images and Hamamatsu Nanozoomer for IHC. 
 
Images of three different fields of the 9 PLA variables for each case were 
taken and the intensity of in situ PLA signals per cell was measured using the 
cell image analysis software Cell Profiler from the Broad Institute (Carpenter, 







Materials & Methods                                                                           Chapter-2                                                        
  81 
 
Building an image analysis pipeline 
 
Using the Cell Profile software, I developed an image analysis tool (pipeline) 
that identifies tumour cells in tissue samples. This enabled the measurement 
of the signal intensity for each tumour cell in a region of interest and the 
results were then exported to Microsoft Excel for further evaluation 
(Carpenter, Jones et al. 2006, Weed, Walker et al. 2013).  
 
In brief, TIF images were split into the separate blue, red and green channels, 
each image was then converted into a gray scale. Nuclei were identified as 
the primary object using the blue channel (DAPI), the diameter of the nuclei 
was set between 10-100 pixels, and objects touching the border were 
discarded. The threshold was calculated manually, primary objects were 
filtered by measuring area, shape and compactness. Once the nuclei were 
identified, cells were identified as secondary objects using the Distance-N 
method in which the edges of the primary object (nucleus) are expanded and 
used to create the secondary objects. The cytoplasm was identified as the 
tertiary object, as the area included in the cells (secondary objects) but not in 
the nuclei (primary object). For each patient sample, regions of interest were 
defined and 30 cells counted from 3 different fields and the signal intensities 
measured (Figure 2-7) (Gajadhar, Bogdanovic et al. 2012). Scoring comprised 
deriving the average cytoplasmic intensity of fluorescence based on imaging 
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Figure 2:7. Image analysis. Cell profiler software was used to build up an image analysis 
pipeline. Primary objects (Nuclei) were identified using the blue channel (DAPI), the primary 
objects were filtered by measuring area shape and compactness. Cells were identified as 
secondary objects using the Distance-N method in which the edges of the primary object 
(Nuclei) were then expanded and used to create the secondary objects. The cytoplasm was 
identified as the tertiary object, as the area included in the cells (secondary objects) but not in 
the nuclei (primary object). Region of interest (ROI) were defined and 30 cells from 3 different 
fields were counted and the signal intensity were measured. 									
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2.2.17 Statistical analysis 	
All the statistical analysis used in this study was performed using either SPSS 
statistical package (Version 22 for Apple MacIntosh) or SASH v 9.3. 
 
Biological markers 
Intensity of markers was not normally distributed; therefore, markers were 
logarithmically transformed in the analysis. Additionally, a dichotomous 
categorisation of markers intensity was employed using the 75th percentile of 
intensity as the cut-off point for high and low intensity.  
 
Statistical analysis of patient data 
Spearman’s rank correlation test was performed to investigate the association 
between the continuous variables. T-tests, and one-way AONVA were 
performed to investigate the association between a patient’s clinical 
characteristics and the PLAs markers. Cox regression was performed to 
assess the association between log-transformed and categories of intensity in 
relation to Loco-regional recurrence (LRR). A multivariate model was also 
performed, adjusting for age at diagnosis. Analysis was repeated while 
stratifying for tumour characteristics at diagnosis including: histological sub-
type, T stage (i.e. size), tumour grade, lymph node status, ER, PR and HER2 
status. Associations were further visualised using cumulative incidence 
function for LRR by intensity categories.  
 
A multivariate analysis and Kaplan- Meier life tables with log rank testing were 
plotted to assess the association between log-transformed and categories of 




Bonferroni correction for multiple analyses was not performed in this study 
based on the advice of the statistician Dr. Wahyu Wulaningsihusing, although 
it is recognised that with numerous multiple comparisons, spurious 
correlations may occur. However, this is only possible if the scientific null 
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hypothesis is correct, i.e. if there is no plausible biological association 
(Rothman 1990) which is unlikely to be the case in our study. Adjusting P-
values for multiple comparisons, albeit convenient in decreasing Type I error, 
may increase Type II error and thus reduce power of detecting a true 
association (Gelman, Hill et al. 2012). Therefore, based on this advice this 
correction was not applied in these analyses. 
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3.1 Introduction 
One of the major challenges of biomedical research is the identification of 
molecular biomarkers that can be used in either diagnosis, prognosis 
and/or in predicting response to treatments. Immunohistochemistry (IHC) 
techniques are well established for the assessment of biomarkers in 
biological samples. However, the reliable assessment of these 
biomarkers has proved challenging. IHC is not well controlled; it is, at 
best, semi-quantified and frequently lacking in the specificity required for 
more challenging proteomic readouts. For example, IHC is limited to 
detecting individual proteins, preventing the analysis of interacting protein 
complexes.   
 
The EGFR receptor family members are up-regulated in different forms of 
cancer, including breast cancer, and the formation of HER dimers leads 
to the activation of multiple intracellular signaling pathways including the 
phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK pathways (Arcaro 
and Guerreiro 2007). The activation of these pathways disrupts normal 
cellular proliferation, survival, metabolism and invasion all of which 
contribute to tumour progression. For the EGFR family members, 
receptor dimerization after ligand binding is the most critical step in the 
activation of intracellular signaling cascades (Lemmon and Schlessinger 
2010). Moreover, the overexpression and co-expression of the HER 
family is linked with endocrine and chemotherapy resistance, driven not 
simply by protein expression but also by signaling via their dimer 
formation (Spears, Munro et al. 2009, Nahta 2012)  
 
This highlights the potential importance of HER family members forming 
dimers and phosphorylation rather than simple protein overexpression in 
breast cancer. Moreover, the aberrant dimerization and phosphorylation 
can be independent of receptor expression level. Therefore, methods 
which directly query signaling pathway activation, via for example 
phosphorylation assays, in breast cancer biopsies are expected to 
provide important insights into the molecular ‘‘logic’’ that distinguishes 
cancer and normal tissues. 
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There is therefore a need to develop a simple technology that reports with 
high specificity, not simply on the concentrations of proteins in patient’s 
samples, but also on their cellular distribution, partner associations and 
their post-translational modification (e.g. phosphorylation), reporting 
protein content, activity and location, that can be applied routinely in both 
research laboratories and clinical settings. Although there are 
technologies available to monitor post-translational modifications (e.g. 
FRET), the high cost and technical demands of these methods prevents 
their routine use.   
 
My objective in this thesis has been to assess the EGFR family status in 
breast cancers. To achieve this, I have needed to develop and test 
technologies that enable functional proteomic questions to be asked. In 
this Chapter the focus is on a novel development. 
 
3.2 Developing a Novel Biodetector   
 
The laboratory has been developing a novel coincidence biodetection 
technology in a format compatible with IHC whilst retaining the specificity 
of a two-site assay. The technology has the ability to detect and visualize 
proteins, protein-complexes and post translational modifications with high 
sensitivity and specificity. The biodetector is based on the principle of 
coincidence detection by which the recognition of two sites generates a 
highly specific signal. It is composed of two entirely recombinant proteins; 
each consists of: 
A - Detection modules (nuclear receptors DNA Binding Domains-DBDs);  
B - Recognition modules (protein domains such as SH2 domains and 
Protein G or A Immunoglobulin (IgG) binding domains) and; 
C - Linkers, which connect the detection module to the recognition 
module. (Figure 3:1).  
 
When the recognition module pairs bind to their specific target, for 
Developing a novel bio-detector                                                  Chapter-3 
 
  88 
example a protein backbone and its posttranslational modification, a 
specific signal is generated through the detection modules which are 
DNA binding domains, coincidence (within ~24 nm) is detected because 
the DNA binding domains of the nuclear receptors act in combinations as 






Figure 3:1 Schematic illustration of the Coincidence biodetector technology, which is 
based on two recognised targets in close proximity. Signal can only be detected when 
the two biodetectors bind their target (through their recognition modules) in proximity to 
each other and in turn are able to form a trimeric complex (through their detection 
modules) with a specific DNA sequence. As the trimeric complex is formed the signal 
can be generated through for example tagging the DNA.  
 		
3.2.1  Structure of the Novel Biodetector   
 
A- Detection Modules (nuclear receptors DBDs) 
 
For coincidence technology, attention has focused on using the 9-cis 
retinoid acid receptor (retinoid X receptor, RXR), which forms 
heterodimers with many other nuclear receptors including the all-trans 
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retinoic acid receptor RAR (Aranda and Pascual 2001). All RXR 
heterodimers preferentially bind DNA response elements composed of 
two AGGTCA sites arranged in a direct repeat (DR) configuration with an 
inter-half-site spacing of 1 to 5 base pair (bp) known as DR1, DR2, DR3, 
DR4 and DR5 respectively (Rastinejad, Wagner et al. 2000, Lefebvre, 
Benomar et al. 2010).  
 
The work has mainly focused on the heterodimer formation between the 
RXR and RAR conferring binding to the direct repeat DR5 (Figure 3:2).  
 
RXR and RAR alone display negligible binding to this site, and only when 
RXR and RAR are in close proximity, is a heterodimer formed and they 
are able to bind DNA response elements (Aranda and Pascual 2001, 
Samarut and Rochette-Egly 2012). The binding of oligonucleotide allows 
tags or amplification approaches to enable a specific coincidence signal 
to be generated in situ.  
 
Figure 3:2 Schematic illustration of the RXR-RAR DBDs heterodimer in complex with 
the DR5 DNA sequence.  
 
B-The Recognition Modules 
Recognition modules recognize the target molecule/s at two sites and 
they can consist of:  
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(A) Protein domains (such as Src homology 2 (SH2) domains as found in 
Grb2 and PLC-γ) which recognize specific post-translational modifications 
of the protein of interest (Songyang, Shoelson et al. 1993, Batzer, Rotin 
et al. 1994) 
(B) Antibody recognition domains (such as Protein G) which has the 
ability to bind to the constant (Fc) region of many mammalian 
immunoglobulins (Sjobring, Bjorck et al. 1989).  
C - The Linkers 
 
The linkers are the spacers that connect the detection modules to the 
recognition modules. These linker peptides serve to connect the protein 
fusions and can provide other functions such as maintaining cooperative 
inter-domain interactions (Chen, Zaro et al. 2013).  
 
3.2.2 The principle of the Novel Biodetector   
 
The principle of the coincidence biodetector and assay readout is 
illustrated in (Figure 3:3). Once the DNA has bound to its cognate DBDs, 
the target can be detected through several means, including: coupling of 
biotin to the DR5 oligomer in conjunction with streptavidin conjugated 
reagents, e.g. streptavidin-Horseradish Peroxidase (HRP), or by using a 
rolling circle amplification (RCA), as illustrated in (Figure 3:3), or by using 
HRP directly conjugated to the ds oligonucleotides. 
 
The aim of the work reported in this Chapter was to produce and test one 
part of the bipartite biodetector recognition modules (Protein G 
recognition modules), which would recognize the backbone of the target 
protein through an antibody. This was to be coupled with other 
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Figure 3:3. Schematic illustration representing the principle of the coincidence 
biodetector. The two detection reagents are added to the sample and incubated. A 
specific signal is generated when RXR and RAR are in close proximity and binds to DR5 
in combination with streptavidin-HRP conjugated or rolling circle amplification (RCA).   
 
3.3 Results 
3.3.1 Developing antibody recognition domains  
(Protein G modules) 
Protein G is a streptococcal cell wall protein, which has a unique 
molecular organization in that it binds to the two major serum proteins, 
albumin and IgG (Sjobring, Bjorck et al. 1991). The IgG binding property 
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has made Protein G a useful reagent in the field of research.  
Different constructs of recombinant Protein G with four different linkers 
were built in frame with RAR or RXR DNA BDs (DBDs) to create four 
different types of Protein G (ProteinG) recognition modules. This was 
designed to provide variations in distances and flexibility that would 
permit selection of a pair that gave the desired behaviour.  
The four ProteinG constructs selected were:  
1- RAR-15nm-ProteinG,  
2- RAR-G/S-ProteinG,  
3- RXR-E3-ProteinG   
4- RXR-K3-ProteinG  
Where the 15nm, G/S, E3 and K3 are the linkers, which connect the two 
fusion proteins (Figure 3:4). 
 
The selection of a suitable linker to join the ProteinG domains with RAR 
or RXR DBDs is important since each type of linker has a unique 
structure and function (Chen, Zaro et al. 2013). The longest linker (15nm) 
has an all-charged α-helical structure formed by 44 amino acids flanked 
at the N-terminal end with 3-Glycines-1 arginine (~1.5nm) and at the C-
terminal end with 2-Glycines-3 serine (~2nm). The shorter linker G/S 
(9nm) is a flexible linker, which contains a glycine-serine sequence but no 
α-helical structure. IAAL-E3 and IAAL/K3 are rigid linkers (~12nm) with α-
helical structures consisting of tightly packed hydrophobic cores flanked 
on either side by charged residues (Litowski and Hodges 2002).  
 
Small monomeric tags in the form of His, EE and S were added to the 
recognition modules to allow the detection of the domains.   
 
(The pENTRY clones used for the production of ProteinG modules were 
constructed previously by Dr Michela Perani, please refer to Chapter 2).  
 
(See appendix for the full-length sequences).  		
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Figure 3:4.  Schematic illustration representing the bio-detector, consisting of detection 
modules and recognition modules that are connected with a linker. Four different 
constructs of Protein G reagent were cloned and purified: RAR-15nm-ProteinG, RAR-
G/S-ProteinG, RXR-E3-ProteinG and RXR-K3-ProteinG. 	
 
3.3.2 Cloning and purification of the biodetector  
reagents 
 
ProteinG modules were cloned and assembled using the Multisite 
Gateway Three Fragment Vector construction Kit (Invitrogen). The pGEX-
4T1 vector expressing the glutathione S-transferase (GST) gene was 
used to clone and purify ProteinG recognition modules (please refer to 
Chapter 2). Protein samples were collected at each step of the 
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purification and analyzed by SDS-PAGE. Figure 3:5 represents the 
results obtained from RAR-G/S-ProteinG purification, other purifications 
results showed very similar patterns of behaviour. As can be seen from 
the coomassie stained gel, the expression of the GST-protein fusion was 
nicely induced (compare lane1 - un-induced to lane 2 - induced). The 
insoluble fraction was separated from the soluble fraction by 
centrifugation (lane 3 - insoluble and lane 4 - soluble).  Lysates were 
incubated with GST- beads, and then washed to remove any unbound 
reagents. GST-protein fusions were cleaved by 3C protease for three 
hours to produce a vector free protein (cleaved protein elution 1 and 2, 
were collected by centrifugation) and then the samples were left to cleave 
overnight (GST-free protein elution 3 and 4) (please refer to Chapter 2). 
The bands of the cleaved proteins can be seen running at the 
approximate molecular weight of 35 kDa (green arrow) (lanes 8, 9, 11 
and 12 represent elutions 1, 2, 3 and 4 respectively) (estimated MW of 
RAR-G/S-proteinG is 32 kDa). We can also observe the decrease in the 
protein amount recovered after each elution. To monitor the amount of 
protein recovered, the beads were collected twice, lanes 10 and 13 after 
3 hours and overnight cleavage respectively. A fraction of the GST-
tagged protein fusions is still not cleaved after 3 hours (at 72 kDa, red 
arrow). In addition, the cleavage resulted in the appearance of three 
bands; 3C protease, GST-free protein and GST tag at approximately 43, 
35 and 27 kDa respectively.  
Protein concentrations for each eluted fraction was determined and 
calculated using BSA as a protein standard as described in Chapter 2. It 
appears that ProteinG fusion proteins were successfully purified, with the 
bands on the gel corresponding to the expected MW following cleavage. 
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Figure 3:5  SDS-PAGE analysis of one of the ProteinG recognition modules (RAR-
G/S-ProteinG) purification. The pGEX-4T1 vector expressing the glutathione S-
transferase (GST) gene was used to clone and purify RAR-G/S-ProteinG. Cells were 
induced with IPTG and harvested by centrifugation at 3000g for 15 minutes at 4°C, the 
cell pellet was lysed using Bug Buster reagent (Novagen) according to the 
manufacturer’s instructions. Fractions were collected from each of the purification steps 
and assayed for proteins by 12% SDS-PAGE. The gel was stained with Coomassie Blue 
Stain Reagent. Lane 1 un-induced whole cell lysate, (lanes 2 -13 IPTG induced). Lane 2 
whole cell lysate, lane 3 insoluble fraction, lane 4 soluble fraction, lane 5 flow through, 
lanes 6 and 7 washes 1 and 5 respectively, lanes 8 and 9 cleaved protein collected by 
centrifugation after being cleaved for 3 hours with 3C protease, running at MW of 35 
(green arrow). Lane 10 beads 1 a fraction of the GST-tagged protein fusions is still not 
cleaved after 3 hours (at 72 kDa, red arrow), Lanes 11 and 12 cleaved protein   
collected by centrifugation after being cleaved overnight with 3C protease, Lane 13 
beads 2. M molecular marker. 									
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3.3.3 Testing the functionality and specificity of the 
ProteinG recognition modules 
 
In order to investigate the functionality of the four purified protein G 
reagents, designed enzyme-linked immunosorbent assays (ELISA) were 
used here to test the functionality of the purified domains due to the high 
sensitivity and specificity of this method compared to other 
immunoassays methods. 
 
ELISA experiments were carried out to test the DBDs functionality and 
coincidence dependence – the criterion of success for the latter was set 
at a signal-to-noise ratio of >5x.  
 
At first, the RAR-15nm ProteinG construct was tested paired with one of 
the SH2 domain reagents (RXR-E3-Grb2-MYC supplied by Dr.Michela 
Perani). The two fusion proteins were captured on an antibody coated 96 
well ELISA plate. Reagents were captured using a combination of α-EE 
and α-MYC antibodies, which recognize the tags expressed at the C-
termini of RAR-15nm-ProteinG and RXR-E3-Grb2-MYC respectively. In 
addition, RAR-15nm-ProteinG also binds to the antibody Fc region 
(Figure 3:6 A). As described, a signal can only be generated when the 
two RAR/RXR domains are in close proximity (~24nm) and bind to their 
target DNA sequence DR5. Two elutions from the purification of the RAR-
15nm-ProteinG module were tested: elution1 (E1), which was obtained 
following cleavage by 3C protease for 3 hours at 4°C and elution3 (E3), 
which was, generated after overnight cleavage.  
 
As can be observed in (Figure 3:6 B), there is clear evidence of 
coincidence readout, but both elutions showed high background in the 
RAR-only condition yielding a low signal to noise ratio (< 2 fold). By 
comparison the batch of the RXR-EE-Grb2-MYC employed showed 
minimal background on its own. Therefore, several assays including 
ELISAs and pull down assays were carried out to test RAR-15nm-
ProteinG for functionality. At the same time several ELISA assays were 
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carried out to test other ProteinG constructs, with different linkers under 
different assay conditions seeking to find a configuration that gave a 
strong coincidence signal with low background. 
	
Figure 3:6. The functionality of the DBDs was tested by ELISA. A - Schematic 
Illustration of the experimental method. B - RAR-15nm-ProteinG was investigated in 
combination with RXR-EE-Grb2-MYC. The wells were coated with anti-EE and anti-MYC 
antibodies diluted 1:100 (4.6 pmol/well) in 100mM carbonate/bicarbonate buffer pH9.6) 
(50µl/well), blocked overnight with 3%BSA in SSC 0.8x pH 7.0. After the addition of the 
domains, (2.72pmol/well), the wells were washed to remove the unbound reagents. 
Biotinylated DR5 was added (5 pmol/well. dilution 1:1,000). The signal was generated 
using streptavidin HRP conjugated. TMB substrate was then added and absorbance 
was measured at 450nm.  	
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3.3.4 Investigating the specificity and functionality of the 
fused ProteinG recognition module. 
 
A pull down assay technique was employed here to determine the 
interaction between the ProteinG module of the fusions and 
immunoglobulins, and thus the functionality of the ProteinG module. The 
binding to the F4 antibody was tested, and this retention was monitored 
by, F4 antibody binding to the Bio-F4 peptide antigen. The latter was 
captured by streptavidin magnetic beads (see schematic illustration in 
Figure 3:7 A).  
 
The beads were first incubated with 3% BSA to block unspecific binding. 
The RAR-15nm-ProteinG module was detected by western blot analysis 
using α-EE antibody, which binds the EE-tag expressed on the C 
terminus of the ProteinG module. Figure 3:7 (B) shows the western blot 
analysis of the pull down assay; lanes 1, 2, 3 represent a serial dilution of 
the amount of RAR-15nm-ProteinG alone loaded in the gel. It is 
equivalent to 100% (1.2µg), 10% (0.12 µg) and 1% (0.012 µg) 
respectively of the amount used in the pull down assay positive control 
(lane 4) (the estimated MW of RAR-15nm-ProteinG is approximately 40 
KD). As can be observed from the gel band, the amount of ProteinG 
module bound to the F4 antibody and recovered in the pull down assay is 
almost half the actual amount used in the experiment (compare lane 4 to 
lane 1). In (Figure 3:7 B - lane 4), we can also detect three bands running 
at 50, 25 and 42 representing the F4 antibody heavy chain, light chain 
and ProteinG module respectively.  
 
This observation indicates the ability of ProteinG module to bind to the Fc 
region of F4 antibody and proves the functionality of ProteinG module as 
an IgG binding module. Interestingly a small fraction of ProteinG showed 
unspecific binding to the beads in the absence of F4 antibody as 
observed in (Figure 3:7 B - lane 5); this represented ~10% of the input. 
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Figure 3:7. A - Schematic illustration of the pull down assay. B - Pull down assay: 
lanes 1, 2, 3 represent the amount of RAR-15m-ProteinG alone loaded in the gel which 
is equivalent to 100% (1.2µg) 10%(0.12 µg) and 1% (0.012 µg), respectively, of the 
amount used in the pull down assay positive control. (The estimated molecular weight of 
RAR-15m-ProteinG is almost 40kDa). Lane 4 - pull down assay positive control (RAR-
15m-ProteinG + F4Ab + Bio-F4 + streptavidin magnetic beads. Lane 5 and 6 - negative 
controls streptavidin magnetic beads + Bio-F4 peptide + RAR-15m-ProteinG (without F4 
antibody) and streptavidin magnetic beads + Bio-F4 peptide + F4Ab (without RAR-15m-
ProteinG) respectively. The molecular weights of the antibody heavy and light chains are 
observed at 50 and 25 kDa respectively (red arrows show the light chains at 25 kDa). 
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3.3.5 Comparing the functionality of RAR-15nm-ProteinG 
Vs. RAR-G/S-ProteinG. 
 
Previous experiments showed that the purified RAR-15nm-ProteinG is 
functional and able to bind the Fc region of the antibody of choice, as 
shown by the pull down assay. However, there was evidence of 
unspecific binding and in the following experiments, another RAR-
ProteinG construct with a different linker (RAR-G/S-ProteinG) was tested 
and compared with RAR-15nm-ProteinG. The two ProteinG modules 
were tested in a coincidence detection method paired with RXR-EE-Grb2-
MYC in an ELISA. As can be seen from the ELISA results shown in 
Figure 3:8, there is a coincidence readout using the RAR-15nm-ProteinG 
paired with SH2 domains, but with low signal to noise ratio, which is 
consistent with previous results (see Figure 3:6). No coincidence signal 
was detected using RAR-G/S-ProteinG. This could be due to the 
saturation limit at these reagent concentrations, the amount of RAR-G/S-
ProteinG module used for these experiments (2.72pmol/well) (Figure 3:8).  
 
Further ELISA experiments were carried out to investigate the reasons 
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Figure 3:8. The functionality of RAR-G/S-ProtG was tested in comparison with 
RAR-15nm-ProtG. ProteinG fusions were paired with RXR-EE-Grb2-MYC. The wells 
were coated with α-EE and α-MYC antibodies diluted 1:100 (4.6 pmol/well) in 100mM 
carbonate/bicarbonate buffer pH9.6) (50µl/well), blocked overnight with 3%BSA in SSC 
0.8x pH 7.0, after the addition of the domains, biotinylated DR5 was added (5 pmol/well, 
dilution 1: 1,000). The signal was generated using a streptavidin-HRP conjugate, TMB 
substrate was then added and absorbance was measured at 450nm.   
 
3.3.6 Is RAR-G/S-protein G module functional ? 
 
According to the previous ELISA results, no coincidence signal was 
detected with RAR-G/S-ProteinG module compared to RAR-15nm-
ProteinG. The following ELISA experiments were carried out using 
titrations of RAR-G/S-proteinG module to determine its functionality and 
the optimum amount that might give a better signal-to-noise ratio. RAR-
G/S-proteinG module was paired with RXR-EE-Grb2-MYC. Reagents 
were captured using α-EE and α-MYC antibodies. As can be seen in 
(Figure 3:9), there is some evidence of coincidence readout at 
intermediate concentrations (at 1.36 and 0.68 pmol/well), which indicates 
that the RAR-G/S- ProteinG module is functional. However, the signal-to-
noise ratio observed was low (< 2 folds) which was not satisfactory.    
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Figure 3:9.  The functionality of RAR-G/S-protein G was investigated using titrations of 
the protein fusion paired with RXR-Grb2-MYC. ELISA plates were coated with α-EE and 
α-MYC antibodies. Blocked with 3% BSA, serial dilutions of RAR-G/S-proteinG was 
used. Biotinylated DR5 was added (5 pmol/well, dilution 1: 1,000 from stock 100 pmol/µl 
in H2O). The   signal was generated using streptavidin HRP conjugated, TMB substrate 
was then added and absorbance was measured at 450nm.   
 
Although we were able to demonstrate the functionality of the purified 
RAR-ProteinG modules as an IgG binding fusion, the high background 
remains a challenge. A hypothesis has been raised that the primary 
antibody used to detect Protein-G modules was not a suitable choice. In 
previous ELISA experiments we used α-EE tag antibody, which can 
recognize and bind Protein-G modules through two different sites at the 
same time located on the same antibody, the EE-tags and the Fc regions 
(for a total of 4 sites) (Figure 3:10).  
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Figure 3:10. Protein-G modules can bind α-EE tag antibody through two different sites 
at the same time, the EE-tags and the Fc regions. For a total of 4 sites located on the 
same antibody. 
 
We hypothesized that there is a high probability of RAR DBD forced 
dimerization due to close proximity of up to four RAR DBDs that can bind 
to the same antibody at the same time.  
 
To explore this hypothesis, the following experiments were undertaken to 
evaluate the binding of ProteinG modules to Bio-DR5 using two different 
antibodies, F4 antibody that binds the ProteinG modules through only the 
Fc regions in addition to the α-EE antibody, as above.  
 
In these experiments I used the RAR-G/S ProteinG module alone with 
serial dilutions of F4 and α-EE antibodies starting with the highest 
concentration used in the previous experiments (4.6pmol/well).    
 
Figure 3:11 shows that RAR-G/S-ProteinG generated a signal in the 
absence of RXR fusions and potentially confirming the theory that a 
forced dimerization could be the reason for the high background 
observed in previous experiments. Interestingly, we can also observe (in 
Figure 3:11) a difference in the signal generated while using the two 
Developing a novel bio-detector                                                  Chapter-3 
 
  104 
different antibodies. When using the F4 antibody we observe a linear 
decrease of the signal by lowering the antibody concentration compared 
to α-EE antibody, confirming the hypothesis that using α-EE antibody in 
the previous experiments was not a suitable option and it could be a 
reason for the increased background.  
 
Since RAR-ProteinG fusions showed high background in the previous 
experiments, more assays were carried out to investigate different 




Figure 3:11. RAR-G/S was tested in ELISA experiments using F4 and α-EE antibodies. 
ELISA plates were coated with serial dilutions of F4 and anti-EE antibodies. Blocked 
with 3% BSA, biotinylated DR5 was added (5 pmol/well, dilution 1:1,000). The signal 
was generated using streptavidin HRP conjugated. TMB substrate was then added and 
absorbance was measured at 450nm. 
 
3.3.7 Testing RXR-protein G modules. 
 
Although we were able to identify some of the issues that could cause the 
high background in previous investigations, the problem still existed. 
More questions were raised about the stability of the purified fusions, 
which was investigated in the following experiments. RXR-E3-ProteinG 
and RXR-K3-ProteinG constructs were tested for functionality paired with 
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RAR-15nm-ProteinG in ELISA assays. The reagents were captured on 
wells using F4 antibody. Due to the lack of the previous batch of RAR-
15nm-ProteinG reagent (i.e. an old batch), a new batch of RAR-15nm-
ProteinG reagent was paired with RXR-K3-ProteinG to investigate the 
stability of the fusion proteins.  
 
Interestingly, we can detect differences in RAR-15nm-ProteinG 
background (Figure 3:12). The new batch of the RAR-15nm-ProteinG 
showed a high signal (5 fold) to noise ratio (Figure 3:12 B) in comparison 
to the old batch of RAR-ProteinG reagent (Figure 3:12 A). This 
observation leads to the conclusion that RAR-ProteinG can lose/alter 
functionality if used after a prolonged period of storage at -20°C 
(repeated freezing and thawing can affect the structure or reduce the 
biological activity of the purified proteins). Also we can observe that RXR-
ProteinG constructs gave a better signal to noise ratio in comparison with 
RAR-ProteinG modules. 
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Figure 3:12. Testing the functionality of RXR-E3-ProteinG and RXR-K3-ProteinG. 
RXR-E3-ProteinG was paired with RAR-15nm-ProteinG (using an old RAR-15nm-
ProteinG batch) and RXR-K3-ProteinG was paired RAR-15nm-ProteinG (using new 
RAR-15nm-ProteinG batch). ELISA plates were coated with F4 antibody. Blocked with 
3% BSA, biotinylated DR5 was added (5 pmol/well, dilution 1:1,000). The signal was 
generated using streptavidin HRP conjugated. TMB substrate was then added and 
absorbance was measured at 450nm.  			
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I carried out further investigations to test RXR-ProteinG domains paired 
with RAR-G/S-ProteinG. The modules were captured using the maximum 
and minimum amounts of F4 antibody that gives a readable signal 
empirically tested previously (4.6pmol/well and 0.575pmol/well 
respectively). Here in (Figure 3:13 A), we can observe that RXR-E3-
ProteinG gave a better signal-to-noise ratio, which is consistent with the 
previous results, in contrast to RXR-K3-ProteinG (Figure 3:13 B) and 
RAR-G/S-ProteinG. Also, we can observe some inconsistency in the 
signal. The source of this variation was attributed to the different batches 
of BSA used. A number of different types of BSA were then tested (data 
not shown). The batch and the level of purity of BSA used made a 
significant difference to variability within duplicate wells. BSA with a ≥98% 
purity and suitable for ELISA applications was then chosen, giving more 
robust and reproducible results.  
 
In addition, different ELISA experiments were carried out using different 
conditions in an attempt to reduce the background that include increasing 
the washing times and using different concentrations of oligonucleotides 
(DR5) but it did not solve the problem of the high background produced 
by the ProteinG modules. However, the high background observed in the 
previous ELISA assays which could be driven by forced dimerization of 
the ProteinG fusions as explained earlier, make ELISA assays limited in 
this setting. The problem of high background cannot be reduced by 
diluting the capture reagents to a much lower level without completely 
losing the possibility of coincidence capture, since the captured detectors 
will be too far apart. Therefore, fixed cell lines were used to investigate 
the functionality of the ProteinG constructs and the ability to visualize the 
target protein using the biodetectors.  
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Figure 3:13. Testing the functionality of RXR-E3-ProteinG and RXR-K3-ProteinG 
constructs. Both RXR-proteinG domains were paired with RAR-G/S-Protein G. ELISA 
plates were coated with F4 antibody. blocked with 3% BSA, biotinylated DR5 was added 
(5 pmol/well, dilution 1:1,000). The signal was generated using streptavidin HRP 
conjugated, TMB substrate was then added and absorbance was measured at 450nm.  
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3.3.8 Can Protein-G fusions detect target proteins in fixed 
cells? 
 
ProteinG fusions were applied to investigate their ability to visualize the 
epidermal growth factor receptor (EGFR) in A431 cell lines. The A431 cell 
line is a human epidermoid carcinoma that highly expresses EGFR (2-
3x106   receptors /cell) (Imai, Leung et al. 1982) and they are therefore 
suitable to be used for optimization of the biodetection protocols, ensuring 
many binding sites for the biodetectors. Here, we demonstrate the results 
obtained from testing RXR-E3-ProteinG (Figure 3:14), which gave 
encouraging results when applied on ELISA assays and cell lines, 
compared to other ProteinG modules (Figure 3:15).  
 
A431 cells were serum starved and stimulated with epidermal growth 
factor (EGF) at 4ºC before fixation to prevent receptor internalization. 
Cells were incubated with α-Y1068 primary antibody (which recognizes 
the phosphorylation site Y1068 on EGFR). RXR-E3-ProteinG-EE was 
added to the cells followed by the addition of α-EE antibody (mouse 
antibody), which was detected by Alexaflour 488 (goat anti-mouse IgG 
antibody) (see experiment illustration in Figure 3:14). The results show 
the functionality of the RXR-E3-ProteinG module by detecting the target 
protein (EGFR) in fixed cells. This is shown by the signal around the 
plasma membrane in stimulated cells (Figure 3:14 A&B) in comparison to 
the unstimulated cells (Figure 3:14 C). However, there was unspecific 
binding of the Protein-G module evident in the nuclear staining.   
 
The functionality of the RXR-E3-ProteinG construct was proven by the 
successful detection of our target protein in A431 cell lines using this 
novel biodetector. Therefore, this construct was chosen for further 
experiments in fixed cells to test RXR-E3-ProteinG module functionality in 
a coincidence detection method paired with an SH2 domain (RAR-G/S-
PLCγ).  
	
There was, nevertheless, strong nuclear signal with no foreground signal 
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(data not shown). This nuclear background could be attributed to the 
unspecific binding of the RXR and RAR DNA binding domains to the 
nucleus or the unspecific binding of the oligonucleotides sequences. 
Many attempts were made to resolve the nuclear background but without 
success. 
 
Figure 3:14. RXR-E3-Protein G functionality was tested on A431 cell line. Cells were 
stimulated with EGF (100nM) for one hour followed by CHASE for 10 minutes at 37°C 
before fixing with 4% paraformaldehyde for 20 minutes. Cells were permeabilised and 
Incubated with primary antibody Y1068. The proteinG fusion was added then the 
secondary antibody anti-EE which was detected by Alexa flour 488 secondary antibody. 
A & B. EGF-stimulated cells incubated with the proteinG fusion; C. - unstimulated cells 
incubated with proteinG fusion; D. - EGF stimulated cells without the addition of 
proteinG fusion; E & F. without  primary and secondary antibodies respectively. Images 
were captured using an epi-fluorescence microscope at X40 magnification. Illustration of 
the method principle is shown in the diagram above. 
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Figure 3:15. Two examples of the results obtained from testing RAR-ProteinG modules 
in A431 cell lines. RAR-Protein G functionality was tested on A431 cell line. Cells were 
stimulated with EGF (100nM) for one hour followed by CHASE for 10 minutes at 37°C 
before fixing with 4% paraformaldehyde for 20 minutes. Cells were permeabilised and 
Incubated with primary antibody Y1068, the proteinG fusion was added then the 
secondary antibody anti-EE which was detected by Alexa flour 488 secondary antibody. 




3.3.9 Visualizing the Coincidence Detection Signal in Fixed 
Cells with Total Internal Reflection Fluorescence 
Microscopy (TIRFM) 
 
To prove the concept of the coincidence detection method and to avoid 
the background given in the previous experiments, the TIRF method was 
used. TIRF microscopy is a suitable method for the study of cellular 
membranes and their environment. It uses the evanescent field 
generated by total reflection to excite fluorophores. Instead of illuminating 
an entire specimen with excitation light, as in epifluorescence 
microscopy, the evanescent field only penetrates the specimen to a depth 
of 70–300 nm. Fluorochromes at deeper levels of the specimen are not 
excited (Axelrod 2008, Mattheyses, Simon et al. 2010). This method 
allows for a considerably improved signal-to-noise ratio, providing a better 
quality of results. Figure 3:16 illustrates TIRF principle in comparison with 
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epifluorescence microscopy.  
Using TIRF microscopy, the Coincidence Detection method was applied 
to T47D cell lines to visualize phosphorylated EGFR. Since the major 
background problem was localized to the cell nucleus, the cells were 
visualized with TIRF, in order to focus on the signal confined to the 
plasma membrane where we expected to find activated EGFR and to 
exclude the background signal of the nucleus.  
 
Cells were serum starved and stimulated with epidermal growth factor 
(EGF) at 4ºC before fixation. The cells were incubated with α-EGFR 
primary antibody, followed with the addition of the biodetector reagents 
(RXR-E3-ProteinG+RAR-G/S-PLCy); then Cy3 labeled DR5 (Please refer 
to Chapter 2).  
In Figure 3:17 we can clearly see detection of phosphorylated EGFR 
using the Coincidence method, shown as spots localized in the plasma 
membrane when using all the reagents (Figure 3:17 A). The fluorescence 
intensity of the signals was thresholded and calculated using image 
analysis software developed in Labview by Dr Simon Poland. (see Figure 
3:17 B & C). In Figure-13:7 C we can see an increase in signal-to-noise 
ratio. The amount of signal detected when using all the reagents is almost 
8 fold higher than the amount of signals detected by using RXR or RAR 
alone. We can also observe that the signal generated when adding RAR 
and RXR alone was at the background level when compared to no 
domains addition. This background signal may be caused by the non 
specific adhesion of the fluorophore dye used to the glass cover slip 
(Zanetti-Domingues, Tynan et al. 2013).  
These results provide a proof of concept of the coincidence detection 
technology and the functionality of the two biodetectors when applied in a 
coincidence detection method. Moreover, the results indicate the 
sensitivity of the biodetectors and their ability to detect low number of 
receptors. T47D cells are known for having a low number of EGFR 
(approximately 7,000 receptors/cell), which by standard fluorescent 
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methods is too low to be visualized.  
By using TIRF microscopy we were able to demonstrate the concept of 
the coincidence detection method in fixed cells, avoiding the visualization 
of background noise that we have in the cell nucleus. However, one of 
the crucial points for the coincidence technology is that we aim to acquire 
information from all the different cell compartments from the plasma 
membrane to the cell nucleus and TIRF confines visualization to the 
plasma membrane. Another drawback is that TIRF imaging requires a 
microscope with specific settings which hinders the simple use of the 
biodetector in any research laboratory or clinical setting. 
In order to address and tackle the problems of the high background in this 
coincidence detection technology more effectively, another approach was 
taken. This involves simplifying the assay into a single capture detection 
method as a more efficient way to optimize the methodology with reduced 
background.   
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Figure 3:16. Schematic illustration of TIRF principle in comparison with 
epifluorescence microscopy. (A) Epifluorescence. The excitation beam travels directly 
through the cover-slip–sample interface and all of the fluorophores in the entire sample 
are excited. (B) TIRF. The excitation beam enters from the left at incidence angle θ, 
which is greater than the critical angle, θc (indicated by the dashed line). The excitation 
beam is reflected off the cover-slip–sample interface and an evanescent field is 
generated on the opposite side of the interface and only fluorophores in the evanescent 
field are excited (indicated with the green colour). Image from (Mattheyses, Simon et al. 
2010).   
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Figure 3:17. The Coincidence detection method was applied in the T47D cell line to 
detect phosphorylated EGFR using TIRF microscopy. Cells were serum starved and 
stimulated with (EGF) at 4ºC before fixation. The cells were incubated with α-EGFR 
primary antibody before adding the biodetector reagents. A - 1 the coincidence detection 
method (RXR-E3-ProteinG+RAR-G/S-PLCy), A - 2, 3 & 4 negative controls. B & C 
Quantification of the signal and the graph representing the signal intensity calculated 
(Data supplied by Dr Michela Perani). 	
 
3.3.10 The single capture method 
 
Single capture technology is, as the name implies, composed of only one 
biodetector binding an antibody or a post-translational modification of 
choice. Here it is composed of ProteinG coupled by a linker (-G/S peptide 
or –E3 peptide sequence) to a DNA binding domain Zif268 that belongs 
to the Cys2His2 zinc finger group of transcription factors. This class of 
zinc fingers was chosen since it is the most studied and characterized 
class of zinc fingers, making it a desirable choice. Zif268 structurally 
contains three zinc fingers recognizing the sequence (5’-GCGTGGGCG-
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3’) where each one of them recognizes a nucleotide sequence of 3 base 
pairs (bp) on one of the DNA helix strands (Jamieson, Kim et al. 1994, 
Elrod-Erickson, Benson et al. 1998).  
For a bound domain, a signal can be generated by sequential addition of 
a double stranded DNA sequence comprising the Zif268 consensus 
sequence coupled to biotin (BIO) or horseradish peroxidase (HRP). 
Signal can be visualized under a fluorescent microscope/confocal 
microscope using a fluorescent substrate (e.g. Tyramide Signal 
Amplification (TSA) plus Cy3 substrate) (Schematic illustration of the 
single capture is shown in Figure 3:18). 
 
 
Figure 3:18. Schematic Illustration of the single capture bio-detection method. 
   
 
3.3.11 Designing and cloning different constructs of 
proteinG recognition modules   	
One of the questions raised while testing the biodetectors is the binding 
affinity of proteinG domains and whether it varies depending on the 
properties and numbers of ProteinG binding domains. We hypothesized 
that a ProteinG with 3 binding domains could provide better antibody 
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binding with higher affinity. Therefore, two different ProteinG constructs 
with 2 and 3 binding domains were made for the single capture method 
and compared. The two different recognition modules for the bio-detector 
PrGC1C3-S-EE-HIS and PrGC1C2C3-S-HA-MYC were designed to 
investigate the choice of recognition module and the best binding affinity. 
Both ProteinG modules are linked with a Glycine-Serine (G/S) linker to 
the zinc finger DNA binding domain Zif268, which is identical for the two 
constructs. 
The full bio-detector Zif268-G/S-PrGC1C3-S-EE-HIS has a ProteinG with 
two binding domains (C1C3) with S-EE-HIS tags attached at the C-
terminal end of the ProteinG sequence, whereas Zif268-G/S-
PrGC1C2C3-S-HA-MYC has a ProteinG with three binding domains 
(C1C2C3) with the S-HA-MYC tags attached in the same position (see 
Figure 3:19).  
Different tags have been chosen for the two constructs for the purpose of 




Figure 3:19. ProteinG 2 domains vs. ProteinG 3 domains. Schematic illustration of 
hypothetical ProteinG binding configurations. The Fc binding region of the ProteinG is 
consisting of either 2 or three C domains (55 amino acids each) the C regions are 
connected with one (ProteinG 2 domains) or two (ProteinG 3 domains) 15 amino acid 
residues called D1 and D2. 
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3.3.12 Testing the functionality of the ProteinG 2D and 3D 
recognition modules 	
The functionality of the purified 2D and 3D ProteinG recognition modules 
were tested first in designed ELISA experiments (carried out by Dr. 
Michela Perani and Dr. Ester Pfeifer) and the results indicate the 
functionality of the two purified proteins tested (data not shown). 
However, in order to investigate if there was any functional differences 
between the Zif268-G/S-PrG 2D and Zif268-G/S-PrG 3D, several ELSA 
experiments were undertaken with a range of biodetector concentrations.  
 
3.3.13 Comparing the functionality of ZIF268-G/S-PRG 2D 
VS. 3D 
ELISA plates were coated with rabbit serum (dilution 1:100), since it is 
affordable for large ELISA experiments, before the addition of the purified 
domains at different concentrations with a starting concentration of 
0.3pmol/well. The results (Figure 3:20) show a difference in signal 
intensity when comparing Zif268-PrG-2D (green) vs. 3D (blue). This can 
be an indication of higher binding affinity for Zif268-PrG 3D and that a 
lower concentration is needed for Zif268-PrG-3D vs. Zif268-PrG-2D to 
reach an equilibrium. Thus, a new set of serial dilutions was assessed, 
increasing the range of protein concentration from 6.25 to 400 
fmoles/well. 
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Figure 3:20.  Testing the functionality of Zif268-G/S-PrG 2 and 3 domains using 
serial dilutions (1.563-100 fmoles/well) in an ELISA experiments. The ELISA plate 
was coated with rabbit serum dilution 1:100, with incubation with TMB for 10 minutes. 
(Data supplied by Dr. Michela Perani). 	
The graph for the fourfold concentration increase is shown in Figure 3:21. 
By looking at the Zif268-PrG 3D there are indications of the signal 
reaching to a maximum and starting to plateau. The Zif268-PrG 2D still 
shows linearity and does not show any signs of reaching plateau. A final 
attempt was made to further increase protein concentration. In a third set 
of dilution series the concentration range was increased from 6.25-
1600fmoles/well. 1600fmoles is a very high concentration to use, but this 
exaggeration was applied to ensure saturation. At this final range of 
concentrations, the experiments were repeated three times and the 
results are outlined in Figure 3:22. From the figure we can observe that 
Zif268-PrG 3D and Zif268-PrG 2D have reached a plateau. The previous 
sets of ELISA results show some differences between the PrG 2 vs. 3 
domains, suggesting a higher affinity for Zif268-PrG 3D and a higher 
concentration of the Zif268-PrG 2D was required in order to reach the 
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same relative signal as Zif268-PrG 3D.   
	
Figure 3:21. ELISA results with serial dilutions (6.25-400fmoles/well) of Zif268-G/S-
PrG 2 and 3 domains. The ELISA plate was coated with rabbit serum, dilution 1:100, 
with incubation with TMB for 10 minutes. Three independent experiments were done 
with the error bars corresponding to the standard deviation (Data supplied by Dr. 
Michela Perani). 
 
Figure 3:22. ELISA  results with serial dilutions (6.25-1,600 fmoles/well) of Zif268-
G/S-PrG 2 and 3 domains. The ELISA plate was coated with rabbit serum, dilution 
1:100, with incubation with TMB for 10 minutes. Three independent experiments were 
done with the error bars corresponding to the standard deviation (Data supplied by Dr. 
Michela Perani). 
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 3.3.14 Using the single capture technology to detect 
target proteins in tumour samples 
 
To test the utility of the single capture biodetector previously shown to be 
functional in ELISA assays, we aimed to apply the technology in fixed 
cells and paraffin embedded tumour tissues. The aim for the developed 
biodetector is to provide a highly sensitive and specific method. 
Therefore, various techniques have been investigated for the detection 
and visualization of the signal in the single detection technology. Initially 
Rolling Circle Amplification (RCA) was investigated as the main signal 
detection method. However, RCA could not be achieved efficiently and it 
was, therefore, decided to use an enzyme (horse radish peroxidase, 
HRP) -based amplification for the signal. For this purpose, Tyramide 
Signal Amplification (TSA) was chosen. TSA is an enzyme-mediated 
detection method that uses horseradish peroxidase (HRP) to generate 
high-density labelling of a target protein or nucleic acid in situ (Litt and 
Bobrow 2002, Faget and Hnasko 2015). This technology can be used 
with Alexa Fluor dyes, conventional fluorescent dyes, or colorimetric 
detection systems; the fluorescent signal can then be visualized with 
standard fluorescent microscopy. Several experiments were carried out to 
test and optimize the single capture technology using the TSA detection 
method.  
 
The optimization was carried out using different cell lines and xenograft 
tumour models under various conditions. An optimized protocol was 
established for the single capture technology that showed clear positive 
results with minimum background, which was consistent in all the 
investigations. 
 
I applied the optimized single capture protocol to detect HER2 receptors 
in HCC1954 xenograft tumour model (HCC1954 is an invasive ductal 
carcinoma cell line that highly expresses HER2 receptors) using Zif268-
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ProteinG 3D vs 2D in parallel with standard Immunofluorescence (IF).  
Tumour sections were cut at 3μm and antigen retrieval was performed 
using MenaPath Access retrieval unit (Dako). Sections were incubated 
with the primary antibody (α-HER2 antibody) before adding the 
biodetectors and the signal was visualized using TSA detection method 
or proceeding with the IF standard protocol (see Chapter 2).  
 
In Figure 3:23 both Zif268-ProteinG 3D and 2D were able to detect HER2 
receptors in a single detection method shown by the specific signal 
observed around the plasma membrane (Figure 3:23 A&C). Moreover, 
we can also observe that the single capture method showed higher 
sensitivity in detecting the target protein compared to the standard IF 
method (Figure 3:23 E).   
 
The specificity of the assay is confirmed in the negative control where the 
α-HER2 antibody was omitted (Figure 3:23 B). However, some 
background observed with the Zif268-ProteinG 2D (Figure 3:23 D). This 
could be attributed to the unspecific binding of Zif268-ProteinG 2D or to 
the high concentrations of the oligonucleotides. 
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Figure 3:23. The functionality of Zif268-PrG 3D and 2D were tested in HCC1954 
xenograft tumour module in parallel with standard Immunofluorescence. Tumour 
samples were incubated with α-HER2 antibody before the addition of the single capture 
biodetectors. A & C, detection of HER2 using the Zif268-PrG 3D and 2D respectively; E 
& F, detection of HER2 receptors using standard IF technique; B & D, negative controls 
where the α-HER2 antibody was omitted, negative control where the α-HER2 antibody 
was omitted. Images were taken with A1R confocal microscope. 								
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3.3.15 Optimizing the In-House Coincidence Technology. 
 
Although I was able to produce a novel and functional biodetector and 
proved the functionality of the Protein G recognition modules, the 
background problems were still an issue when using the Protein G 
recognition modules combined with SH2 domains recognition modules in 
a coincidence detection method. The novel single capture technology 
developed by itself is a very useful and sensitive detection technology to 
visualize protein expression and a significant optimization of the single 
detection method towards eliminating the background was achieved. The 
optimized protocol for the single capture method showed positive signals 
with minimum background, as demonstrated in Figure 3-23, and this was 
consistent in all investigations. However, this method cannot detect 
protein complexes and phosphorylation (with specificity) and coincidence 
signal cannot be obtained using this method. Thus this is not suitable for 
our main goal in assessing the HER family status in breast cancers. 
Nevertheless, simplifying the single capture method allowed the 
identification of the problems that caused the background issues (e.g. 
designing and cloning different constructs of ProteinG recognition 
modules-ProteinG 3D) and made it possible to optimize and yield very 





The up-regulation of the HER receptors family is found in different forms 
of cancer (Stern 2000, Roskoski Jr 2014). HER2 overexpression is found 
in various human cancers, including up to 30% of invasive breast cancers 
with invariable association with gene amplification (Slamon, Clark et al. 
1987, Iqbal and Iqbal 2014, Lee, Park et al. 2014). EGFR is found to be 
overexpressed or mutated in different forms of cancer such as non-small 
cell lung cancer (NSCLC), gliomas and breast cancer (Ciardiello and 
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Tortora 2001) and has also been associated with poor prognosis (Newby, 
Johnston et al. 1997, Knoop, Bentzen et al. 2001).  Although less studied, 
HER3 overexpression is also reported in breast cancer as associated 
with metastasis, local recurrence risk and decreased survival (Travis, 
Pinder et al. 1996).  
 
As an obligate partner of HER2, HER3 plays an important role in HER2 
transforming and accelerating progression in human cancers. In vivo 
studies have shown that the HER3/HER2 combination results in more 
aggressive tumour growth and induces higher levels of VEGF than other 
EGFR family combinations (Spears, Taylor et al. 2012). Therefore, the 
HER2/HER3 hetero-dimer is considered the most potent HER pair as an 
oncogenic unit. Moreover, the formation of HER dimers leads to the 
activation of multiple intracellular signaling pathways including the 
phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK pathways. The 
activation of these pathways disrupts cellular proliferation, survival, 
metabolism and invasion all of which contribute to tumour progression 
(Spears, Taylor et al. 2012).  
 
Additionally, the overexpression and co-expression of the HER family has 
been linked with endocrine and chemotherapy resistance, driven not 
simply by protein expression but also by signaling via their dimer 
formation. Moreover aberrant dimerization and phosphorylation can be 
independent of receptor expression level (Kong, Leboucher et al. 2006, 
Gajadhar and Guha 2010). This highlights the potential importance of 
HER dimer formation and phosphorylation rather than simple protein 
overexpression in breast cancer.  
 
Immunohistochemistry (IHC) is frequently used for the in situ detection of 
proteins. However, it has disadvantages, as previously described, such 
as potentially poor reproducibility and the difficulty of quantifying the 
signals objectively, which requires the use of sometimes complicated 
scoring systems (Gown 2008). Furthermore, quantification of signals is 
mainly by visual means, which could lead to observer bias. Additionally, 
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IHC can only be applied for the presence of proteins. 
 
Therefore, when aiming to monitor the functional states of the HER family 
proteins, there is a need to have a simple, cost effective technology that 
reports with high specificity and sensitivity not simply on the concentration 
of the proteins but also on their partner associations and their post-
translational modifications. It would be ideal if such a technique could be 
used routinely in a research lab or ‘routine’ clinical settings. Starting from 
this premise, a novel biodetector was built from molecular building blocks 
(from single protein domains) to a fully functional construct. 
 
There are available coincidence technologies to monitor post-translational 
modifications such as Fluorescence Resonance Energy Transfer (FRET) 
(Ng, Squire et al. 1999, Ganesan, Ameer-beg et al. 2006), this involves 
the transfer of energy from a donor fluorophore to an acceptor 
fluorophore and energy can only be transferred within a limited distance 
(<10nm). The energy of transfer in FRET depends on several factors that 
include: distance between the two fluorophores, extent of the overlap 
between the donor emission and acceptor excitation spectra, the 
fluorescence lifetime of the donor, the quantum yield of the donor and the 
relative orientation of the donor and the acceptor (Padilla-Parra and 
Tramier 2012).  Although FRET has been used for many years, the high 
equipment cost and technical demands of this method prevents its routine 
use and it is generally more applicable to biomedical research (Day, 
Periasamy et al. 2001).   
Mass Spectroscopy (MS) is another method used for the detection of 
protein expression, protein-protein interactions and post-translational 
modifications. After separation and isolation of proteins from tissue and 
cell samples, MS can detect the proteins depending on specific 
characteristics e.g. charge and mass. Variants of MS have been 
established to increase sensitivity and protein distribution in cells. 
Examples of these variants are surface-enhanced laser-desorption 
ionization time-of-flight MS (SELDI-TOF-MS) (Issaq, Veenstra et al. 
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2002), without the need of enzymatic protein digestion and tandem mass 
spectrometry (MS/MS) for sensitive protein detection in multiple samples 
(Sharma, Martin et al. 2012). Albeit very sensitive, it does not provide 
sub-cellular information about protein localization. Moreover, since it 
requires expensive equipment it is not possible to implement it in a 
standard laboratory or clinical procedure.  
The VeraTag assay is another technology used to detect proteins and 
protein interactions (Desmedt, Sperinde et al. 2009, Shi, Huang et al. 
2009). However, the limitation of this method is that the signal needs 
detection in liquid phase so the exact physical source of the protein 
dimers is unknown; it cannot, for example, distinguish DCIS from invasive 
components or unaffected tissue. 
The recently developed method, the proximity ligation assay (PLA) is yet 
another method, which also has the ability to detect proteins, protein-
protein interactions and post-translational modifications in fixed cells and 
tissues (Soderberg, Gullberg et al. 2006, Soderberg, Leuchowius et al. 
2008, Weibrecht, Leuchowius et al. 2010). The PLA method involves 
using primary antibodies that bind specifically to their target antigens, 
followed by the addition of PLA probes (comprising two secondary 
antibodies that are specific for the two primary antibodies, and have 
oligonucleotides covalently linked to the 5' ends), the probes bind to the 
primary antibodies and when in close proximity (30-40nm), the DNA 
strands can interact through the subsequent addition of two other circle-
forming DNA oligonucleotides. After joining of the two added 
oligonucleotides by enzymatic ligation, they are amplified via rolling circle 
amplification (RCA) (Soderberg, Gullberg et al. 2006).   
 
There are several advantages of the PLA method since it can be 
performed in any laboratory setting and still maintain a high sensitivity 
and spatial resolution. However, the PLA method is disadvantageous in 
some of the technical steps such as the ligation step and oligonucleotide 
conjugation to the secondary antibody. For RCA to take place both sides 
of the circles need to be ligated. Problems occur in the ligation step if only 
Developing a novel bio-detector                                                  Chapter-3 
 
  129 
one side of the circle has been ligated, there is a loss of signal due to 
RCA not taking place. Another obstacle can be that the conjugation 
between the oligonucleotide and the secondary antibody never reaches 
100% efficiency. If conjugation of the oligonucleotide to the secondary 
antibody bound to the target fails, no signal will be detected.  
The novel coincidence biodetector developed and described addresses 
the limitations of previous methods. The technology is created from two 
recombinant fusion proteins, which include ProteinG fusions, and SH2 
domains that can be employed routinely in any research laboratory or 
clinical setting to detect proteins and their posttranslational modifications 
with high specificity and sensitivity. I have constructed and cloned four 
types of recombinant Protein G fusion named RAR-15nm-Protein G, 
RAR-G/S-Protein G, RXR-E3-ProteinG and RXR-K3-ProteinG (Figure 
3:4). I established purification protocols and the purified recombinant 
proteins were tested for functionality in designed enzyme-linked 
immunosorbent assays (ELISA) that provides accurate and sensitive 
results.   
 
RAR-ProteinG fusions were tested first for functionality (RAR-15nm-
protein G and RAR-G/S-proteinG) and to demonstrate the technology of 
the coincidence detection paired with RXR-EE-Grb2-MYC. The results 
showed some evidence of a coincidence readout using RAR-15nm-
protein G modules but with low signal to noise ratio (< 2 folds) (Figures 
3:6). This raises the question as to whether Protein-G module was 
functional or not. Therefore, pull down assays were employed to test the 
functionality of the purified modules. The results shown in (Figure 3:7) 
prove the functionality of the ProteinG modules but the results also 
indicate unspecific binding of the ProteinG. No readout was detected with 
RAR-G/S-proteinG (Figure 3:8). However, by attempting to reduce the 
concentration of RAR-G/S-proteinG used per well a better signal-to-noise 
ratio was observed at intermediate concentrations (Figure 3:9). 
 
More ELISA assays were carried out to test the functionality of RXR-
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ProteinG modules (RXR-E3-ProteinG and RXR-K3-ProteinG). The RXR-
proteinG modules were tested paired with either RAR-15nm-ProteinG or 
RAR-G/S-proteinG. ELISA results indicated that both RXR-ProteinG 
fusions were functional as an IgG binding fusions, which was also proved 
by the pull down assay. However, the high background was persistent in 
all the investigations.  
 
We were able to identify some of the issues that caused the high 
background in the previous ELISA assay and, by identifying these issues, 
we were able to resolve them and improve the results. One of the 
reasons identified is the choice of the antibody used in the previous 
experiments. α-EE tag antibody used in the previous ELISA experiments 
can recognize and bind Protein-G modules through two different sites at 
the same time; we hypothesized that there is a high probability of RAR 
DBD forced dimerization due to close proximity of up to four RAR DBDs 
that can bind to the same antibody at the same time. This was 
investigated in ELISA experiments using different concentrations of α-EE 
tag antibody in comparison with another antibody, F4. ELISA results 
confirmed the hypothesis that using the α-EE antibody was not a suitable 
option and it was one of the reasons for the increased background 
(Figure 3:11). This was resolved by using F4 antibody in the subsequent 
experiments. 
 
There were variations detected between duplicate wells (in ELISA plates) 
(Figures 3:12 & 3:13), which was attributed to the different batches of 
BSA used. This was resolved by using BSA with a ≥98% purity. Variability 
was detected using different batches of ProteinG modules which 
indicates that the protein is unstable and could lose functionality if stored 
for a prolonged period of time at -20°C (Figure 3:12). Furthermore, 
different ELISA experiments were carried out using different conditions in 
an attempt to reduce the background that include increasing the washing 
times and using different concentrations of oligonucleotides (DR5). 
However, the issue of the high background produced by the ProteinG 
modules was still persistent.  
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Although testing ProteinG fusion reagents by ELISA assays proved their 
functionality, the value may be limited since we could not reduce the 
problem of high background by diluting the capture reagents to a much 
lower level without completely losing the possibility of coincidence 
capture (since the captured detectors would potentially be too far apart). 
Therefore, the utility of ProteinG fusions were investigated and tested in 
fixed cells and the results proved the functionality of RXR-E3-Protein-G 
fusions as detection reagents in principle as indicated by the detection of 
EGFR receptors in A431 cell lines (Figure 3:14). However, the issue of 
the unspecific binding was persistent as observed by nuclear staining in 
the negative control (Figure 3:14). This nuclear background might be 
attributed to the unspecific binding of the RXR and RAR DNA binding 
domains to the nucleus, or the unspecific binding of the oligonucleotides 
sequences. While many attempts were made to resolve the nuclear 
background they were without success. 
 
However, by avoiding detection of the nucleus through using TIRF 
microscopy in fixed cells, we were able to provide evidence for the 
functionality of the biodetectors reagents and provide proof of concept of 
the coincidence detection method without the background or nuclear 
noise (Figure 3:17). However, the information about the rest of the cell 
compartments was lost, therefore it is a very limited technique. 
Furthermore, TIRF requires sophisticated equipment set up, which we 
would like to avoid. 
In an attempt to address the issues of the high background more 
effectively, a different approach was taken. This involved simplifying the 
assay into a single capture detection method as an efficient way of 
optimizing the coincidence detection technology and allowing modification 
of conditions for a single reagent at a time. These new biodetectors 
(Zif268-PrG 3D and Zif268-PrG 2D), were successfully cloned and 
purified, their functionality was assessed and optimized and proof of utility 
was demonstrated in xenograft tumour models.  
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An optimized protocol for the single capture method showed positive 
signals with minimum background, which was consistent in all the 
investigations. I applied this optimized single capture protocol using the 
new biodetectors in parallel to the standard Immunofluorescence (IF) 
technique to detect HER2 receptors in HCC1954 xenograft tumour 
model. The results show the successful detection of HER2 receptors with 
minimum background using the single capture method. The results also 
indicate that the single capture method developed by our Lab is more 
sensitive and specific than the standard IF technique.  
The single capture technology by itself is a very useful and sensitive 
detection technology to visualize proteins. Moreover, the single capture 
technology has made it possible to optimize and yield useful information 
for implementation in coincidence technology. Notwithstanding this 
advance with the new methodology, concurrent testing of PLA technology 
(see next Chapter) became my platform of choice for the breast cancer 
TMA analyses. 
It should be noted however that building on the work undertaken here, 
others have since optimized the coincidence detection protocol to yield 
more promising results with less background when applied in xenograft 
tumour models. This gives hope for the future that we will reach the goal 
of providing a simple, specific, efficient and sensitive proteomic biomarker 
detection method giving diagnostic, prognostic and therapeutically 
important information to improve the management of patients with cancer. 
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4.1 Introduction 
 
The previous Chapter outlines the development and optimization of a 
novel coincidence biodetection method with the ability of detecting target 
proteins with a high sensitivity and specificity. However, more 
optimization is required for this new coincidence detection method. By 
simplifying the method into single capture technology we were able to 
tackle most of the background issues and this simplified method by itself 
may be a useful tool for detecting proteins and their post-translational 
modifications in tissue samples with high sensitivity. 
 
However, in order to investigate the significance of EGFR family 
receptors dimerization and activation status in breast cancers, in parallel 
we investigated the use of proximity ligation assays (PLA). This relatively 
recently developed method has been shown to be highly useful for 
detecting protein-protein interactions, their post-translational 
modifications and expressions in situ even at very low level of protein 
expression [exemplified in (Soderberg, Gullberg et al. 2006, Halle, Lando 
et al. 2011, Gajadhar, Bogdanovic et al. 2012)]. 
  
The PLA method involves using primary antibodies that bind specifically 
to their target antigens, followed by the addition of PLA probes 
(comprising two secondary antibodies that are specific for the two primary 
antibodies, and have oligonucleotides covalently linked to the 5' ends). 
The probes bind to the primary antibodies and, when in close proximity 
(30-40nm), the DNA strands can interact through the subsequent addition 
of two other circle-forming DNA oligonucleotides. After joining of the two 
added oligonucleotides by enzymatic ligation, they are amplified via 
rolling circle amplification (RCA) using Φ 29 DNA polymerase 
(Soderberg, Gullberg et al. 2006). After the amplification reaction, 
several-hundredfold replication of the DNA circle has occurred, and 
fluorescently labeled complementary oligonucleotide probes can be 
employed to visualize the product (Figure 4:1). Each fluorescently labeled 
red dot represents the formation of one molecular interaction, facilitating 
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the visualization, quantitation of protein expression, phosphorylation and 
dimer/oligomer formation in cells (Figure 4:2) (Gullberg, Gustafsdottir et 
al. 2004, Soderberg, Gullberg et al. 2006, Jarvius, Paulsson et al. 2007).  
 
Prior to detection of EGFR family dimer formation and activation status in 
breast cancer patients, the validity of this approach, the sensitivity and 
specificity of the method had to be assessed. This Chapter outlines the 
assessment and the validation of the PLA method using human cell lines, 
xenograft tumour models and a tissue microarray (TMA) of invasive 




Figure 4:1. lllustration representing the principle of the PLA assay in detecting 
protein phosphorylation.  
1, Two primary antibodies raised in different species (e.g. mouse and rabbit) bind to 
their target protein; 2, PLA probes are added (e.g. anti-mouse IgG and anti-rabbit IgG) 
and bind to primary antibodies specifically; 3 & 4, when the secondary antibodies are in 
close proximity (<40 nm), the DNA strands allow two added DNA oligonucleotides to 
form a circle; 5, after joining of the two added oligonucleotides by enzymatic ligation, 
they are amplified via rolling-circle amplification using a polymerase; 6, the amplification 
reaction yields a several hundred–fold replication of the DNA circle, and labelled probes 
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Figure 4:2. PLA results, each fluorescently labeled red dot represents the formation of 
one molecular interaction, facilitating the visualization, relative quantitation of protein 
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4.2 Results 
 
4.2.1 Investigating the specificity and sensitivity of the 
PLA assay in fixed cell lines. 
 
The sensitivity and specificity of the PLA method was first tested in 
different human cell lines showing various expression levels of HER 
family receptors. However, since the biological relevance of the 
generated PLA signals critically depends on the performance of the 
primary antibodies used, this requires testing in different contexts such as 
in Immunofluorescence (IF). The functionality and the specificity of the 
different primary antibodies chosen in this thesis against HER1, HER2 
and HER3 and their specific phosphorylation sites were tested first by IF 
and western blot analysis. All the primary antibodies chosen show 
functionality and specificity in detecting their target proteins. The following 
represent the results obtained from testing α-EGFR antibodies. 
 
The primary antibodies against EGFR used in this study are, α-EGFR 
mouse monoclonal primary antibodies (Clone F4, Sigma) and (Clone 384, 
Leica) recognizing the intracellular domains of the EGFR and α-pEGFR 
rabbit monoclonal antibody (Y1068, Cell signaling), which detects EGFR 
receptors only when phosphorylated at tyrosine 1068 (Downward, Parker 
et al. 1984). Two primary antibodies against EGFR were chosen, α-
EGFR mouse monoclonal primary antibody (Clone F4, Sigma) was used 
first and gave very good results while testing on cell lines and embedded 
cell pellets but showed background staining while optimizing the PLA 
assays on paraffin embedded sections. A second antibody α-EGFR 
mouse monoclonal primary antibody (Clone 384, Leica) was therefore 
tested. The second primary antibody gave better and more consistent 
results without background and was chosen for the subsequent 
experiments, which will be described in detail later in this Chapter.  
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A431 cells which expresses high levels of EGFR (2-3x106 receptors per 
cell) (Haigler, Ash et al. 1978) were chosen for optimizing the PLA assays 
using α-EGFR antibodies. The cells were serum starved overnight and 
then either left un-stimulated or stimulated with EGF to trigger 
phosphorylation of EGFR, subsequently the cells were lysed and 
analyzed by western blotting. For the IF experiments the cells were either 
left un-stimulated or stimulated with EGF followed by a 30 minutes 
CHASE for EGFR internalization before fixation (see Chapter 2) 
(Oksvold, Skarpen et al. 2000).  
 
Figure 4:3 shows the specific detection of EGFR and pEGFR indicated as 
a band running at a molecular weight of approximately 170 kDa in 
western blot analysis. Total tyrosine phosphorylation increases with EGF 
stimulation indicated by the difference in band intensity between 
stimulated and non-stimulated cells detected by the α-pEGFR (Y1068) 
antibody.  
 
Figure 4:4 shows the IF results from testing α-EGFR mouse monoclonal 
primary antibodies. There is specific staining around the plasma 
membrane representing EGFR in un-stimulated cells (Figure 4:4 A&B). 
There is also some staining asymmetrically, localized around the nucleus; 
this would be consistent with staining of the Golgi on the biosynthetic 
route for EGFR (Keller and Simons 1997). In EGF stimulated cells EGFR 
was detected in small vesicles dispersed in the cytoplasm and near the 
nucleus, reflecting endocytosed and trafficked EGFR (Figure 4:4 C&D) 
(Tomas, Futter et al. 2014). Figure 4:4 E&F represent the negative 
controls where no secondary antibodies were added. 
 
Similar experiments were carried out to investigate the specific and 
sensitive detections of HER2 and HER3 primary antibodies. Figure 4:5 
shows the results obtained from one of the western blot analyses for the 
specific detection of EGFR, HER2 and HER3 performed in two different 
cell lines using the chosen α-HER primary antibodies. The two cell lines 
are HCC1954 and T47D that show various expression levels of HER 
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receptors; the results show the detection of the three receptors indicated 
as a band running at a molecular weight of approximately 170 kDa for 
EGFR and 185 kDa for HER2 and HER3. We can also observe a 
difference in the intensity of the bands for HER1, HER2 and HER3 
between the two cell lines since the expression of HER receptors is 
different in both cell lines. Figure 4-6 shows the IF results from testing α-
HER2 and α-HER3 primary antibodies in T47D cell line. In Figure 4:6 A 
we can observe the specific detection of HER2 indicated by the staining 
around the plasma membrane while the specific detection of HER3 is 
shown in Figure 4:6 B. Figure 4:6 C&E and Figure 4:6 D&F represent the 
negative controls for HER2 and HER3 experiments respectively where no 







Figure 4:3. Testing α-EGFR primary antibodies by western blot analysis. 
A431 cells were serum starved overnight in DMEM with 0.1% FBS and then either left 
un-stimulated or stimulated with 250 ng/ml EGF for one hour at 4ºC. Denatured lysates 
were collected and 15 µg of these lysates was separated by SDS/PAGE and transferred 
to nitrocellulose membrane (see Chapter 2). The membrane was probed with α-EGFR –
F4 antibody, α-EGFR-384 antibody and α-pEGFR (Y1068) at a dilution 1:2000. The 
signal was detected using the appropriate HRP-conjugated secondary antibody. EGFR 
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Figure 4:4. Testing α-EGFR primary antibodies by standard immunofluorescence. 
 
A431 cells were serum starved overnight in DMEM with 0.1% FBS and then either left 
un-stimulated (A&B) or stimulated with 250 ng/ml EGF for one hour at 4ºC followed by a 
30 minutes CHASE (C&D) before fixation with 4% paraformaldehyde. The cells were 
stained with α-EGFR–F4 antibody or α-EGFR-384 antibody at a dilution 1:200. The 
signal was detected using α-mouse Alexa Fluor-488 conjugated secondary antibody. 
Nuclei were counterstained with DAPI. E&F are negative controls where no secondary 
antibodies were added. Images were taken using with A1R confocal microscope.  The 
scale bar = 5µm. 
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Figure 4:5. Testing α-HER primary antibodies by western blot analysis. 
HCC1954 and T47D denatured lysates were collected and 40 µg of the lysate was 
separated by SDS/PAGE and transferred to nitrocellulose membrane (see Chapter 2). 
The membrane was probed with α-EGFR–F4 mouse antibody, α-HER2 rabbit antibody 
and α-HER3 mouse antibody at dilutions 1:2000, 1:1000 and 1:500 respectively. The 
signal was detected using the appropriate HRP-conjugated secondary antibody. EGFR 
was detected at approximately the MW of 170 KDa while HER2 and HER3 were 








	Proximity Ligation Assays (PLAs)                                              Chapter-4 																																																																																																




Figure 4:6. Testing α-HER2 and α-HER3 primary antibodies by standard 
immunofluorescence. 
T47D cells were stained with α-HER2 rabbit monoclonal antibody (A) or α-HER3 mouse 
monoclonal antibody (B) at dilutions 1:100 and 1:50 respectively. The signal was 
detected using the appropriate Alexa Fluor-488 conjugated secondary antibody. Nuclei 
were counterstained with DAPI. Panels C, D, E and F are negative controls where no 
primary or secondary antibodies were added. Images were taken using with A1R 
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4.2.2 Investigating the Specificity of the Proximity Ligation  
Assay 
 
For most of the PLA assessment experiments in this study described in 
this Chapter, EGFR was chosen as the target protein. The following 
assay was designed to investigate the specificity of the PLA method in 
detecting EGFR phosphorylation. The binding of EGF ligand to EGFR 
induces its dimerization and results in EGFR phosphorylation at specific 
tyrosine residues within the intracellular domain that include the Y1068 
residues (Wee, Shi et al. 2015). 
 
The following dual recognition PLA assay was employed using two 
primary antibodies raised in two different species α-EGFR (F4) mouse 
monoclonal antibody and α-pEGFR (Y1068) rabbit monoclonal antibody 
for more specific detection of phosphorylated EGFR, Illustration of the 
assay is shown in (Figure 4:7 A).  
 
A431 cell lines were chosen for this assay since the line highly expresses 
EGFR as stated earlier. Cells were serum starved overnight and then 
either left un-stimulated or stimulated with EGF to trigger phosphorylation 
of EGFR before fixation with 4% paraformaldehyde. The cells were 
blocked for half an hour with Duolink blocking reagents then incubated 
with the two primary antibodies for one hour at room temperature before 
staining with the Duolink staining kit (see Chapter 2).  
 
In Figure 4:7 B each red signal represents phosphorylated EGFR, an 
increase in signal observed in EGF stimulated cells compared to those 
non-stimulated since the total tyrosine phosphorylation increases with 
EGF stimulation (Bae, Kang et al. 1997). This indicates the specificity of 
the PLA assays in detecting phosphorylated EGFR in tumour cells.  
 
The basal activation of A431 cells detected in the non-stimulated cells 
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could be attributed to an autocrine pathway triggered by endogenously 
produced ligands such as TGF-α (Van de Vijver, Kumar et al. 1991). The 
specificity of the assay was confirmed in the negative controls where no 
signals were observed on omitting either one of the primary antibodies, 
either primaries or both secondary antibodies (PLA probes). The 
corresponding quantification of the PLA signals per cell is presented 
(Figure 4:7 C). 
 
 
	Proximity Ligation Assays (PLAs)                                              Chapter-4 																																																																																																








Figure 4:7. Detecting EGFR in A431 in dual recognition event using PLA assay. 
A - Illustration of the PLA dual recognition assay, B - A431 cells were serum starved 
overnight in DMEM with 0.1% FBS and then either left un-stimulated or stimulated with 
250 ng/ml EGF for one hour at 4ºC before fixation with 4% paraformaldehyde. The cells 
were blocked and stained with α-EGFR–F4 antibody and α-pEGFR (Y1068) at a dilution 
of 1,200. The Duolink method was followed according to the manufacturer’s instruction. 
Nuclei were counterstained with DAPI. C - Quantification of the PLA signals per cell. 
This is one of at least 3 similar experiments. Images were taken using A1R confocal 
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4.2.3 Can the PLA method detect low-level expressed 
proteins? 
 
The sensitive detection and analysis of low level expressed proteins have 
been a challenge in medical research. The PLA method was developed 
as a protein detection method that modifies protein detection into target 
DNA detection which after PCR amplification, provides a higher sensitivity 
in detecting target proteins (Fredriksson, Gullberg et al. 2002). In order to 
investigate the sensitivity and the advantages of using the PLA detection 
over traditional immunofluorescence methods, I conducted a head-to-
head comparison of standard Immunofluorescence EGFR detection 
against PLA detection. In this case, a single recognition PLA assay (using 
one primary antibody α-EGFR–F4) is used and a pair of MINUS and 
PLUS secondary probes raised in the same species were used. This 
approach was selected to make the comparison conditions more 
equivalent since the IF method is also conducted using a single primary 
antibody.  
 
The T47D cell line expressing a low number of EGFR (7x103) (Imai, 
Leung et al. 1982) was chosen to test the sensitivity of the PLA assay. 
T47D cells were blocked for half an hour with Duolink blocking reagent for 
the PLA experiment or 1% BSA in PBS for the IF experiment for half an 
hour, then incubated with α-EGFR mouse monoclonal antibody for one 
hour at room temperature (see Chapter 2). The results show the sensitive 
detection of low expressed EGFR using the PLA method (Figure 4:8 A), 
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Figure 4:8. Investigating the sensitivity of the PLA method in comparison with 
standard immunofluorescence. 
T47D cells were blocked for half an hour with Duolink blocking reagent for the PLA 
experiment or 1% BSA in PBS for the IF experiment for half an hour, then incubated with 
α-EGFR mouse monoclonal antibody for one hour at room temperature (see Chapter 2). 
Nuclei were counterstained with DAPI. A - Detection of EGFR with PLA single 
recognition assay. B - EGFR detection with standard IF method. Images were taken 
using A1R confocal microscope.  This is one of at least 3 similar experiments. The scale 
bar = 5µm. 
  
More experiments were carried out in T47D to investigate further the 
sensitivity and specificity of the assay. Double recognition PLA assays 
were conducted in T47D cell line to test the specific detection of 
phosphorylated EGFR. Cells were serum starved overnight and then 
either left un-stimulated or stimulated with EGF before fixation. The cells 
were blocked for half an hour with Duolink blocking reagents then 
incubated with the two primary antibodies α-EGFR mouse monoclonal 
antibody and α-pEGFR rabbit monoclonal antibody for one hour at room 
temperature.  
 
Figure 4:9. A, shows the clear detection of EGFR when using both 
antibodies in EGF stimulated and non stimulated EGFR. Moreover, an 
increase in PLA phosphorylation signals were observed in stimulated 
cells compared to non-stimulated cells which signifies the specific 
detection of phosphorylated EGFR. No signals were observed in the 
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negative controls (omitting one of the primary antibodies) as observed in 
the previous experiments. Figure 4:9 B illustrates the quantification of 
PLA signals per cell.  
 
 
Figure 4:9. Investigating the sensitivity of the PLA assay. 
A- T47D cells were serum starved overnight in RPMI with 0.1% FBS and then either left 
un-stimulated or stimulated with 250 ng/ml EGF for one hour at 4ºC followed before 
fixation with 4% paraformaldehyde. The cells were blocked and stained with α-EGFR 
antibody and α-(Y1068) at a dilution 1,200. Duolink method was followed according to 
the manufacturer’s instructions; nuclei were counterstained with DAPI (see Chapter 2). 
B- Quantification of the PLA signals per cell. Images were taken using A1R confocal 
microscope.  This is one of at least 3 similar experiments. The scale bar = 5µm. 
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The sensitivity and specificity of the PLA method was further investigated 
in three different cell lines showing various expression levels of EGFR 
receptors. In order to determine the right cell lines to use for the PLA 
experiments, western blot analysis was carried out first to screen four 
different cell lines that are known to express EGFR. Cell lysates were 
separated with SDS/PAGE, and transferred to nitrocellulose; the 
membranes were probed with α-EGFR (F4) antibody. 
 
The western blot analysis shows the presence of EGFR in all the cell 
lines with various expression levels of antigen running at a molecular 
weight of 170 kDa (Figure 4:10 A). Figure 4:10 B shows quantification of 
the gel bands carried out using Image-J software on the scanned 
western.  
 
From these results we can observe that Hela cells show moderate 
expression of the receptor in comparison to the other cell lines, therefore 
these cells were chosen alongside T47D and A431 cell lines which show 
low and high expression of EGFR as noted above.  
 
Cells were serum starved overnight and then either left un-stimulated or 
stimulated with EGF before fixation. The cells were blocked for half an 
hour with Duolink blocking reagents then incubated with the two primary 
antibodies α-EGFR (F4) mouse monoclonal antibody and α-pEGFR 
(Y1068) rabbit monoclonal antibody for one hour at room temperature 
before staining with Duolink kit. The expected differences in EGFR 
expression level in the three cells were detected with PLA, the difference 
in PLA signals was also observed between phosphorylated and non-
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Figure 4:10. Testing α-EGFR primary antibodies by western blotting. 
A - Denatured lysates were collected and 15µg of these lysates was separated by 
SDS/PAGE and transferred to nitrocellulose (see Chapter 2). The membrane was 
probed with α-EGFR–F4 antibody, at a dilution of 1,2000. The signal was detected using 
the appropriate HRP-conjugated secondary antibody. EGFR was detected at the MW of 
170 KDa (Red arrowhead). B - Quantification of receptor expressions level is shown. 
This was determined from scanned westerns using Image J (mean and SD for n=3 
experiments). 
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Figure 4:11. Testing the sensitivity and specificity of the PLA assay.  
 
A-Cells were serum starved overnight in their appropriate media with 0.1% FBS and 
then either left un-stimulated or stimulated with 250 ng/ml EGF for one hour at 4ºC 
followed by fixation with 4% paraformaldehyde. The cells were blocked and stained with 
α-EGFR–F4 antibody and α-pEGFR (Y1068) at a dilution 1:200. The Duolink method 
was followed according to the manufacturer’s instructions (see Chapter 2) B- 
Quantification of the PLA signals per cell. Images were taken using A1R confocal 
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4.2.4 Testing the PLA method in paraffin embedded cell 
lines and xenograft tumour models 
	
The specificity and sensitivity of the PLA method was demonstrated in the 
previous cell line experiments, however, since our aim eventually is to 
apply the method in paraffin embedded breast tissue samples, this 
method was further assessed in paraffin embedded samples.  
 
Histological tissue samples are fixed with formalin before paraffin 
embedding to retain the cellular components in their natural 
compartments. The widely used neutral buffered formalin is a cross 
linking fixative which fixes tissues by making methylene bridges between 
amino acids as well as between amino acids and nucleotides. The cross-
linking mechanism leads to alteration in proteins, mainly in the tertiary 
and quaternary structures (Paavilainen, Edvinsson et al. 2010). The 
conformational change induced by formalin fixation affects antigen-
binding sites, consequently requiring antigen retrieval for successful 
antibody binding.  
 
The next step for the assessment of the PLA assays was to establish this 
method in formalin fixed and paraffin embedded cell lines and xenograft 
tumour models in order to identify the optimum antigen retrieval method 
and primary antibody dilutions.  
  
To detect the sensitivity and specificity of the PLA assay in paraffin 
embedded samples, a dual recognition PLA assay was employed first in 
paraffin embedded cell pellets to detect pEGFR. Two cell lines were used 
for these experiments A431 and T47D cell lines (very high and low 
expressing cells). Cells were left to grow to 70% confluence before serum 
starved in their appropriate medium without FBS overnight. Cells were 
then stimulated with EGF followed by 30 minutes chase or left un-
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stimulated before fixation with 4% paraformaldehyde and embedded as 
paraffin blocks (see Chapter 2).  
 
Sections were freshly cut at 3µm and kept overnight at 37°C, before 
staining, the slides were kept in the oven at 60°C for one hour. Slides 
were deparaffinized and dehydrated with xylene and alcohol respectively 
before washing with H2O. Antigen retrieval was performed for this 
experiment using the MenaPath Access retrieval unit (Dako). Keeping the 
same standard protocol used for the cell line experiments, sections were 
blocked for half an hour with Duolink blocking reagents then incubated 
with the two primary antibodies, α-HER1 (F4) mouse monoclonal 
antibody and α-pEGFR (Y1068) rabbit monoclonal antibody at the same 
dilution used in the previous experiments (1:200) for one hour at room 
temperature before staining with the Duolink staining kit.  
 
 
The results, as illustrated in (Figure 4:12), show the successful detection 
and the localization of the phosphorylated EGFR shown as red signals in 
EGF stimulated A431 and T47D cell pellets. Nevertheless, a 
heterogeneous pattern of staining was observed which could be due to 
insufficient penetration of the primary antibodies, due to insufficient 
deparaffinization, or unmasking of the antigen epitopes. Few signals were 
detected in the un-stimulated cells, no signals were observed in the 
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Figure 4:12. Detecting phosphorylated EGFR in A431 and T47D paraffin embedded 
cell pellets. Cells were stimulated with EGF followed by a 30 minutes chase or left un-
stimulated before fixation with 4% paraformaldehyde and embedded as paraffin blocks. 
Sections were cut at 3µm and kept overnight at 37°C, before staining.  Antigen retrieval 
was done using the MenaPath Access retrieval unit (Dako). Sections were blocked for 
half an hour with Duolink blocking reagents then incubated with the two primary 
antibodies α-HER1 (F4) mouse monoclonal antibody and α-pEGFR (Y1068) rabbit 
monoclonal antibody (dilution 1:200) for one hour at room temperature before adding the 
proximity probes. The nuclei were counterstained with DAPI. Images were taken using 
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4.2.5 Assessment of the PLA method in xenograft tumour 
models 
 
Tumour xenografts are one of the most widely used experimental models 
to investigate the factors involved in malignant transformation, invasion 
and metastasis as well as to examine response to therapy. In xenograft 
tumour models, human tumour cells are transplanted either under the 
skin (subcutaneous) or into the organ type where the tumour was 
generated (orthotopic) in immune-deficient mice (Richmond and Su 
2008). The tumour will develop typically over 1-8 weeks depending on the 
number of cells injected or the size of the tumour transplanted, this allows 
the study of responses to appropriate therapeutic regimens in vivo. For 
the purpose of this study xenograft tumour models were generated from 
A431 and HCC1954 cell lines (which highly express HER1 and HER2 
receptors respectively). 
 
Cell lines were cultured in their appropriate media until they were near 
confluent, 1.5 million A431 and HCC1954 cells were injected 
subcutaneously into three female CD-1 Fox nu/nu mice (5-6 weeks old; 
CRL) (see Chapter-2). Tumour-bearing mice were kept up to 3 weeks. 
Tumour volume was calculated using the formula v = l x (w)2/2, where v = 
volume, l = length and w = width of tumour (Figure 4:13 A). After three 
weeks, tumours were harvested, fixed in 10% buffered formalin overnight, 
processed and embedded as paraffin blocks. H&E sections were 
prepared first from the xenograft tumour sections to assess the presence 
of tumour cells. (Figure 4:13 B) shows the H&E staining of one of the 
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Figure 4:13. Growth rate of the A431 and HCC1954 cell lines. 
 
Cell lines were cultured in their appropriate media until they were near confluent (80-
90%). 1.5 million of A431 and HCC1954 cells were re-suspended in 50µl sterile PBS-/- 
and injected subcutaneously into three female CD-1 Fox nu/nu mice (5-6 weeks old; 
CRL) (see Chapter-2). Tumor-bearing mice were kept up to 3 weeks. Tumour volume 
was calculated using the formula v = l x (w)2/2, where v = volume, l = length and w = 
width of tumour. A - Tumour growth curve. B - H&E staining of one of the A431 
xenograft tumours. 
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In the previous experiments we were able to demonstrate the sensitive 
and specific detection of EGFR and phosphorylated EGFR using the PLA 
assays in cell lines and paraffin embedded cell pellets. However, by 
applying the method to detect phosphorylated EGFR in A431 xenograft 
tumour sections where we were expecting strongly positive signals due to 
the overexpression of EGFR, the results showed weak staining (Figure 4-
14 A). Several factors could be the reason for the weak staining including, 
the antigen retrieval protocol used, the primary antibody concentration 
used or the incubation time or temperature.  
 
At first the antibody concentration and incubation time were investigated, 
and by keeping the same antigen retrieval protocol the primary antibody 
incubation time was increased from one hour at room temperature to 
overnight. By prolonging the incubation time, we ensure penetration 
through out tissue sections. In (Figure 4:14 B) we can observe an 
improvement in the quality of stain by incubating the sections overnight 
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Figure 4:14. Detecting pEGFR in A431 xenograft tumour model. 
A - Results from incubating A431 xenograft sections for one hour with the two primary 
antibodies α-HER1 (F4) mouse monoclonal antibody and α-pEGFR (Y1068) rabbit 
monoclonal antibody (dilution 1:200) at room temperature before adding the proximity 
probes. B - Results from incubating A431 xenograft sections overnight with the two 
primary antibodies α-EGFR (F4) mouse monoclonal antibody and α-pEGFR (Y1068) 
rabbit monoclonal antibody (dilution 1:200) for one hour at room temperature before 
staining with the Duolink kit, Nuclei were counterstained with DAPI. Images were taken 
with A1R confocal microscope. This is one of at least 3 similar experiments.  
 
Other experiments were carried out to determine the optimum F4 and 
Y1068 antibody concentrations. Similar to the previous PLA assay and 
keeping the incubation time overnight at room temperature, a double 
recognition assay was performed with different dilutions of the primary 
antibodies, 1:200, 1:100 and 1:50 (stock 1mg/ml), starting from the 
dilution used in the previous experiments and then increasing the 
concentration two fold. In Figure 4:15 we can see that the intensity of the 
staining was improved with higher concentrations, and the signal 
increased to almost three fold with the highest dilution of 1:50 used for 
both antibodies. However, more background was observed using α-
EGFR-F4 antibody at higher concentrations when compared to another 
α-EGFR antibody (α-EGFR-384 antibody), the latter was found to give 
more specific staining with no background at higher concentrations. 
Therefore, α-EGFR-384 antibody was chosen for the subsequent PLA 
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experiments.  
 
Using the same systematic approach, further optimization experiments 
were performed to investigate the optimum concentrations for HER2 and 
HER3 primary antibodies. Different antigen retrieval protocols were also 
investigated using the MenaPath Access retrieval unit (Dako) and the 
BenchMark ULTRA® (Ventana Medical Systems, Inc, Tucson, AZ) 
automated staining system. Similar results were obtained from both 
protocols, thus it was decided to use the BenchMark ULTRA® (Ventana 






Figure 4:15. Testing different dilutions of α-EGFR primary antibodies. 				
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4.2.6 Detecting HER phosphorylation and co-expression 
 
The previous assessment and optimization of the PLA allowed 
establishment of a protocol for application of the method to xenograft 
tumour models. HER1 phosphorylation and protein expression was 
detected successfully in A431 xenograft tumour models using double 
recognition and single recognition PLA assays respectively. The results in 
Figure 4:16 show the specific detection of EGFR and phosphorylated 
EGFR in A431 tumour cells; no unspecific staining was observed in the 
stromal cells, though, some signal was observed associated within 
necrotic cells. Similarly, the total protein expression of HER2 and 
phosphorylated HER2 was also detected successfully in HCC1954 which 
highly expresses HER2 receptors. Figure 4:17 shows the specific 
detection of total HER2 and phosphorylated HER2 in HCC1954 tumour 
cells.  
 
Previous studies have reported that the HER3/HER2 complex is 
prognostic for more aggressive tumour growth and causes a high level 
induction of VEGF when compared to other EGFR family complexes 
(Aceto, Duss et al. 2012). Since the PLA method allows detection of 
protein complexes in situ, I investigated its ability to detect HER2/HER3, 
HER1/HER2 and HER1/HER3 dimers. Therefore, PLA double recognition 
assays were carried out to detect the co-expression between EGFR 
family in xenograft tumour models. 
 
In Figure 4:18 A & C each red signal represents the detection of 
HER1/HER2 and HER1/HER3 dimers respectively. No signals were 
observed in the negative controls. Figure 4:18 B & D shows some of the 
negative controls where one of the primary antibodies was omitted, 
indicating the specific detection of the HER dimers in situ and 
demonstrating the requirement for both antibodies for signal detection. 
However, some issues were encountered while detecting total HER3 
using the single capture PLA assay. High background was observed in all 
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the conducted experiments, despite testing different conditions. This was 
resolved by using PLA double recognition assay using two α-HER3 
antibodies raised in two different species for the detection of total HER3. 
Figure 4:19 A shows the expression of HER3 total protein level in 
HCC1954 and in Figure 4:19 C each red signal represents the detection 
of HER2/HER3 dimers.  Similar to the previous assays, Figure 4:19 B & D 
show negative controls where one of the primary antibodies was omitted, 






Figure 4:16. EGFR expression and phosphorylation detected by PLA assays in 
A431 xenograft tumour models. Sections were cut at 3µm and kept overnight at 37°C, 
before staining.  Antigen retrieval was done using the Ventana antigen retrieval protocol. 
Sections were blocked for half an hour with Duolink blocking reagents then incubated 
with α-EGFR primary antibody only for the single recognition assay (A) and α-EGFR 
antibody and α-pEGFR for the double recognition assay (B). Sections were incubated 
overnight at room temperature before staining with the Duolink staining kit. The nuclei 
were counterstained with DAPI. Images were taken with A1R confocal microscope. This 
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Figure 4:17. Total HER2 and phosphorylated HER2 detected by PLA assays in 
HCC1954 xenograft tumour models. Sections were cut at 3µm and kept overnight at 
37°C, before staining.  Antigen retrieval was done using the Ventana antigen retrieval 
protocol. Sections were blocked for half an hour with Duolink blocking reagents then 
incubated with α-HER2 rabbit antibody for total HER2 single recognition (A) and α-HER2 
rabbit antibody plus α-pHER2 mouse antibody for the double recognition assay for the 
detection of phosphorylated HER2 (B). Sections were incubated overnight at room 
temperature before staining with the Duolink staining kit. The nuclei were counterstained 
with DAPI. Images were taken with A1R confocal microscope. This is one of 3 similar 
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Figure 4:18. Detecting HER1/HER2 and HER1/HER3 dimerization in a xenograft 
tumour model.	 Sections were cut at 3µm and kept overnight at 37°C, before staining.  
Antigen retrieval was undertaken using the Ventana antigen retrieval protocol. Sections 
were blocked for half an hour with Duolink blocking reagents then incubated with α-
EGFR mouse monoclonal antibody plus α-HER2 rabbit monoclonal antibody or α-HER3 
rabbit monoclonal antibody for the double recognition assay. Sections were incubated 
overnight at room temperature before staining with the Duolink staining kit. The nuclei 
were counterstained with DAPI. A- each red signal represents HER1/HER2 dimerization. 
B- one of the negative controls where one of the primary antibodies was omitted. C- 
each red signal represents HER1/HER3 dimerization. D- one of the negative controls 
where one of the primary antibodies was omitted. Images were taken with A1R confocal 




	Proximity Ligation Assays (PLAs)                                              Chapter-4 																																																																																																







Figure 4:19 Detecting HER3 total protein expression and HER2/HER3 dimerization 
in HCC1954 xenograft tumour model. Sections were cut at 3µm and kept overnight at 
37°C, before staining.  Antigen retrieval was performed using the Ventana antigen 
retrieval protocol. Sections were blocked for half an hour with Duolink blocking reagents 
then incubated with α-HER3 mouse monoclonal antibody (Clone 2B5, Thermo Fisher 
Scientific) and α-HER3 rabbit monoclonal antibody (Clone IB2, Cell Signalling 
Technology) for total HER3 expression in double recognition assay (A) and α-HER2 
rabbit antibody plus α-HER3 mouse monoclonal antibody for the double recognition 
assay for the detection of HER2/HER3 dimers (C). Sections were incubated overnight at 
room temperature before staining with the Duolink staining kit. The nuclei were 
counterstained with DAPI.  B&D: one of the negative controls where one of the primary 
antibodies was omitted. Images were taken with A1R confocal microscope. This is one 
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4.2.7 Assessment of PLA method in invasive breast cancer  
 
Having established a protocol that allowed the successful and 
reproducible detection of our target proteins and their post-ranslational 
modifications and co-expression in paraffin embedded tissue with the 
different PLA assays designed, the next step was to examine and assess 
the method in clinical samples. For this purpose, a tissue microarray 
(TMA) block was constructed from 10 different cases of invasive 
carcinoma that expressed various levels of HER1 and HER2 receptors, 
A431 xenograft tumor section was included in the TMA as a positive 
control, plus a kidney section which was used to help in the orientation 
(see Chapter 2). An H&E section was prepared from the TMA to assess 
the quality of the cores and the presence of tumour cells (Figure 4:20). 
The H&E section confirmed the presence of invasive tumour cells in 6 
cores, 2 cores were missing and 2 cores showed normal breast tissue, 
which was excluded from the analysis. The cores, which showed the 
presence of tumour cells, were labeled from A to F and this labeling is 
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Figure 4:20 A - H&E section of the TMA. Tissue Microarray (TMA) block that was 
constructed from cases of invasive ductal carcinoma with various levels of HER1 and 
HER2 receptors. A431 xenograft tumor section was included in the TMA as positive 
control, plus a kidney core which was used to help in the orientation. Two cores were 
subsequently not retained in microscopic sections and two contained only normal breast 




4.2.8 PLA method shows higher sensitivity compared to 
standard techniques in detecting target proteins in TMA 
 
PLA was proven to be advantageous compared to the standard IF 
method in fixed cell lines. A comparison of PLA with IHC and IF 
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techniques was conducted using the test TMA. The presence of HER1 
was evaluated with IHC, IF and PLA single recognition assays using the 
same α-EGFR antibody to make the comparison conditions more 
equivalent. 
 
Sections were freshly cut at 3µm and kept overnight at 37°C, before 
staining. Sections were blocked for half an hour either with Duolink 
blocking reagents or 1% BSA in PBS for the PLA method and IF 
respectively, then incubated with α-EGFR (384) mouse monoclonal 
antibody overnight at room temperature (see Chapter 2).  
 
IHC and IF results show the presence of EGFR in tumour F and A431 
xenograft only (Figure 4:21), while the rest of the cores did not show any 
membrane staining. PLA shows the overexpression of EGFR in A431 
xenograft and tumour F, which correspond to the IHC and IF results. 
However, the PLA single recognition method was able to detect EGFR at 
low levels of expression in other tumour samples that were negative by 
the IHC and IF approaches (Figure 4:22). The extensive characterization 
of the PLA assay and its behaviour gives confidence to the finding of low-
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Figure 4:21. IHC and IF shows the detection of EGFR in Tumour F and A431 
xenograft tumour model. Sections were cut at 3µm and kept overnight at 37°C, before 
staining.  Antigen retrieval and IHC staining for HER1 was performed using a 
BenchMark ULTRA® (Ventana Medical Systems, Inc, Tucson, AZ).  For IF method, 
sections were blocked with 1% BSA in PBS for the PLA method and IF respectively, 
then incubated with α-EGFR (384) mouse monoclonal antibody overnight at room 
temperature. The signal was detected using α-mouse Alexa Fluor-488 conjugated 
secondary antibody. Nuclei were counterstained with DAPI. Images were taken with 
A1R confocal microscope and Hamamatsu Nanozomer for IHC images. 
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Figure 4:22. EGFR expression detected with PLA single recognition assay. 
Sections were cut at 3µm and kept overnight at 37°C, before staining.  Antigen retrieval 
was undertaken using the Ventana antigen retrieval protocol. Sections were blocked for 
half an hour with Duolink blocking reagents then incubated with α-EGFR mouse 
monoclonal antibody overnight at room temperature before staining with the Duolink 
staining kit. The nuclei were counterstained with DAPI. Quantification of the PLA signals 
shown in the graph below. Images were taken using with A1R confocal microscope. This 
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4.2.9 Assessment of receptor phosphorylation and 
complex formation in the TMAs 
 
In order to investigate the ability of the PLA method to detect 
phosphorylated EGFR and HER1/HER2 dimers in these sets of tumour 
samples, double recognition PLA assays were carried out in the test TMA 
using the optimized protocol. Figure 4:23 shows the quantitative analysis 
of the average PLA signal intensity per cell from the different double 
recognition PLA assays for the specific detection of EGFR 
phosphorylation and HER1/HER2 dimerization in TMA. It can be seen 
that phosphorylated EGR and HER1/HER2 dimers can be observed in 
tumour samples using the PLA double recognition assays. The results 
also indicate the detection of a high level of phosphorylated EGFR in the 
positive control and in Tumour F correlating with EGFR expression levels. 
A high level of HER1/HER2 dimers was also observed in the positive 
control (A431 xenograft).  
 
Similar experiments were conducted to investigate HER2 expression and 
activation states in these sets of tumour sections. High expression of 
HER2 was detected in most of the tumours in PLA single recognition 
assays (Figure 4:24). However, the PLA double recognition assay 
conducted for the specific detection of phosphorylated HER2 in the test 
TMA show the detection of low levels of phosphorylated HER2 in all the 
tumours and this did not correlate with HER2 expression levels in these 
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Figure 4:23. Quantitative analysis of the average PLA signal intensity per cell. 
   
Differently designed PLA assays were applied in the test TMA for the detection of HER1 
expression, phosphorylation and co-expression. EGFR overexpression was observed in 
Tumour F and the xenograft tumour samples. A high level of phosphorylated EGFR was 
detected in Tumour F and the positive control. A high level of HER1/HER2 dimers was 
observed in the positive control. This is one of 3 similar experiments. The PLA signal 
intensity from tumours A to E are presented on an expanded scale in the lower diagram. 
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Figure 4:24. PLA analysis of HER2 expression level in test TMA. Sections were cut 
at 3µm and kept overnight at 37°C, before staining.  Antigen retrieval was undertaken 
using the Ventana antigen retrieval protocol. Sections were blocked for half an hour with 
Duolink blocking reagents before incubation with α-HER2 rabbit monoclonal antibody 
overnight (see Chapter 2). The nuclei were counterstained with DAPI. Images were 
taken using with A1R confocal microscope. This is one of 3 similar experiments. The 
scale bar = 5µm. 
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Figure 4:25. Quantitative analysis of the average PLA signal intensity per cell. 
    
 PLA assays were applied to the test TMA for the detection of HER2 expression and 
activation status. HER2 overexpression is observed in most of the tumours. The PLA 
assay detected low levels of phosphorylated HER2 and this was independent of its 
expression level. This is one of 3 similar experiments. 
 
 
In the previous experiments conducted in different cell lines and paraffin 
embedded tissue sections I was able to investigate and optimize the 
different PLA assays using the different primary antibodies. The 
assessment was successful and this allowed for an established protocol 
that permitted the successful and reproducible detection of the target 
proteins and their post-translational modifications and co-expression in 
paraffin embedded tissue with the different PLA assays designed. The 
final designed PLA assays, and the final primary antibody dilutions, which 
were subsequently applied to breast cancer samples (described in the 
next Chapter) are summarized in Figure 4:26 and Table 4-1. (See 
Chapter-2 for full description of the primary antibodies).  
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Figure 4:26. Illustration of the designed PLA assays used to evaluate 9 different 
biomarkers. The studied biomarkers represent HER1, HER2 and HER3 expression, 
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4.3 Discussion 
 
Genomic and proteomic methods have facilitated mapping of the human 
genome and proteome. These achievements have influenced our 
understanding of life and diseases, providing the blue-print of cells and 
how in a cell the genetic information is translated into biological 
processes. Information at a single cell level in multicellular organisms is 
fundamental for our understanding of how individual cells are disrupted in 
malignancy. In order to gain insight in molecular mechanism of diseases, 
it is increasingly important to investigate not only levels of protein 
expression but also their post-translational modifications and, for some, 
their interaction with other proteins. This can provide important clinical 
understanding for application to diagnostics and therapeutic purposes.  
 
To achieve this aim for endogenous proteins, affinity reagents, e.g. 
antibodies, will have to be used. To assess protein interactions and 
impose specificity of detection (two-site assays) it is also necessary to 
determine if antibodies are in close proximity, i.e. pairwise binding to 
epitopes on a post-translational modification in combination with an 
epitope on the protein, or binding to epitopes on interacting proteins. 
Although, immunohistochemistry (IHC) is far more frequently used for the 
in situ detection of proteins, it has some disadvantages such as the 
difficulty of quantifying the signals objectively (Gown 2008). Furthermore, 
IHC can only assess proteins or protein modifications as limited by the 
intrinsic specificity of reagents. While there is a technology to monitor 
post-translational modifications through proximity assays with 
combinations of antibodies, i.e. Fluorescence Resonance Energy 
Transfer (FRET), the high equipment cost and technical demands of this 
method prevents its routine use. 
 
As discussed in the previous Chapter there is an urgent need to have a 
simple and cost effective technology that can be used in any laboratory 
setting that reports with high sensitivity and specificity protein proximities 
and post-translational modifications, as well as their expression. This has 
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lead to the development of the in-house novel biodetector described in 
the previous Chapter, which was built from molecular building blocks 
(from single protein domains) to a fully functional construct. The 
continuous efforts carried out to optimize the novel biodetector generated 
promising results with less background. This gives hope with regard to 
producing a simple, specific and sensitive proteomic biomarker detection 
method that can be used in any clinical setting.  
 
However, since the main aim of this study was to investigate the role of 
the EGFR family in breast cancers, in parallel with optimizing the novel 
biodetector, the recently developed method, the Proximity Ligation assay 
(PLA), has been assessed. This method, which was established in 2006, 
has the ability to detect proteins, protein-protein interactions and post-
translational modifications in fixed cells and tissues (Soderberg, Gullberg 
et al. 2006). The PLA method utilizes DNA-conjugated antibodies 
(proximity probes) as hybridization templates for a pair of circularization 
oligonucleotides. The circular DNA molecule experimentally created acts 
as a surrogate marker for the pairwise binding of the proximity probes. By 
using the oligonucleotides on the proximity probes as a primer, the circle 
can be amplified by phi29 DNA polymerase. The rolling circle 
amplification (RCA) product can be visualized by hybridization of 
fluorophore-labeled oligonucleotides. Since each RCA product consists of 
several hundred repeats, single RCA products are easily visible by 
regular bright–field microscopy and epifluorescence (Soderberg, 
Leuchowius et al. 2008). 
The PLA method allows for the direct demonstration of endogenous 
protein interaction in tissue samples, as demonstrated previously (Halle, 
Lando et al. 2011, Gajadhar, Bogdanovic et al. 2012, Spears, 
Cunningham et al. 2012). Additionally, the PLA method has the 
advantage of allowing the analysis of interactions between proteins for 
which suitable pairs of antibodies are available (Soderberg, Gullberg et 
al. 2006, Greenwood, Ruff et al. 2015). Moreover, the method has a 
unique specificity due to the double recognition assays and a signal is 
only generated when the two antibodies are in close proximity (<40nm) 
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(Jarvius, Paulsson et al. 2007, Gullberg and Andersson 2009). 
Furthermore, the method offers high sensitivity due to signal amplification 
by RCA, as described in several different studies (Gajadhar and Guha 
2010, Gajadhar, Bogdanovic et al. 2012, Liccardi, Hartley et al. 2014, 
Greenwood, Johnson et al. 2015, Nahalkova 2015). 
 
This Chapter outlines the characterization of PLA for the in situ detection 
of the HER family receptors expression, post-translational modification 
and co-expression. This assessment is a step forward toward applying 
this method in paraffin embedded breast cancers. Initially the method was 
investigated for its ability to specifically detect the target protein and its 
post-translational modification in vitro. Fixed cell lines were used to 
assess the system, where we could manipulate the behaviour of the 
system to provide a robust test. Here, EGFR and its phosphorylation 
were chosen as the main target for PLA assay optimization and the A431 
cell line was used since it highly expresses EGFR. Antibody specificity 
and the ability to quantify induced differences with respect to EGFR and 
its phosphorylated level were evaluated. 
 
Cells were stimulated with EGF to trigger phosphorylation and a designed 
double recognition PLA assay was applied using two primary antibodies 
raised in two different species against the protein and its phosphorylated 
site. This was combined with secondary anti-mouse and anti-rabbit 
proximity probes carrying both plus and minus oligonucleotides to permit 
ligation and signal detection. 
 
The results shown in Figure 4-7 demonstrates the specific detection of 
phosphorylated and non-phosphorylated EGFR since PLA signals were 
only detected when both antibodies were present. By removing one of the 
primary antibodies (in the negative controls) no signals were observed. 
Moreover, the results confirmed the expected differences between EGF 
stimulated and un-stimulated cells. EGF stimulated cells showed an 
increase in the signal compared to those cells that were not stimulated as 
monitored by western blots in parallel. Similar results were reported in a 
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recent study in which they were able to prove the ability of the PLA 
method to detect the post-translational modifications of a set of proteins 
in fixed cell lines and paraffin embedded cells (Elfineh, Classon et al. 
2014).  
 
The PLA technology was developed as a protein detection method that 
converts protein detection into target DNA detection after PCR 
amplification. This allows for a higher sensitivity in detecting target 
proteins (Jarvius, Paulsson et al. 2007, Leuchowius, Weibrecht et al. 
2009). Previous studies has reported the ability of the PLA method to 
detect the target proteins with higher sensitivity compared with standard 
methods (Gajadhar, Bogdanovic et al. 2012). Here I have assessed the 
sensitivity of antigen detection in the EGFR low expressing cell line 
(T47D cell line) in comparison with Immunofluorescence (IF). The single 
recognition PLA assay-detecting EGFR in T47D was conducted with both 
methods using the same α-EGFR mouse antibody combined with 
secondary anti-mouse antibodies carrying both plus and minus 
oligonucleotides for the PLA assay. The results presented in Figure 4-8 
show the successful detection of total EGFR at low levels of expression 
using the PLA method while the standard IF technique was not sensitive 
enough and gave a negative detectable signal.  
 
To investigate further the sensitivity and specificity of the PLA assays, 
double recognition PLA assays were conducted in the T47D cell line to 
test both the sensitive and specific detection of phosphorylated EGFR. 
The results show the clear detection of EGFR itself under basal and 
stimulated conditions as shown in Figure 4-9. An increase in 
phosphorylated receptor was also observed in stimulated cells. This 
indicates that the PLA method provides good sensitivity for both protein 
and phospho-protein expression in double recognition assays. 
 
I screened and selected three different cell lines with different expression 
levels of EGFR, to investigate further the graded behaviour of the 
method. The results as demonstrated in Figure 4-11 show the expected 
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variation in the PLA signals in the three-cell lines for both the receptor 
and its phosphorylated form.  
 
Having provided evidence of the sensitivity and specificity of the PLA 
method in fixed cell lines, the compatibility of the PLA to work on formalin 
fixed and paraffin embedded samples was evaluated. This is important 
since paraffin embedded tissue samples are fixed with formalin, which is 
a cross-linking fixative that leads to alteration in proteins, mainly in the 
tertiary and quaternary structures (Paavilainen, Edvinsson et al. 2010). 
This conformational change affects antigen-binding sites, consequently 
requiring antigen retrieval for successful antibody binding and possibly 
influencing the proximity of epitopes required for coincidence detection 
assays such as those used in PLA.  
 
The application of the PLA method on paraffin embedded patient samples 
has reported to be successful in several studies (Gajadhar, Bogdanovic 
et al. 2012, Spears, Cunningham et al. 2012, Green, Barros et al. 2014).  
Likewise, my assessment of PLA in paraffin embedded cell pellets was 
successful, however uneven patterns of staining or weak staining were 
observed in A431 EGF stimulated paraffin embedded cell pellets and in 
xenograft tumour models. This could be due to several reasons, including 
insufficient penetration of the primary antibodies due to insufficient 
deparaffinization, or unmasking of the antigen epitopes (Bai, Tolles et al. 
2011). Different factors were therefore investigated, such as the antigen 
retrieval protocol, antibody titration and incubation time. Improved 
staining was obtained, as demonstrated in Figure 4-14 by increasing the 
primary antibody incubation time from one hour at room temperature to 
overnight, indicative of slow/poor penetration.   
 
Further experiments were carried out to determine the optimum antibody 
concentration for these studies. The intensity of the staining was 
improved at higher concentrations, and the signal increased almost three 
fold with the highest dilution of 1:50 used for both α-EGFR-F4 and Y1068. 
However, by carrying out PLA experiments at this level of antibody more 
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background was observed using α-EGFR-F4 antibody. This was not the 
case for the α-EGFR-384 antibody, which gave more specific staining 
with no background at higher concentrations. Therefore, α-EGFR-384 
antibody was chosen for the subsequent PLA experiments.  
Similar systematic testing was also carried out to investigate the optimum 
concentration levels for HER2 and HER3 primary antibodies. It is notable 
that to achieve specific staining for HER3 it was necessary to adopt the 
dual recognition of the protein using two different antibodies (Figure 4-
19); neither antibody alone produced signal without some background. 
This observation directly gives evidence of the value of two-site assays in 
these types of study. 
 
The previous assessment and optimization of the PLA allowed 
establishment of a protocol for application of the method to xenograft 
tumour models. This allowed for the sensitive and specific detection of 
HER1, HER2 and HER3 protein expression and its post-ranslational 
modification in the xenograft tumour models using double recognition and 
single recognition PLA assays as shown in Figure 4-16 and Figure 4-17. 
No non-specific staining was observed in the stromal cells, although 
some signals were observed associated with necrotic cells.   
 
As stated earlier when it comes to detecting protein complexes, existing 
methods have their limitations; classical IHC techniques are limited to 
detecting individual proteins, preventing analysis of protein complexes. It 
is difficult to implement the presently available techniques for 
investigating protein complexes, such as FRET, in the routine setting. 
Previous studies have reported that the PLA method provides a robust 
and reproducible assessment of HER dimers in situ (Spears, Taylor et al. 
2011, Barros, Abdel-Fatah et al. 2014, Green, Barros et al. 2014). In this 
study we were able to detect HER dimers in xenograft tumour models as 
shown in Figure 4-18 and Figure 4-19 using the PLA double recognition 
assays. The results indicate the ability of the PLA method to detect and 
allow quantification of HER family dimers at single cell resolution, which 
was robust and reproducible in all the experiments.  
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The final aim of optimizing the PLA technology was to apply it in clinical 
samples to evaluate the HER family expression level, co-expression and 
activation status and examine how this relates to patient outcome. A 
further assessment of the PLA method was carried out in a constructed 
tissue microarray (TMA) containing clinical samples. This ‘test’ TMA 
contained patient samples that express EGFR, HER2 and HER3 at 
various levels. This provided us with a good opportunity to assess further 
the PLA method specificity and sensitivity in detecting the variation of 
HER family expression level in patient’s samples.  
 
This assessment was successful and the results were consistent in that 
we were able to study the HER family in clinical samples. The PLA 
method showed a higher sensitivity compared to standard techniques, by 
detecting HER family receptors even at low levels of expression in tumour 
samples. Interestingly, by using the PLA method to study the HER family 
we were able to extract valuable information from the patient samples. 
Most of the tumours showed strong signals for HER2 however the PLA 
double recognition assay detected low levels of phosphorylated HER2 in 
all the tumours and this was independent of its expression level. This 
indicates that the simple view of high HER2 concentration driving 
autophosphorylation requires some re-evaluation.  
 
 
In conclusion, the optimization and the assessment of the PLA method 
was successful and the specificity and sensitivity in detecting the target 
proteins were proven.  This will allow the successful assessment of HER 
family total protein level, phosphorylation and co-expression in situ in 
clinical samples. This may in turn lead to the identification of particular 
biomarkers that could help better classify tumours, predict prognosis of 
patients and possibly inform on response to therapy. 
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5.1 Introduction 
 
The Proximity Ligation Assay (PLA) method was chosen as the most 
appropriate tool for detecting, visualizing and quantifying HER family 
activation status, complex formation and protein levels in a breast cancers 
and to correlate these with patient and tumour features and prognosis.  The 
previous Chapter outlines the assessment of PLA as a novel detection 
method for tissue samples. The method was validated for its sensitive and 
specific detection of proteins, their post-translational modification and co-
localization/complex formation (for the purposes of further discussion, the 
term complex formation will be employed with the implicit understanding that, 
within the limits of detection, close co-localization would also score positive in 
these assays). The assessment was successful in all the conducted 
experiments and the results were consistent and protocols established for 
application of PLA in breast cancer tumour samples. 
 
Breast cancer is a heterogeneous group of tumours with variable phenotypic 
and genotypic features, behavior and response to therapy (Rakha, Soria et al. 
2014). The range of treatment options now available for patients with breast 
cancer has resulted in difficulties in decision-making regarding the most 
appropriate treatment choice, especially in cases of apparent low risk. 
Personalized treatments require accurate risk-stratification, based not only on 
outcome prediction but also on a biological basis beyond these in use.  There 
are established criteria that help in breast cancer management, for example, 
the Nottingham Prognostic Index (NPI) (Galea, Blamey et al. 1992), St Gallen 
Consensus Criteria (Goldhirsch, Ingle et al. 2009) and The National 
Comprehensive Cancer Network (NCCN) guidelines (Carlson, Brown et al. 
2006). The NPI depends on the morphologic characteristics of the tumour, 
including invasive tumour size, lymph node status and tumour grade and can 
be used to stratify breast cancer patients; as the NPI value increases the 
prognosis worsens, indicating more aggressive treatments would be 
appropriate (Galea, Blamey et al. 1992). However, the clinical/survival 
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outcome heterogeneity observed in breast cancer patients is not embedded in 
the descriptive NPI criteria. Additional biological characteristics of the cancer 
are important and could improve significantly the delivery of personalized 
treatments in breast cancer patients. 
 
cDNA microarray studies have identified distinct molecular tumour groups 
which have been useful in predicting the outcome of breast cancer patients 
(Perou, Sorlie et al. 2000, Sorlie, Perou et al. 2001, van 't Veer, Dai et al. 
2002).  This provides further evidence that tumour biology is an important 
variable needed for decision-making in personalized breast cancer treatment 
(van 't Veer, Dai et al. 2002). The heterogeneity within these groups and their 
incorporation with the prognostic indices adds complexity in decision-making. 
There is evidence that in the different molecular subclasses, clinico-
pathological factors have different effects, for example in the luminal/ 
oestrogen receptor positive (ER+) classes histological grade and tumour size 
are prognostically significant, but in HER2 positive cases these have less 
prognostic power (Foulkes, Smith et al. 2010). There are also limitations in 
implementing such molecular assays as routine due to cost (Russo, Zegar et 
al. 2003) and the difficulty in designing arrays in which multiple DNA/RNA 
sequences will not bind to the same probe on the array, especially for 
complex mammalian genomes, reviewed in (Bumgarner 2013).  
 
There is still a pressing need to identify more biomarkers for better 
classification of patients, prediction of prognosis and response to therapy. 
One approach is to stratify breast cancer patients using a panel of proteins 
with known /predicted relevance of breast cancer. As noted previously, 
overexpression of the HER family is seen in breast cancer and is associated 
with a poor prognosis. For example, high expression level of EGFR has been 
associated with advanced tumour stage as well as resistance to both 
hormonal therapy and chemotherapeutic agents (Newby, Johnston et al. 
1997, Knoop, Bentzen et al. 2001). Overexpression of HER2 is found in up to 
30% of invasive breast cancers and is associated with gene amplification. 
Furthermore, HER2 overexpression causes inappropriate activation of 
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intracellular signaling pathways via two mechanisms: the spontaneous 
formation of HER2 dimers and via increased heterodimerization with EGFR, 
HER3 or HER4. HER3 overexpression is also found in breast cancer and it is 
associated with increased risk of metastasis and local recurrence and 
decreased survival (Witton, Reeves et al. 2003, Chiu, Masoudi et al. 2010). 
Conversely, HER4 expression is associated with a good prognosis, which 
could be due to the pro-apoptotic function of the HER4 intracellular domain 
(Knoop, Bentzen et al. 2001, Naresh, Long et al. 2006). 
 
Additionally In vivo studies showed that the HER3/HER2 combination results 
in more aggressive tumour growth and induced high levels of VEGF 
compared to other EGFR family combinations (Spears, Taylor et al. 2012). 
Therefore, the HER2/HER3 hetero-dimer is considered the most potent HER 
pair as an oncogenic unit. Moreover, preferential HER3 phosphorylation, not 
EGFR, was observed in HER2-amplified breast cancer tumours. Furthermore, 
several recent studies showed, by applying the PLA method, that protein 
overexpression could be independent of its phosphorylated form, as 
previously described using the more technically demanding FRET approach 
(Kong, Leboucher et al. 2006, Gajadhar, Bogdanovic et al. 2012). This 
highlights the importance of investigating HER dimer formation, as well as 
activation status, rather than simple protein expression in breast cancer 
patients. Phosphorylated forms of the HER receptors as well HER complex 
formation could be candidate biomarkers that could allow for better 
classification of patients, as well as better prediction of prognosis. 
 
The aim of this Chapter is to assess the significance of the HER family 
expression, phosphorylation and complex formation in breast cancer patient’s 
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5.2 Materials   
 
Tissue Microarrays (TMAs) and Patient Characteristics. 
 
The Consecutive Tissue Microarrays (cTMAs) used in this study were 
collected from Guy’s and St Thomas’ (King’s Health Partner’s) Breast Cancer 
Biobank archive and were generated previously by Mr. John Brown (see 
Chapter 2). The cTMAs contain a cohort of 293 patients presenting 
consecutively with primary operable invasive breast carcinoma between 1990 
and 1992; the patients’ characteristics are summarized in (Table 5-1).   
 
An H&E section was prepared first from the cTMAs to assess the quality of 
the cores and the presence of tumour cells. Overall 89.4% of all cores, 
(262/293) showed the presence of tumour, the remaining cores 10.6% (31 
cores) either were missing, or had insufficient tumour material or did not 
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Table 5-1 Patients Clinical Characteristic 	
Clinical Characteristics No of patients % 
Histopathological type  
Ductal 249 85 
Lobular 42 14.3 
Unknown 2 0.7 
Tumour size, cm  
≤2 (T1) 136 44.7 
2-5 (T2) 148 50.5 
>5 (T3-4) 9 3.1 
Unknown 5 1.7 
Histological grade  
    1 53 18.1 
2 132 45.1 
3 100 34.1 
Unknown 8 2.7 
Lymph node status  
N0 (node negative) 125 42.7 
N1 (1-3 nodes positive) 86 29.4 
N2 (> 3 positive) 60 20.4 
Unknown 22 7.5 
ER status  
Negative 68 23.2 
Positive 216 73.7 
Unknown 9 3.1 
PR status  
Negative 109 37.2 
Positive 175 59.7 
Unknown 9 3.1 
HER2 status  
Negative 197 67.2 
Positive 62 21.2 
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Figure 5:1. H&E sections from one of the cTMAs. A - Example of an H&E staining from one 
of the cTMA sections shows some missing cores (red circles). B - Example of one core with 
insufficient tumour material. C - Example of one core with no tumour cells present.  Images 
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5.3 Methods 
 
Proximity Ligation Assays (PLAs) 
 
Following the optimization of PLA method as described in Chapter 4, double 
and single recognition PLA assays were designed to assess the 9 different 
biomarkers representing HER1, HER2 and HER3 total protein expression, 
heterodimerization and activation status for each patient in the cohort of 262 
cases of invasive breast cancer. The final designed PLA assays and the 
primary antibodies used to assess HER family in breast cancer patients’ 
samples are summarized in Figure 5:2 and Table 5-2. 
 
(See Chapter 2 for full description of the primary antibodies and PLA 


































Figure 5:2. Illustration of the PLA assays designed to evaluate 9 different biomarkers 
representing HER1, HER2 and HER3 expression, phosphorylation and complex formation in 
breast cancer patients.	
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Table 5-2. The primary and PLA probes used in the designed PLA assays.		
Designed PLA 
Assays 
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5.4 Image and statistical analysis 	
5.4.1 Image analysis 
Images were taken at 40x to a resolution of 0.181 μm/pixel with an Ariol SL-
50 automated slide scanner (Leica Biosystems) or captured by A1R confocal 
microscopy (Nikon imaging Center) using a 40x or 60x objective for the PLA 
images and Hamamatsu Nanozoomer for IHC.  
Images of three different fields of the 9 PLA variables for each case of the 262 
cases assessed were taken (approximately 7,000 images were analyzed) and 
the intensity of in situ PLA signals per cell was measured using the cell image 
analysis software Cell Profiler from the Broad Institute (Carpenter, Jones et al. 
2006). Using the Cell Profiler software I was able to develop an image 
analysis tool (pipeline) that identifies tumour cells in tissue samples and to 
measure the signal intensity for each tumour cell in a region of interest and 
the data were then exported to Microsoft Excel for further evaluation (refer to 
Chapter 2 for the cell profiler pipeline modules) (Carpenter, Jones et al. 2006, 
Weed, Walker et al. 2013).  
 
5.4.2 Biological markers 
The intensity of markers was not normally distributed; therefore, markers were 
logarithmically transformed in the analysis. Additionally, a dichotomous 
categorization of markers intensity was employed using the 75th percentile of 
intensity as the cut-off point for high and low intensity (Spears, Taylor et al. 
2012).  
5.4.3 Statistical analysis of patient’s data 
All the statistical analysis used in this study were performed with the help of 
Dr. Wahyu Wulaningsihusing from the Epidemiology department at Guy’s and 
St Thomas’ Hospital using either SPSS statistical package (Version 22 for 
MAC) or SASH v 9.3.   
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As previously mentioned in Chapter 2, Spearman’s rank correlation test was 
performed to investigate the association between the continues variables 
since the data display abnormal distribution (Mukaka 2012). Student’s T-test, 
and One-way AONVA were performed to establish the statistical significance 
between the means of patient clinical characteristics and the 9 PLAs 
variables. Cox regression was performed to assess the association between 
log-transformed and categories of intensity in relation to loco-regional 
recurrence (LRR).  
 
A multivariable model was also performed, adjusting for age at diagnosis, 
analysis was repeated while stratifying for tumour characteristics at diagnosis: 
histological type, T stage (i.e. invasive tumour size), histological grade, lymph 
node status, ER, PR and HER2 status. Associations were further visualised 
using cumulative incidence function for LRR by intensity categories.  
 
A multivariate analysis and Kaplan- Meier life tables with log rank testing were 
plotted to assess the association between log-transformed and categories of 
intensity in relation to overall survival (OS). A value of p=0.05 was considered 
statistically significant.  
Bonferroni correction for multiple analyses was not performed in this study 
based on the advice of the statistician Dr. Wahyu Wulaningsihusing. Although 
in numerous multiple comparisons, spurious correlations may occur, this is 
only possible if scientifically the null hypothesis is correct, i.e. if there is no 
plausible biological association (Rothman 1990) which is unlikely to be the 
case in our study. Adjusting P-values for multiple comparisons, albeit 
convenient in decreasing Type I error, may increase Type II error and thus 
reduce the power of detecting a true association (Gelman, Hill et al. 2012), so 
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5.5 Results 
 
5.5.1 Assessment of receptor phosphorylation and complex 
formation in breast cancer patients. 
 
The total protein level of HER receptors and the presence of phosphorylated 
EGFR, HER2 and HER3 and HER dimers were analyzed using PLA single 
and double recognition assays on the cohort of patients. Figure 5-3 shows the 
median distribution of the 9 different biological markers among patient’s 
samples using boxplot.  
 
 
Figure 5:3. The median distribution of the 9 variables among this cohort of breast cancers, 
the circles in the plot indicate outliers (the value in the log). 
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5.5.2 Detection of protein expression and PLA staining pattern 
in invasive breast cancer 
 
The expression of HER1, HER2 and HER3 in tumour samples was evaluated 
using IHC (Ventana Medical Systems, Inc, Tucson, AZ) combined with PLA 
single recognition assays. The results show a correlation between IHC and 
PLA methods in detecting overexpression of receptors in positive cases. 
Figure 5:4 shows two examples of HER2 positive, grade 3 ductal carcinoma 
cases that score 3+ with standard IHC method and the PLA results are 
positive within the high level score.   
   
However, due to the higher sensitivity of the PLA assay, the various 
expression of HER receptors in breast cancer samples was more easily 
detected with the PLA method. For example, the evaluation of HER1 
receptors by PLA showed the presence of the protein in 19.0% (50/262) of the 
cases that were categorized within the high level groups but 
immunohistochemistry (IHC) showed the presence of the protein in 0.76% 
(2/262) of all tumours. Figure 5:5 shows one case, negative for HER1 with 
IHC, while with PLA single recognition assay using the same α-EGFR primary 
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Figure 5:4. The results of IHC and PLA methods. The results show correlation in detecting 
overexpression of receptors in positive cases. Two HER2 positive grade 3 ductal carcinoma 
cases that score 3+ with standard IHC method (A&C). With PLA the results are positive within 
the high level score (B&D). (IHC Images were taken with the Hamamatsu Nanozoomer and 
PLA images at 40x resolution of 0.181 μm/pixel with an Ariol SL-50 automated slide scanner 
(Leica Biosystems). 			
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 Figure 5:5. More cases were detected as positive using the PLA method than showed 
detectable protein expression levels with IHC. A - IHC stain for HER1 in one case in which 
no protein was detected; B - PLA staining for the same tumour show readily detectable 
expression of HER1 receptor. (IHC Images were taken with the Hamamatsu Nanozoomer 
and PLA images at 40x resolution of 0.181 μm/pixel with an Ariol SL-50 automated slide 
scanner (Leica Biosystems). 		
5.5.3 The PLA staining patterns in invasive breast cancer 
 
In tumours showing relatively high protein expression, PLA staining was seen 
in both the cell membrane and the cytoplasm for all the three receptors, 
similar to the pattern of IHC staining (Figure 5:6 A&B). However, the 
phosphorylated forms of the receptors were mostly observed in the cytoplasm 
and near the nucleus, reflecting endocytosed and trafficked receptors (Figure 
5:6 C&D).  
 
In many positive tumours the expression of the proteins, co-localization and 
their phosphorylated forms were generally heterogeneously distributed within 
the tumour cells, although a few showed homogenous distribution (Figure 5:6 
A). Thus, in many positive tumours, weakly stained, or negative regions were 
seen adjacent to the more strongly stained areas.   
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Figure 5:6. In many positive tumours the expression of the proteins and their 
phosphorylated form were generally heterogeneously distributed within the tumour, 
although a few showed homogenous distribution. A & B - examples of homogenous and 
heterogeneous distribution of HER2 protein respectively in two different tumours. C&D - 
phosphorylated HER1 and HER2 heterogeneous distribution respectively within the tumour 
parenchyma. Images were taken at 40x to a resolution of 0.181 μm/pixel with an Ariol SL-50 
automated slide scanner (Leica Biosystems). 							
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5.5.4 Direct observation of protein complexes and post-
translational modification in breast cancer patient’s samples. 
 
The co-localization between the HER family and their activation status was 
detected using double recognition PLA assays in breast cancers, as 
previously noted. An example of HER1 and HER2 phosphorylation detection 
is presented in Figure 5:6; Figure 5:7 shows an example of HER1/HER2 and 









Figure 5:7. HER complex formation was analyzed in tumour samples using PLA double 
recognition assays; each red signal indicates a complex formation.  
A - an example of HER1/HER2 complex formation; B - an example of HER1/HER3 complex 
formation in a different tumour. Images were taken at 40x to a resolution of 0.181 μm/pixel 
with an Ariol SL-50 automated slide scanner (Leica Biosystems). 						
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5.5.5 The association between HER heterodimers, 
phosphorylation and total protein levels. 
 
Further analysis was undertaken to investigate the association between HER 
total protein levels and the incidences of HER dimers formation and 
phosphorylation using non-parametric Spearman’s rank tests as previously 
noted.  
 
The results show positive and significant associations between the three HER 
family total protein levels. Increased levels of total HER1 were positively and 
significantly associated with total HER2 and HER3 protein levels (rs = 0.161, 
n=194,p=0.025; rs = 0.278, n=194, p= p< 0.0001 respectively). There was also 
a positive association between HER2 and HER3 total protein levels (rs = 
0.225, n=195, p= 0.002). 
 
There were positive and significant associations between total HER2 protein 
levels and the formation of all the three heterodimers HER1/HER2, 
HER1/HER3 and HER2/HER3 (p= 0.001; p= 0.028; p< 0.0001, respectively) 
(Table 5-3). Increased levels of total HER2 protein are seen to have a positive 
association with increased levels of HER2 and HER3 phosphorylation (p= 
0.046; p= 0.024 respectively) (Table 5-4).  
 
Total HER1 protein levels were found to have a positive and significant 
association with the formation of HER1/HER3 and HER2/HER3 dimers and 
increased levels of HER3 phosphorylation (p<0.0001; p< 0.0001; p= 0.016 
respectively; Tables 5-3 and 5-4). However, no association was found 
between total HER1 protein levels and HER1/HER2 dimer formation, or with 
phosphorylated HER1. This suggests phosphorylated EGFR and HER1/HER2 
dimer is independent of total protein levels, perhaps being dominated by 
ligand dependent heterodimerization (Kong, Leboucher et al. 2006, Halle, 
Lando et al. 2011, Barros, Abdel-Fatah et al. 2014).   
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Similarly, the results also show positive and significant associations between 
total HER3 protein levels and the formation of HER1/HER3 and HER2/HER3 
dimers (p< 0.0001 for both; Table 5-3). Furthermore, increased levels of 
HER3 were found to be positively associated with increased levels of HER3 
and HER1 phosphorylation (p= 0.021 and p< 0.0001 respectively; Table 5-4). 
 
The association between HER heterodimer formation and phosphorylation 
was also investigated and the results indicate positive associations between 
the incidences of HER1/HER2 dimer formation and the phosphorylation of 
HER2, HER1 and HER3 (p= 0.001; p< 0.0001 and p= 0.026 respectively; 
Table 5-5). Likewise, there were positive and significant associations between 
HER2/HER3 dimer formation and the phosphorylation of HER2, HER1 and 
HER3 (p= 0.004; p= 0.014 and p= 0.001 respectively; Table 5-5).  The results 
also show a positive association between HER1/HER2 dimer formation and 
the phosphorylation of HER3 (p= 0.026). 
 
The results also show positive and significant association between the 
incidences of HER1/HER3 dimers formation and HER1 phosphorylation only 
(p< 0.0001; Table 5-5). 
 
Furthermore, there were positive and significant association between the 
incidences of the three heterodimers. Increased levels of HER1/HER2 were 
positively and significantly associated with increased levels of HER1/HER3 
and HER2/HER3 dimers (rs = 0.312, n=152, p< 0.0001; rs = 0.280, n=148, 
p=0.001) respectively. Likewise, there was a positive and significant 
association between HER1/HER3 and HER2/HER3 dimer formation (rs = 
0.323, n=184, p< 0.0001). 
 
In addition, there were positive and significant associations between all the 
three HER phosphorylation. Increased levels of HER1 phosphorylation have a 
positive and significant association with HER2 and HER3 phosphorylation  
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(rs = 0.176, n=213, p=0.01; rs = 0.324, n=176, p< 0.0001) respectively. 
However, no association found between HER2 and HER3 phosphorylation 
was seen.   
 
The following Tables (5-3, 5-4 and 5-5) summarize the associations between 
total protein levels and HER heterodimers formation, the associations 
between total proteins levels and HER phosphorylation and the associations 
between HER heterodimers formation and HER phosphorylation respectively. 
Figures 5:8 and 5:9 illustrate an example of the association between total 
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Figure 5:8. A significant association was found between total HER2 protein level and 
HER1/HER2 dimer formation by spearman’s correlation test. (rs =correlation coefficient, 





Figure 5:9. A significant association found between total HER2 protein level and 
phosphorylated HER2 by spearman’s correlation test. (rs =correlation coefficient, N=number 
of cases, p= p value). 
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5.5.6 The Association between PLA Variables and Patient and 
Clinical Characteristics 
 
The associations between HER family expression, activation status and 
dimerization and the clinical characteristics, including tumour size, grade, 
tumour stage and lymph node status were investigated. 
 
Using one-way ANOVA test the results show significant association between  
histological grade of tumour and the total HER2 level (p= 0.001) (Figure 5:10). 
A higher level of HER2 is associated with higher grade in these invasive 
breast cancer patients. No other significant associations were found between 







Figure 5:10. A significant association (one-way ANOVA) was found between total HER2 and 
tumour grade in which higher level of total HER2 is found in tumours of higher grade. 
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5.5.7 The importance of receptor phosphorylation and 
dimerization on patient’s prognosis. 
 
The main focus of this project is on the detection of receptor tyrosine kinase 
signal transduction pathway states in breast cancers and an assessment of 
how these activation states relate to patient outcome. The successful 
detection of HER family activation status, as well as complex formation and 
their total protein expression, lead to the next step of studying how these 
variables relate to breast cancer patient’s outcome. We therefore examined 
which variables among the 9 different parameters correlated with the risk of 
loco-regional recurrence (LRR) using Cox proportional hazard’s model.  
 
Follow-up from the study included the date of surgery and ended at the first 
manifestation of LRR, death or at the end of the follow-up (31 December 
2005) without LRR or death. Among all patients, 19.5% (51) developed local 
recurrence while the rest 80.5% (211) did not.  
 
The expression of the 9 variables was first categorized as high (upper 
quartile) or low (remaining quartiles) as previously described (Spears, Taylor 
et al. 2012).  	
Overall risk of recurrence in stratified multivariate analysis, adjusting for age 
at diagnosis, invasive tumour size, nodal status, histopathological type, 
histological grade, ER, PR and HER2 status, we found that some of the 
parameters were associated with the patient risk of local recurrence. 
 
Analysis shows that higher levels of phosphorylated HER2 are associated 
with a higher risk of local recurrence among patients with invasive lobular 
carcinoma (p = 0.04 HR 0.99, 95% CI: 0.997-1.002). Figure 5:11 shows the 
accumulative incidence risk curves. From the curves we can detect a 
significant difference between the two groups after almost two years; the risk 
increases with time in those patients with higher levels of phosphorylated 
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HER2. However, the numbers of patients in the HER2 phosphorylation high 










Figure 5:11. Cumulative incidence functions for loco-regional recurrence (LRR) by intensity 
of phosphorylated HER2 in patients with invasive lobular breast cancer.  	
 
In multivariate analysis adjusting for patient age at diagnosis, grade, 
histological subtype, nodal status, ER, PR and HER2 status, higher levels of 
HER1/HER3 dimer are associated with a higher risk of having local 
recurrence in T1 (<2cm) breast cancer patients, (p = 0.02, HR 1.84, 95% CI: 
1.08-3.13). Figure 5:12 shows the accumulative incidence risk curves; 
although the curves suggest no differences between the two groups in the first 
5 years after almost 6 years, the risk increases within the higher-level group. 
Here the numbers of patients in the two groups give confidence that this 
difference is not due to chance. 
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Figure 5:12. Cumulative incidence function for loco-regional recurrence (LRR) by intensity of 
HER1/HER3 dimer in T1 (<2cm) breast cancer patients. 
 
In multivariate analysis adjusting for patient age at histopathological 
diagnosis, grade, histopathological subtype, nodal stage, ER, PR and HER2 
status, we found that higher levels of HER1/HER3 and HER2/HER3 dimers 
are associated with a higher risk of local recurrence in breast cancer patients 
with N1 nodal status (p <0.0001, HR 1.84, 95% CI: 0.58-1.93) and (p <0.0001, 
HR 0.64, 95% CI: 0.45-0.90) respectively). Figures 5:13 & 5:14 show the 
accumulative incidence risk curves. These show an increased risk of local 
recurrence among the higher-level group. However, as indicated in 5:14, it is 
worth noting that the numbers of events here are very small and there is the 
possibility that the differences are down to chance. This is not the case with 
the data shown in 5:13 where in the high group there are multiple events. 
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 Figure 5:13.  Cumulative incidence function for loco-regional recurrence (LRR) by intensity 







Figure 5:14.  Cumulative incidence function for loco-regional recurrence (LRR) by intensity of 
HER2/HER3 dimers in breast cancer patients with N1 nodal status. 
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No other variables showed a significant association with risk of local 
recurrence in multivariate analysis. However, interesting trends were noted 
between low and high level groups in some of the analyses; for example, 
there was an interesting difference noted between the HER1/HER3 low group 
and the high group in ER negative breast cancer patients (Figure 5:15). Allred 
score of 3 was used to define ER positive tumours (Harvey, Clark et al.1999). 
Interesting differences between high and low level groups were also noted in 
grade 2 and HER2 negative patients with higher total HER1 (Figures 5:16 & 
5:17). This interesting trend was also observed in younger patients with higher 
level of total HER3 (Figure 5:16). Again, it worth noting that the numbers of 







Figure 5:15. Cumulative incidence functions for loco-regional recurrence (LRR) by intensity 
of HER1/HER3 dimers in breast cancer patients with ER negative breast tumours. Although 
not statistically significant (p=0.06), an interesting difference is observed between the low and 
high-level groups. The lack of significance could be due to the low number of patients in this 
study (ER negative patients = only 61 in this study cohort).   
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 Figure 5:16. Cumulative incidence functions for loco-regional recurrence (LRR) by intensity 
of total HER1 in patients with grade 2 breast cancers. Although not statistically significant 






Figure 5:17. Cumulative incidence functions for loco-regional recurrence (LRR) by intensity 
of total HER1 in patients with HER2 negative cancers. Although not statistically significant 
(p=0.06) an interesting apparent difference is observed between the low and high level 
groups.  
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Figure 5:18. Cumulative incidence functions for loco-regional recurrence (LRR) by intensity 
of total HER3 in patients of younger age. Although not statistically significant (p=0.07) an 
interesting apparent difference is observed between the low and high-level groups.  
		
5.5.8 The predictive value of the parameters  
on patient overall survival   
 
After investigating the prognostic significance of the 9 parameters on patients’ 
local recurrence risk, and identifying three parameters, which showed a 
significant correlation with risk of local recurrence, further analysis was 
undertaken to investigate the prognostic value of these parameters on 
patient’s survival risk.  
 
An overall survival analysis was carried out using Kaplan Meier curves, which 
showed no significant association between the different variables and survival 
risk. However, some trends for worse survival were observed with higher total 
HER1 protein (Figure 5:19), and total HER2 protein level (Figure 5:20).  By 
examining the association between overall survival and the 9 variables using 
stratified Cox regression, the risk of death was found to be greater in patients 
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with higher total HER2 protein in ductal type invasive cancers with an age-
adjusted HR of 1.95 (95% CI: 1.01-3.74).  A greater risk of death was found to 
be associated with higher HER2-HER3 dimerisation in grade 3 breast 
tumours, with an age-adjusted HR of 2.58 (95% CI: 1.15-5.83). 
  
A higher risk of death was also found to be associated with higher expression 
of total HER3 in patients with grade 1 tumours, and in T1 (<2cm) breast 
cancers, with an age-adjusted HR of 15.54 (95% CI: 1.19-203.64) and HR of 
2.67 (95% CI: 1.14-6.28), respectively. A higher risk of death was also 
associated with higher HER2-HER3 dimerisation in N2 tumours, with an age-
adjusted HR 7.17 (95% CI: 2.22-23.10).  
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Figure 5:19. Kaplan-Meier curve for overall survival (OC). Green: patients with high level of 
total HER1. Blue: patients with low level of HER1. Although there is no difference in survival 
between the two groups, there is trend for worse survival observed among patients with 
higher total HER1 protein. 																	
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Figure 5:20. Kaplan-Meier curve for overall survival. Green: patients with high level of total 
HER2. Blue: patients with low level of HER2. Although there is no difference in survival 
between the two groups, there is trend for worse survival observed among patients with 
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5.6 Discussion 
 
To improve breast cancer treatment more accurate tailoring is needed, which 
requires incorporation of additional cancer biological information to ensure all 
known variables that could possibly influence patient outcome and response 
to therapy are considered. In this context, there has been an increasing 
interest in the clinical utility of multigene assays such as the Mammaprint test 
(van 't Veer, Dai et al. 2002) and Oncotype DX (Paik, Shak et al. 2004) and 
their incorporation into strategies of breast cancer management. While the 
concept of molecular taxonomy of breast cancer using gene expression 
profiling has received great interest in the scientific community, incorporation 
into the routine clinical setting has not, as yet, proven successful for various 
reasons, including cost and reproducibility (Hergueta-Redondo, Palacios et al. 
2008). 
 
There is now extensive evidence connecting overexpression of HER1, HER2 
and HER3 with poor prognosis and clinical resistance to therapy (Ritter, 
Perez-Torres et al. 2007, Eccles 2011, Gajria and Chandarlapaty 2011, Dey, 
Williams et al. 2015), but until recently it has been technically difficult to 
analyse the expression and formation of HER family member hetero-
dimerization in situ. Proximity Ligation Assay (PLA), a novel technology for the 
in situ detection of HER post-translational modification and complex 
formation, as well as total expression levels (Soderberg, Gullberg et al. 2006), 
was applied here in a series of formalin fixed, paraffin embedded routine 
clinical breast cancer samples. The PLA provided a robust, reproducible and 
quantifiable assessment of 9 different biological parameters including HER1, 
HER2 and HER3 total protein expression, phosphorylation and complex 
formation. Following optimization of this method (described in Chapter 4), I 
have applied the PLA method to fixed material from a large cohort of women 
with invasive breast cancer, which supports other studies that have used PLA 
in clinical settings (Aubele, Spears et al. 2010, Spears, Taylor et al. 2011, 
Gajadhar, Bogdanovic et al. 2012, Barros, Abdel-Fatah et al. 2014).  
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However, in this study I have also investigated and analysed 9 different 
biological parameters associated with this receptor family. The data indicate 
that this approach may provide novel and useful information on both the 
prognostic and predictive value of the various HER family interactions and 
their activation status. 
 
A potential clinical role for the determination of HER:HER protein-protein 
interactions has been suggested in a previous study using the VeraTag 
assay. This showed that patients with tumours that had high levels of HER2 
homodimers were more likely to benefit from trastuzumab (Desmedt, 
Sperinde et al. 2009). However, an important limitation of the VeraTag system 
is that the signal needs to be detected in a liquid phase, so the precise source 
of the protein dimers is unknown. It cannot thus differentiate between invasive 
cancer and ductal carcinoma in situ (DCIS) components and cannot be 
routinely applied to tissue microarrays of large cohorts or clinical trials 
(Spears, Taylor et al. 2012).    
 
The ability of PLA to demonstrate protein complexes and post-translational 
modifications is a useful innovation and provides an opportunity to improve 
our understanding of the signaling pathways involved in disease, through the 
in situ detection of protein complexes and activation status. In this study the 
PLA assay implicates a role not only for HER1, HER2 and HER3 expression 
in invasive breast cancer but also for HER1/HER2, HER1/HER2 and 
HER2/HER3 protein interactions and their phosphorylated forms. It also 
shows that these complex systems can be examined in routinely handled 
clinical samples. 
 
The distribution of the PLA signals in breast cancers as examined and the 
expression of the proteins and their phosphorylated forms were generally 
heterogeneously distributed within the tumour, in many positive tumours 
weakly stained regions were adjacent to more strongly stained areas. 
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Our findings also show a positive and significant association between various 
HER dimers and phosphorylated forms and total protein levels. This shows 
that, for these receptors, complex formation and phosphorylation was 
prominent in cases with high protein levels. However, no significant 
correlation was found between total HER1 and its phosphorylated form, which 
could suggest that the expression level of the HER1 total protein is 
independent of its activation status; similar findings were also reported in 
previous studies (Kong, Leboucher et al. 2006, Halle, Lando et al. 2011, 
Gajadhar, Bogdanovic et al. 2012). 
 
The results confirm that HER2 plays an important part in the formation of HER 
heterodimers with a positive association as found between increased levels of 
HER2 and the formation of all the three heterodimers, i.e. HER1/HER2, 
HER1/HER3 and HER2/HER3 and in which a strong positive association was 
observed with HER2/HER3 dimer formation. These findings are 
unsurprisingly, since HER2 is the preferred partner of the HER family 
members, despite the fact that HER2 has no known ligand (Dean-Colomb and 
Esteva 2008, Roskoski Jr 2014). This is due to an intrinsically extended 
interaction loop rendering it constitutively available for dimerization and hence 
prolonging the MAPK pathway (Graus-Porta, Beerli et al. 1997, Burgess, Cho 
et al. 2003, Roskoski Jr 2014) connecting these cases with high biological 
activity. Similarly, HER3 is also considered the preferred partner of the HER 
family (Eccles 2011, Kol, Terwisscha van Scheltinga et al. 2014). 
Furthermore, the increase in HER1/HER2 dimers leads to an increase in 
growth signaling, due to the decrease in recycling of HER1 and increased 
signaling from HER2/HER3 dimers. This may lead to more aggressive tumors 
and a decrease in survival (Witton, Reeves et al. 2003, Kol, Terwisscha van 
Scheltinga et al. 2014). 
 
These results also show that increased levels of HER2 have a positive 
association with HER1 and HER3 total protein levels in invasive breast 
cancer, which explains the positive association between HER2 protein levels 
and HER1/HER3 heterodimer formation. However, no association was found 
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between total HER1 protein level and HER1/HER2 dimerization, which may 
indicate that total HER1 can be independent of HER1/HER2 dimer formation. 
Similar findings were reported in a different study in which HER1 expression 
level was reported to be independent of HER1/HER2 dimerization in HER2+ 
breast cancers (Barros, Abdel-Fatah et al. 2014).  
 
These observations underscore the importance of targeting HER2 in breast 
cancer patients that show protein overexpression. HER2 is the target for two 
therapeutic agents, trastuzumab and lapatinib, which are beneficial in the 
treatment of HER2 positive breast cancer patients. Trastuzumab targets the 
extracellular subdomain IV of the HER2 receptor (Vu and Claret 2012). This 
leads either to HER2 internalization and degradation through promoting the 
activity of tyrosine kinase-ubiquitin ligase, the inhibition of the MAPK/PI3K/Akt 
pathways which lead to increase in cell cycle arrest, or it can attract immune 
cells to tumour sites by a mechanism called antibody-dependent cellular 
cytotoxicity (ADCC) (Vu and Claret 2012).  Patients can also benefit from the 
dual action of lapatininb in combination with Trastuzumab. Lapatinib is a 
tyrosine kinase inhibitor, directed against HER2 and EGFR pathways 
(Baselga, Bradbury et al.). 
 
Moreover, our findings show that increased levels of total HER2 in invasive 
breast cancer is associated with increased levels of HER2 and HER3 
phosphorylation, which confirm the notion that HER2/HER3 is the major 
oncogenic unit in breast cancer (Spears, Taylor et al. 2012). These results 
suggest that HER3 may be an appropriate therapeutic target in breast cancer 
and the targeting HER3 in HER2+ invasive breast cancer with Pertuzumab 
(2C4). Pertuzumab inhibits formation of ligand-induced dimerization by 
binding to the subdomain II dimerization arm of HER2 (Agus, Akita et al. 
2002, Franklin, Carey et al. 2004) and in association with trastuzumab, 
Pertuzumab could lead to substantial clinical benefit. In addition, 
Phosphorylated HER3 was found be associated with HER1/HER2 dimer 
formation and although it is difficult to explain this association in functional 
terms and requires confirmation in larger series 
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However, the main focus of this study was to assess how these biological 
parameters related to the patient outcome. Using Cox proportional hazards 
model we examined the correlation between the 9 parameters and patient risk 
of local recurrence. We have shown that higher level of phosphorylated HER2 
is associated with higher risk of local recurrence among patients with invasive 
lobular carcinoma.  
 
Invasive lobular carcinoma (ILC) is the second most common subtype of 
invasive breast cancer after invasive ductal (no special type) carcinoma and 
accounts for 10-15% of all invasive breast cancers (Sawyer, Roylance et al. 
2014). Despite the fact that the majority of ILCs express oestrogen and 
progesterone receptor but lack HER2 amplification (Bilous, Ades et al. 2003, 
Yu, Dabbs et al. 2011, Lien, Chen et al. 2015), our findings indicate the 
presence of HER2 overexpression and an association with local recurrence in 
ILC. Furthermore, a different study identified a group of classical ILC with 
HER2 overexpression  (Yu, Dabbs et al. 2011). HER2 over-expression in ILC 
could be due to gene mutation (Shah, Morin et al. 2009, Lien, Chen et al. 
2015).  
 
ILC has been the subject of increasing interest because of rising incidence 
among postmenopausal women. Although patients with ILC have a similar 
disease free survival to invasive ductal carcinoma, there is some evidence 
that these tumours are particularly sensitive to hormone therapy and that 
patients fare worse if this is not received (Yu, Dabbs et al. 2011).  These 
invasive carcinomas also have different patterns of metastasis to other breast 
cancers and thus may behave in a different manner to other subtypes. 
Overall, it seems likely that any improved management for patients with ILC 
should be based on individual patient and tumour characteristics and the 
identification that higher level of phosphorylated HER2 holds an increased risk 
of local recurrence for ILC patients is of clinical interest.  
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The multivariate analyses also generated data suggesting that the level of 
HER1/HER3 and HER2/HER3 heterodimers may be prognostically significant 
and associated with local recurrence. High levels of HER1/HER3 expression 
were associated with higher risk of local recurrence in T1 (<2cm) breast 
cancer patients. Also, higher levels of HER1/HER3 and HER2/HER3 
expression were associated with higher risk of local recurrence in N1 breast 
cancer patients. In one study HER2/HER3 heterodimers were found to be the 
only interaction with significant association with distant metastases in HER2 
positive breast cancer (Barros, Abdel-Fatah et al. 2014). Another recent study 
of a cohort of breast cancer patients similarly showed that the presence of 
higher levels HER2/HER3 expression were significantly associated with 
reduced relapse free survival (RFS) and overall survival (OS) (Spears, Taylor 
et al. 2012). However, in the present series, no significant association was 
found between the different parameters and overall survival. 
 
In summary, PLA provided an apparently successful and quantifiable 
assessment of the HER family protein interactions, activation status and 
expression levels. In multivariate analyses, three different parameters were 
identified to be associated with higher risk of local recurrence of breast 
cancer: (1) higher expression of phosphorylated HER2 were found to be 
associated with higher risk of recurrence in patients with invasive lobular 
carcinoma; (2) high levels of HER1/HER3 expression were associated with 
higher risk of local recurrence in T1 (<2cm) breast cancer patients; (3) higher 
levels of HER1/HER3 and HER2/HER3 expression were associated with 
higher risk of local recurrence in N1 breast cancer patients. These findings 
could be built on, in order to potential improve current prognostic methods, for 
example by combining well recognised clinico-pathological variables presently 
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6.1 Introduction 
 
The clinical presentation of ductal carcinoma in situ (DCIS) has been changed 
dramatically by the introduction of national mammographic screening 
programmes. Lesser subsequent changes include the increasing use of 
magnetic resonance imaging (MRI) and digital mammography. Prior to this, 
DCIS was only diagnosed in patients presenting with a palpable mass, nipple 
discharge or occasionally found by accident and accounting for only 2.3% of 
10,000 cases treated in the 1980s (Rosner, Bedwani et al. 1980). Currently, 
DCIS comprises 20-25% of all detected breast cancers in population 
screening programs (Pinder 2010).  
 
DCIS is a heterogeneous group of lesions rather than a single entity disease, 
with different and unpredictable biological behaviour (Pinder 2010). Although 
it is considered to be the precursor of invasive breast cancer, not all DCIS will 
progress (Patani, Khaled et al. 2011). The progression to invasive breast 
cancer has been reported to be between 14% and 75% in untreated patients 
within 5-6 years of initial diagnosis (Patani, Khaled et al. 2011). Hence, the 
major challenge in the modern management of DCIS is to avoid over-
treatment.  
 
The management of DCIS includes surgical excision of the disease with clear 
margins, which may involve breast conservation surgery (BCS) or 
mastectomy, the former with or without radiation therapy, and potentially with 
hormone therapy added in some cases (Figure 6:1) (Sakorafas and Farley 
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Figure 6:1.	 Standard treatment options for DCIS patients include lumpectomy followed by 
radiotherapy treatment, which is the most common option, lumpectomy alone, or mastectomy 
with or without hormonal therapy.  
 
Total mastectomy was the standard treatment for women with DCIS until the 
mid 1980s (Rosner, Bedwani et al. 1980, Ernster, Barclay et al. 1996). This 
aggressive treatment was seemingly justified since less than 5% of diagnosed 
breast cancers were DCIS and the lesions were typically large (Ernster, 
Barclay et al. 1996). In the light of increasing use of breast conservation 
surgery for invasive cancers, the role of mastectomy as the treatment of 
choice for DCIS was, however, questioned. The fact that most women with 
invasive cancer do not need mastectomy highlights a paradox of using a 
drastic approach for a non-invasive cancer that is more extensive than that for 
the disease one is trying to prevent. However, the move away from 
mastectomy to breast conservation surgery without adjuvant therapy carries 
an increased risk of local recurrence, to approximately 20% within 10 years 
(Cuzick 2003).  
 
Furthermore, there is a trade-off between treatments; aggressive treatment 
potentially reduces the risk of recurrence, but it may lead to side effects, either 
caused by radiation and/or hormonal therapy as well as disfiguration caused 
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by mastectomy. Given that DCIS is a heterogeneous disease the one size-fits 
all approach to treatments appears unsuitable (Wang, Shamliyan et al. 2011). 
In addition, the importance of achieving clear margins in surgical specimens 
has now been established (Pinder 2010) , but there is doubt about the need 
for additional treatment in women with low grade DCIS which has been 
completely excised. Even more doubt exists as to what constitutes a 
completely excised lesion and how extensively does the surgical specimen 
need to be sampled to determine margin status (Pinder 2010).   
 
The previous Chapter outlines the assessment of the HER family protein 
interactions, activation status and expression level in a cohort of invasive 
breast cancers using the PLA method and how these parameters relate to 
patient outcome. The multivariate analysis identified three different 
parameters that were significantly associated with risk of having local 
recurrence.  The aim of this Chapter is to apply the same 9 different HER 
parameters to a cohort of patients with pure DCIS to assess HER dimer 
formation and activation status, as well as protein expression levels. This 
could allow investigation of possible differences in the expression of HER 
dimer formation and activation status between DCIS lesions and invasive 
breast cancer and potential provides a better understanding of the biological 
characteristics of pre-invasive tumour.   
6.2 Materials 
 
Tissue Microarrays (TMAs) and Patient Characteristics. 
 
The Tissue Microarrays (TMAs) used in this study were collected from Guy’s 
and St Thomas’ (King’s Health Care Partner’s) Breast Cancer Biobank 
archive and were generated previously by Mr. John Brown (please refer to 
Chapter 2). The TMAs contains 37 cases presenting with pure ductal in situ 
carcinoma (DCIS) between 1988 and 2001; the patient’s characteristics are 
summarized in Table 6-1.  
An H&E section was prepared first from the TMAs to assess the quality of the 
cores and the presence of DCIS. Overall 73% of all cores, (27/37) contained 
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DCIS, therefore they were included in the analysis, the remaining cores (27% 
10 cores) either did not contain DCIS, or the cores were missing, and these 
were excluded from the analysis.  
 
Table 6-1. Patient clinical characteristics 	
Clinical Characteristics No of patients % 
 
Age at surgery 
 
< 50 14 51.9 
≥50 13 48.1 
 
Main DCIS architecture  
 
Solid 12 44.4 
Cribriform 10 37 
Micropapillary 3 11.1 
Papillary  2 7.4 
 
DCIS size  
 
≤20 mm  17 63 
20-30 mm 9  33.3 




    Low grade  2 7.4 
Intermediate grade 14 51.9 





Absent 4 14.8 




Negative 9 33.3 




Negative 18 66.7 




Negative 23 85.2 
Positive 4 14.8 
 
History of Recurrence 
  
Recurrence 3 11.1 
  No recurrence 24 88.9 
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6.3 Methods 		Proximity Ligation Assays (PLAs). 
 
The double and single recognition PLA assays used to assess the 9 different 
biomarkers representing HER1, HER2 and HER3 total protein expression, 
heterodimerization and activation status for each patient in the cohort of 27 
cases of pure DCIS cases are illustrated in Figure 6:2. The primary antibodies 
used to assess the HER family in breast cancer patient samples are 
summarized in Table 6-2 (please see also Chapter 2). 
 


































Figure 6:2. Illustration of the PLA assays used to evaluate 9 different biomarkers 
representing HER1, HER2 and HER3 expression, phosphorylation and co-expression in 
these breast cancer patients. 								
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Table 6-2. The primary and PLA probes used in the designed PLA assays.		
Designed PLA 
Assays 
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6.4 Image and Statistical Analysis 	
6.4.1 Image analysis 
Images were taken at 40x to a resolution of 0.181 μm/pixel with an Ariol SL-
50 automated slide scanner (Leica Biosystems) or captured by A1R confocal 
microscopy (Nikon imaging Center) using a 40x or 60x objective for the PLA 
images and Hamamatsu Nanozoomer for IHC. Images of three different fields 
of the 9 PLA variables for each case of the 27 cases assessed were taken 
and the intensity of in situ PLA signals per cell was measured using the cell 
image analysis software Cell Profiler from the Broad Institute (Carpenter, 
Jones et al. 2006).  
 
6.4.2 Biological markers 
Intensity of markers was not normally distributed; therefore, markers were 
logarithmically transformed in the analysis. Additionally, a dichotomous 
categorization of markers intensity was employed using the 75th percentile of 
intensity as the cut-off point for high and low intensity (Spears, Taylor et al. 
2012).  
6.4.3 Statistical analysis of patient’s data 
As previously noted in Chapter 5, all the statistical analysis used in this study 
were performed with the help of Dr. Wahyu Wulaningsihusing from the 
Epidemiology department at Guy’s and St Thomas’ hospital using either 
SPSS statistical package (Version 22 for MAC) or SASH v 9.3.  Spearman’s 
rank correlation test was performed to investigate the association between the 
continuous variables since the data display abnormal distribution (Mukaka 
2012). One-way AONVA were performed to establish the statistical 
significance between the means of patient’s clinical characteristics and the 9 
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6.5 Results  
6.5.1 Assessment of HER family phosphorylation and 
complex formation in DCIS 
 
The expression of total HER proteins and the presence of phosphorylated 
EGFR, HER2 and HER3 and HER dimers complex were analyzed using PLA 
single and double recognition assays on these DCIS cases. Figure 6:3 shows 
the median distribution of the 9 different variables among patients’ tissue 




Figure 6:3. Median distribution of the 9 variables among DCIS patients, the circle in the plot 
indicates outliers. 
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6.5.2 The PLA staining patterns in DCIS 
 
The evaluation of HER1, HER2 and HER3 expressions in tumour samples 
was performed using IHC (Ventana Medical Systems, Inc, Tucson, AZ) 
combined with PLA single recognition assays. 
 
There was a correlation between both methods in detecting receptors 
overexpression in positive cases; Figure 6:4 A&B shows a solid architecture 
DCIS with positive HER2 stained with PLA and IHC respectively. 
  
There was also a correlation between both methods in some of the negative 
cases; Figure 6:4 C&D shows a HER2 negative solid architectural DCIS case 
stained with both methods. However, due to the higher sensitivity of the PLA 
assay, and as observed in the invasive breast cancer cases, the expression of 
various HER receptors in DCIS tumors was easily detected with the PLA 
method.  
 
Figure 6-5 shows a solid architecture DCIS with negative HER2 results using 
IHC and by PLA in the same case for total HER2 protein in single recognition 
assay; the results shows high expression of HER2.   
  
The pattern of PLA staining in DCIS was seen both in the cell plasma 
membrane and the cytoplasm for all the three HER receptors in cases with 
higher protein expression and it shows a homogenous distribution (Figure 6:4 
A).  However, the expression of the proteins and their phosphorylated forms 
were generally heterogeneously distributed within the DCIS cells in many 
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Figure 6:4. The expression of HER family was evaluated using IHC and PLA methods, in 
which both methods show correlation in detecting receptor overexpression in positive cases 
and no staining in negative cases. A & B show a solid architecture DCIS with positive HER2 
staining with both PLA and IHC respectively. C & D show a different Solid architecture DCIS 
case with negative HER2 staining with PLA and IHC respectively. Images were taken at 40x 
to a resolution of 0.181 μm/pixel with an Ariol SL-50 automated slide scanner (Leica 
Biosystems) for the PLA images and the Hamamatsu Nanozommer for IHC. 
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Figure 6:5 The various expressions of HER receptors were easily detected with the PLA due 
to the higher sensitivity of the method. A – Solid/flat architecture DCIS with HER2 positivity 
detected with PLA. B - The same case, and region, shows negative HER2 staining with IHC. 
Images were taken at 40x to a resolution of 0.181 μm/pixel with an Ariol SL-50 automated 






Figure 6:6. The PLA staining pattern in many positive tumours was general heterogeneously 
distributed within the DCIS. A - Heterogeneous distribution of total HER1 in a DCIS case. B - 
A heterogeneous distribution of phosphorylated HER2. Images were taken at 40x to a 
resolution of 0.181 μm/pixel with an Ariol SL-50 automated slide scanner (Leica Biosystems). 		
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6.5.3 Detection of protein complexes and post-translational 
modification in DCIS 
 
The co-localization and dimer formation between the HER1, HER2 and HER3 
and their post-translational modifications were assessed and detected in the 
DCIS cases using PLA double recognition assays.  
 
Figure 6:7 shows the co-localization between HER1/HER2 and HER2/HER3 
detected in two different cases. The association between complex formations, 
receptors protein level and activation status was investigated using 
Spearman’s rank correlation test.  
 
Despite the low number of pure DCIS cases used in this study, the results 
indicate a positive association between HER2 protein level and HER2/HER3 
dimer formation (p=0.05) Table 6-3. However, there were no associations 
found between total HER1 or HER2 protein level and HER1/HER2 dimer 
formation (Table 6-3). No association was found between HER2 protein level 
and HER2 phosphorylation. Nevertheless, the analysis show a positive 
association between HER1/HER2 dimer formation and total HER3 protein 
level (p=0.020) Table 6-3, although it is difficult to explain in functional terms 
the association between HER1/HER2 and total HER3 and it needs 
confirmation in larger series. 
 
The analysis shows that HER1/HER3 complex formation was significantly 
associated with total HER1 and HER3 protein level (p=0.046) and (p=0.036) 
respectively; Table 6-3. In addition, HER1/HER3 complex formation was 
significantly associated with phosphorylated HER1 and HER1/HER2 dimer 
formation (rs = 0.597,n=24, p=0.002; rs = 0.584,n=23, p=0.003, respectively).  
Furthermore, a positive and significant association was found between 
phosphorylated HER3 and its protein level (rs = 0.539, n=15, p=0.038) and 
HER1/HER2 dimer formation (rs = 0.611, n=15, p=0.016); between total HER3 
protein level and HER2/HER3 complex formation (p=0.022), Table 6-3.   
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Figure 6:7. Co-localization and dimer formation between HER receptors was detected in 
DCIS using PLA double recognition assays. A - Co-localization between HER1/HER2 in a 
solid architecture DCIS case. B - The co-localization between HER2/HER3 in another case.  
 
 
Table 6-3. The association between HER total protein level and the incidence 
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6.5.4 The importance of receptor phosphorylation and 
dimerization in relation to patient prognosis 
 
The successful application of PLA assays in pure DCIS proved our ability to 
study protein complexes and post-translational modifications, as well as 
protein expression, in pre-invasive breast cancer. However, one of the major 
challenges when studying biomarkers in DCIS, and the limitations of 
published studies, is that they are limited to small numbers of cases (Lari and 
Kuerer 2011). This is true in this present study; the small number of cases 
with history of local recurrence limited our ability to investigate the absolute 
effect of the expression of the various biological markers on disease 
recurrence and on patient prognosis.   
 
However, we were able to investigate the association between various 
parameters and clinical characteristics which have been shown to be 
associated with increased risk of local recurrence in DCIS. Several studies, 
and randomized clinical trials of the management of DCIS, have investigated 
the association between DCIS characteristics including grade, presence of 
comedo-type necrosis, margin width and completeness of excision and DCIS 




A higher probability of local recurrence has been found to be consistently 
associated with DCIS that has been assigned a higher pathological or nuclear 
grade (Leonard and Swain 2004, Fisher, Land et al. 2007, Pinder, Duggan et 
al. 2010, Wai, Lesperance et al. 2011).  
 
The association between DCIS grade and the 9 different HER parameters 
were investigated using one-way ANOVA test. The analysis shows a 
significant association between cytonuclear grade and total HER2 expression 
(p< 0.0001). In Figure 6:8 we can see a higher expression of HER2 found in 
high cytonuclear grade DCIS compared with low and intermediate grades.   
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 Figure 6:8. A significant association (one-way ANOVA) was found between total HER2 




Comedo-type necrosis is a commonly assessed feature in DCIS (Wang, 
Shamliyan et al. 2011). Comedo-type necrosis DCIS is seen as eosinophilic 
debris containing pyknotic nuclei within the duct space, sometimes defined as 
requiring the presence of five pyknotic nuclei (Douglas-Jones, Gupta et al. 
1996). 
 
An association between the presence of comedo-type necrosis in DCIS and a 
higher risk of local recurrence has been reported in several studies (Habel, 
Daling et al. 1998, Leonard and Swain 2004, Warren, Weaver et al. 2005, 
Rudloff, Jacks et al. 2010). The association between HER parameters and 
comedo-type necrosis was investigated using one-way ANOVA test. The 
results indicate a significant correlation between total HER2 and the presence 
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of comedo-type necrosis (p< 0.0001). In Figure 6:9 we can observe that 









Figure 6:9. A significant association (one-way ANOVA) was found between total HER2 and 




DCIS size is typically measured directly from the histological sections and 
requires meticulous specimen handling and reporting. No defined cut-offs for 
classifying DCIS is widely used; some series define tumours as small if they 
measure less than 20mm in extent (Wang, Shamliyan et al. 2011). An 
association between DCIS size and risk of local recurrence has been reported 
in many studies with an increase risk of local recurrence in patients with a 
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larger lesion size, for example ≥ 20mm (Wang, Shamliyan et al. 2011). The 
association between DCIS size and HER parameters was investigated using 
one-way ANOVA test. No significant association was found between the 
different parameters and DCIS tumour size. 
 
Margins & other biomarkers 
 
In terms of defining completeness of excision of DCIS and the width of 
surrounding normal tissue required there is considerable variation across 
studies. A positive margin has been classified as involved by DCIS or with 
DCIS less than 1mm from the margin; margins more than 1mm are often 
classified as free margins or negative margins (Wang, Shamliyan et al. 2011). 
Several studies have shown that women with positive margins have a higher 
risk of developing local recurrence (Pinder, Duggan et al. 2010). The DCIS 
cases in this project either were associated with negative margins or no data 
was available; therefore, no analysis was performed to investigate the 
association between the parameters and margin width.   
 
The association between oestrogen receptor (ER), progesterone receptor 
(PR) and HER2 status and risk of local recurrence was also investigated. 
Some studies (largely observational rather than randomized clinical trial data) 
have shown a lower risk of local recurrence in women with ER and PR 
positive DCIS (Provenzano, Hopper et al. 2003). However, a higher risk of 
recurrence has been reported to be associated with HER2 positive DCIS 
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6.6 Discussion 
 
DCIS is not one single disease; rather this term encompasses a different 
group of lesions with varying malignant potential. The inability to predict which 
DCIS will progress to invasive carcinoma has led to a menu of treatment 
options similar to those used for the management of invasive breast cancer 
that include surgery, either mastectomy or breast conservation surgery (BCS), 
with radiotherapy, or BCS alone in selected patients (Sakorafas and Farley 
2003).  
 
BCS is considered the standard of care today for the majority of patients with 
DCIS (Burstein, Polyak et al. 2004, Virnig, Tuttle et al. 2010).  However, 5-
10% of DCIS patients treated with BCS alone have a higher risk of developing 
subsequent invasive breast carcinoma within 5 years than after mastectomy, 
which could be mainly because of the difficulty of obtaining clear surgical 
margins (Hetelekidis, Collins et al. 1999, Fisher, Land et al. 2001, Millar and 
Leong 2001, Meijnen, Oldenburg et al. 2008). Therefore adjuvant 
radiotherapy has been added to BCS largely with the aim of sterilizing occult 
residual disease (Solin 2010). This approach has reduced the risk of local 
recurrence to 61%, even though 13% of patients may developed an ipsilateral 
recurrence in comparison to patients with invasive breast cancer treated in the 
same manner (Fisher, Dignam et al. 1998). 
 
Moreover, the addition of tamoxifen to BCS seems appropriate in some 
cases; some studies have shown that the risk of subsequent cancer in DCIS 
patients could be reduced with the use of tamoxifen (Houghton, George et al. 
2003). However, subsequent analysis showed that the benefits of tamoxifen 
are confined to those patients with ER-positive disease (Allred, Anderson et 
al. 2012, Morrow 2012). Nevertheless, the risk of breast cancer death after 
surgical treatments to DCIS is very low and ranges from 2.3% to 4.7% after 
BCS at 15 years compared to less than 1% after mastectomy treatment (Lee, 
Silverstein et al. 2006). 
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The increasing incidence of DCIS, its biological heterogeneity and the 
continuing debate about its treatment has made the management of DCIS 
challenging. It is not clear which, if any, DCIS patients can be safely treated 
with local excision alone, which patients require radiotherapy after local 
excision and which patients need mastectomy. To resolve this dilemma 
attempts have focused on the identification of prognostic and risk factors for 
local recurrence after breast sparing treatments for DCIS. 
  
New approaches in recent studies to stratify DCIS patients risk of subsequent 
invasive cancer have included assessment of additional biomarkers and 
genomic scores. In a recent study undertaken by Kerlikowske et al, 2010 they 
suggested that high expression of Ki67, p16 and COX-2 were predictive 
factors of high invasive local recurrence in DCIS patients (Kerlikowske, 
Molinaro et al. 2010).  
 
The biomarkers indicative of aggressive invasive carcinoma have been tested 
in DCIS, such as gain of mutant p53, high Ki-67 index and loss of p16, to 
attempt to identify aggressive DCIS; the results indicate that these biomarkers 
are favourable for breast cancer progression (Pape-Zambito, Jiang et al. 
2014). However, these findings are based on small numbers of clinical 
samples from patients diagnosed with invasive ductal carcinoma and DCIS.  
 
Moreover, albeit in a group of DCIS patients treated with BCS alone, 
promising data has been shown for a 12 gene Oncotype DX DCIS score with 
prognostic value for 10 year risk of invasive local recurrence that was 
independent of classical clinical characteristics (Solin, Gray et al. 2013). This 
study was confirmed in a larger cohort of DCIS patients treated with BCS 
alone (Rakovitch, Nofech-Mozes et al. 2015). Interestingly, another recent 
study has used the pathological features of DCIS to predict the Oncotype DX 
DCIS score. The study found a correlation between DCIS score and two 
pathological features of DCIS, not routinely assessed, dense chronic 
inflammation around DCIS and mitotic activity along with progesterone 
expression (Knopfelmacher, Fox et al. 2015).     
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Despite these different and various approaches, DCIS remains a complex 
disease and accurate determination of a patient’s recurrence risk will probably 
be ascertained by consideration of a combination of clinical, pathological and 
molecular characteristics of the tumour. Moreover, there is a pressing need to 
investigate additional factors that will help in improving risk stratification of 
DCIS patients. 
 
The significant role of the HER family in invasive breast cancer prognosis is 
well documented; studies have shown that overexpression of HER2 and 
HER3 represent the most common phenotype in early invasive disease 
(Witton, Reeves et al. 2003, Bartlett, Munro et al. 2008, Spears, Taylor et al. 
2012). This, joined with data that indicate that increased phosphorylation and 
activation of HER2 is linked to overexpression and dimerization, demonstrates 
the importance of investigating HER dimer formation and activation status in 
addition to protein expression in early breast cancer.  
 
The expression of HER1, HER2 and HER3 has been investigated in DCIS in 
previous studies using IHC (Lebeau, Unholzer et al. 2003, Altintas, Lambein 
et al. 2009). HER2 is the most extensively studied biological marker, which 
has prognostic significance in invasive breast cancer (Lari and Kuerer 2011). 
However, DCIS is rarely tested routinely for HER2, for example the College of 
America Pathologists’ protocol does not include HER2 as a minimum dataset 
item (Lester, Bose et al. 2009); this is because trastuzumab or other anti-
HER2 targeted agents are not currently recommended for patients with DCIS.  
However, ongoing trials are studying the promise of treating HER2 positive 
invasive tumours with trastuzumab and/or lapatininb and/or pertuzumab (de 
Azambuja, Holmes et al. 2014) and these results could shed light on whether 
there is value is assessing the HER family members’ status and their 
interactions in DCIS.  
 
The PLA method proved to be a useful tool that provides a robust, sensitive 
and quantifiable assessment of HER dimer formation and activation status in 
situ, as proven in the previous Chapters. This has allowed us to examine the 
role of the different parameters in breast lesions. In this Chapter I was able to 
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demonstrate the ability to successfully assess HER dimer formation and 
activation status, as well as protein expression levels, in pure DCIS cases. 
This allows investigation of possible differences in the expression of HER 
dimer formation and activation status between DCIS lesions and invasive 
breast cancer and potential provides a better understanding of the biological 
characteristics of pre-invasive tumour.   
 
We were able to detect and quantify the co-localization and dimer formation of 
HER1, HER2 and HER3 and their post-translational modifications, as well as 
their expression level in pure DCIS cases using the 9 different designed PLA 
assays.  
 
This has enabled us to investigate the correlations between the 9 different 
biological biomarkers in the pure DCIS cases.  
 
Our results indicate no association between HER1, HER2 and HER3 total 
protein level, which is different from our results obtained from the cohort of 
invasive breast cancer presented in Chapter 5 in which we showed a positive 
correlation between all the three receptors total protein level. However, this 
lack of associations could be due to the small number of DCIS cases used in 
this study. 
 
Similarly, the association between HER2 and phosphorylated HER2 was not 
significant in the analyzed DCIS cases, although some of the DCIS cases 
showed HER2 overexpression. The majority of cases showed a low level of 
phosphorylated HER2. These results are different from the results obtained in 
the invasive breast cancer cases presented in the previous chapter in which 
there was a significant and positive correlation between HER2 total protein 
level and phosphorylated HER2. Interestingly some studies have reported a 
difference between HER2 expression and phosphorylated HER2 in breast 
samples.  
 
This could be due to pre-analytical variables, as a significant association is 
recognized between rapid sample handling and fixation after excision and loss 
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of phospho-proteins (Leonard and Swain 2004, Pinhel, Macneill et al. 2010, 
Wang, Shamliyan et al. 2011, Bai, Cheng et al. 2013). Additionally, there was 
no association between HER2 total protein level and HER1/HER2 dimer 
formation, however, a positive association was seen between HER2 protein 
level and HER2/HER3 dimer formation (p=0.05). 
 
The results indicate no association between total HER1 expression level and 
its phosphorylated form, which was observed in invasive breast cancers (see 
Chapter 5); this could support the finding that total HER1 expression is 
independent of its activation status (Halle, Lando et al. 2011). Our results 
show no association between HER1/HER2 dimer and total HER1; the same 
conclusion was drawn from the cohort of invasive breast cancer and similar 
results were also reported in one other independent study (Barros, Abdel-
Fatah et al. 2014). 
 
A significant association was found between total HER3 and phosphorylated 
HER3 (p=0.038) suggesting that either phosphorylated HER3 is more robust 
and not affected as much by pre-analytical variables, or that the finding in 
relation to phosphorylated HER2 is real. Moreover, a positive association was 
found between HER3 total protein level, HER1/HER3 and HER2/HER3 dimer 
formation. A significant association was found between HER1/HER2 dimer 
formation and total HER3 and phosphorylated HER3 (p=0.020) and (p=0.016) 
respectively. As stated earlier it is difficult to explain in functional terms these 
significant associations between HER1/HER2 and total HER3 and 
phosphorylated HER3 and it needs confirmation in larger series. 
 
In the previous Chapter we were able to identify three parameters associated 
with higher risk of local recurrence in invasive breast cancer, which include 
phosphorylated HER2, HER1/HER3 and HER2/HER3 dimers. However, and 
as stated earlier, one of the major challenges when studying biomarkers in 
DCIS and the limitations of published studies is that they are limited to a small 
number of cases (Lari and Kuerer 2011). This is true in this study; the small 
number of cases with subsequent local recurrence limited our ability to further 
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investigate the absolute effect of the expression of the various biological 
markers on prognosis.   
 
However, numerous studies have recorded DCIS characteristics associated 
with a higher risk of local recurrence in DCIS (Wang, Shamliyan et al. 2011); 
these include DCIS grade, comedo-type necrosis, margin width, other 
biomarkers and DCIS size. Therefore, the association between the PLAs 
parameters and the patient’s and clinical characteristics were investigated. 
  
Our results show a significant association between total HER2 expression 
level and DCIS grade, with higher expression of HER2 associated with higher 
grade DCIS. The association between increased levels of HER2 and DCIS 
grade has been reported in previous studies (Altintas, Lambein et al. 2009). 
This consistency provides a degree of validation for the approach taken here. 
Our results also indicate a significant association between HER2 expression 
level and the presence of comedo-type necrosis; these are all associated with 
high risk of recurrence in DCIS (Leonard and Swain 2004, Wang, Shamliyan 
et al. 2011). No other significant association was found. 
 
The data could potentially indicate a role for total HER2 level and the risk of 
local recurrence in DCIS and warrants further investigation. In particular, it 
would be important to determine how the more sensitive assessment of HER2 
by PLA relates to the established means of determining HER2 levels. It may 
transpire that a change in methodology would provide a clearer evaluation. 
 
In conclusion, PLA provided a quantifiable and successful assessment of the 
HER family protein expression level, interactions and activation status in pure 
DCIS cases. There are limitations due to the small number of cases used in 
this study; however, we were able to show some differences between the 
pure DCIS tumours and the invasive tumours presented in Chapter 5. In the 
pure DCIS, no association was found between the three receptors total 
protein level. and no association was also found between HER2 protein level 
and phosphorylated HER2, in contrast to the invasive lesions.  In pure DCIS 
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as in the invasive breast tumour, no association was found between HER1 
protein level and HER1 phosphorylation or HER1/HER2 dimer formation.  
 
Although our findings may, to some extent, reflect only a small number of 
cases, the lack of associations between HER2 expression level and 
phosphorylated HER2 observed in the pure DCIS tumour could be potentially 
interesting from a biological perspective. Future work would be to apply the 
PLA method on DCIS associated with invasive disease to investigate if the 
level of phosphorylated HER2 in the two adjacent stages of the tumour is 
different, as well as to investigate the other different parameters, in particular 
ligand expression. 
 
Perhaps the most important correlate identified here is the consistent poor 
prognosis correlation for cases where HER2 is “high” as defined by PLA 
methods. The sensitivity of this assay may prove crucial to our ability to 
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7.1 Overview of project aim 
Breast cancer represents a heterogeneous collection of different diseases 
characterized by different pathological and biological features, clinical 
presentation, clinical behaviour, response to treatment and outcome (Dieci, 
Orvieto et al. 2014). The histological diversity of breast cancer has led to its 
classification as up to 21 histological subtypes according to the World Health 
Organization (WHO) on the basis of cell morphology, architecture patterns 
and growth (Tavassoli FA 2003). In current practice, pathological diagnosis 
and classification of breast cancer is based mainly on well-established 
traditional morphological features. However, morphological features alone do 
not adequately reveal the molecular heterogeneity and complexity of breast 
cancer. 
 
Immunohistochemistry (IHC) currently remains the preferred technique for 
biomarker profiling in routine pathology laboratories. On the basis of IHC, 
breast cancer may be classified into three main groups: hormone receptor 
(HR) ER/PR positive, Epidermal Growth Factor Receptor 2 (HER2) positive, 
and triple-negative disease (i.e. HR and HER2 negative) (Dieci, Orvieto et al. 
2014). The IHC technique is well established and useful in detecting the levels 
of proteins in tumour samples but can it provide us with all the information 
needed? In situ hybridization was introduced later and is used routinely now 
to further classify breast cancer into HER2 gene amplified or non-amplified 
groups (Hanna, Ruschoff et al. 2014).  
 
Still, there are relatively few biomarkers widely used in prognostication in 
invasive breast cancer and in predicting response to targeted therapies, and 
even fewer of value in the clinical management of pre-invasive disease, i.e. 
DCIS. There is therefore an unmet need for biomarkers for better 
classification, better prediction of prognosis and of response to therapy for 
invasive carcinoma and DCIS. 
 
Outcomes, Limitations and Future work                                             Chapter-7 
  251 
 
More recently, there has been an exponential development of high throughput 
technologies and their application in cancer research. For example, 
microarray technology has led to a greater understanding of the altered 
expression patterns underlying breast cancer progression and development. 
This has led to the molecular classification of breast cancer into intrinsic 
molecular subtypes based on different gene expression profiles (Sorlie 2004).  
Furthermore, the assembly of more complex datasets including gene 
expression and gene copy number data has led to the identification of 10 
different clusters of primary breast cancer, each with a different prognosis 
(Curtis, Shah et al. 2012). 
 
Despite advances, the identification of genes, for example associated with 
increasing metastatic incidence, does not bring progress to understanding of 
how these events actually occur; these gene expression profiles are 
signatures, they do not define mechanistic drivers. The function of the gene 
products, i.e., the proteins, must be assessed to address this. Although 
genetic aberrations cause disease, the functional consequences are largely 
mediated through protein networks. Moreover, clinicians still rely on traditional 
clinico-pathological features and readily available and reproducible tumour 
biomarkers such as HER2, ER and PR. This is unlikely to change, but it is 
inevitable that, as we gain greater understanding of the underlying molecular 
events in breast cancers and other cancers, these molecular parameters will 
contribute to the markers we interrogate and so impact on the clinical decision 
making process.  
 
The aim of this thesis has been directed at assessing candidate biomarkers in 
breast cancer. Not those traditionally based on altered expression, but rather 
using attributes associated with known functional properties of candidate 
drivers of disease or resistance to treatment. Here, in the context of breast 
cancer, work was directed at the HER1-HER3 members of the EGFR family of 
growth factor receptor. 
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The role of the EGFR family is well known; over-expression of the HER1-3 
members is seen in breast cancer and associated with a poor prognosis, 
advanced tumour stage, as well as resistance to both hormonal therapy and 
chemotherapeutic agents (Newby, Johnston et al. 1997, Knoop, Bentzen et al. 
2001). Moreover, studies have shown the potential clinical role of the 
determination of HER:HER protein-protein interactions; this showed that 
patients with tumours that had high levels of HER2 homodimers were more 
likely to benefit from trastuzumab (Desmedt, Sperinde et al. 2009).  
 
Furthermore, it has been reported that an increase in HER1:HER2 dimers 
leads to an increase in growth signaling, due to the decrease in recycling of 
HER1 and increased signaling from HER2/HER3 dimers, this may lead to 
more aggressive tumors and a decrease in survival (Kol, Terwisscha van 
Scheltinga et al. 2014).  
 
Interestingly, several studies have shown that protein overexpression could 
be independent of the phosphorylated form of HERs (Kong, Leboucher et al. 
2006, Halle, Lando et al. 2011, Gajadhar, Bogdanovic et al. 2012). This 
indicates that the phosphorylated forms of the HER receptors, as well HER 
complex formation, are independent candidate biomarkers that could allow for 
better classification of patients, as well as prediction of prognosis. Therefore, 
these parameters were the target for investigation in this study in these breast 
cancer patients. 
 
7.2 Assessing and developing technologies. 
The methods of extracting this complex information are not routine and hence 
a part of my thesis work involved assessing and developing applications of 
the Proximity Ligation Assay (PLA) technology that is competent to deliver the 
data required. The constraints being, specificity for post-translational 
modification (phosphorylation site) recognition in patient samples, and an 
Outcomes, Limitations and Future work                                             Chapter-7 
  253 
ability to detect complex formation in these samples based on the close 
proximity of proteins.  
 
Using cell based studies we have rigorously assessed the use and the 
specificity of PLA assays and have derived protocols that gave robust data. 
This is compatible with manipulations and portable to xenografts derived from 
the same cell models. We also assessed TMAs containing human clinical 
breast cancer samples. Furthermore, the sensitivity of PLA assays was 
determined and shown to be better than conventional methods (IF and IHC). 
However, the limitation of this technology is the inefficient ligation as part of 
the process of PLA, creating a typically punctate patterns in cells and tissues; 
this means that there is still much to improve with PLA or in the development 
of other methods. 
  
As part of my thesis work, I have worked on the development of an alternative 
and novel technology (the biodetector technology) that is being created de 
novo. This technology has the potential to be even more sensitive than PLA, 
as shown for the single capture protocol developed employing the Protein G 
fusion I created and tested. This development was not without its demands, 
including problems with background staining, but concerted efforts with Dr 
Perani have to help resolve these, and have produced a protocol that can now 
be fed back into the complex coincidence detection technology. It will be 
important to see how this develops and whether it can bring these more 
difficult biomarker questions into the repertoire of more routine analysis.  
 
7.3 The prognostic value of the studied biomarkers.  
In the current study, and by using PLA, we were able to study in parallel for 
the first time the prognostic role of 9 different HER family related biomarkers 
in invasive breast cancer and in DCIS. These different biomarkers represent 
HER1, HER2 and HER3 expression, complex formation and post-translational 
modification (phosphorylation).  
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The evidence presented from the use of PLA in this study indicates that in 
invasive cancers, HER2 complex formation and phosphorylation correlate and 
are indicative of aggressive disease.  
 
It might be argued that this was known, and to some extent this is the case, 
and as such provides reassurance of the accuracy and validity of the methods 
applied and the data obtained. However, these correlations are also 
statistically based and, additionally, there are tumours where complex 
formation and phosphorylation are not associated with HER2 3+ 
immunoreactivity. Potentially patients with such tumours may benefit from 
lapatinib, or the promising irreversible agent neratinib, both directed at 
HER1/2 catalytic activity (Geyer, Forster et al. 2006, Canonici, Gijsen et al. 
2013). 
 
It is noted that an increased level of total HER1 and HER3 is significantly 
associated with an increase in HER1/HER3 dimerization and phosphorylation. 
The overexpression of HER1 and HER3 has been associated with advanced 
tumour stage, metastasis, local recurrence risk and decreased survival as well 
as an increased resistance to hormonal and chemotherapy (Kol, Terwisscha 
van Scheltinga et al. 2014). Another recent study of a cohort of breast cancer 
patients has similarly showed that the presence of higher levels of 
HER2/HER3 expression was significantly associated with reduced relapse 
free survival (RFS) and overall survival (OS) (Spears, Taylor et al. 2012).   
 
These findings were extended here and the association of HER1/HER3 and 
HER2/HER3 was found to be prognostic ally significant and associated with a 
higher risk of local recurrence and overall survival. This shows that HER3 is a 
serious ‘partner in crime’ and emphasizes the importance of assessing and 
targeting HER3 beside HER2 and HER1 in invasive breast cancers. Targeting 
HER3 in HER2+ invasive breast cancer with pertuzumab in association with 
trastuzumab could lead to substantial clinical benefit (Agus, Akita et al. 2002, 
Franklin, Carey et al. 2004).  
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Additionally, we were able to detect and quantify the same 9 different HER 
family biomarkers in pure DCIS cases. In the DCIS portion of the series, albeit 
as an entirely novel study, the number of further events was insufficient to 
derive clear indicators of prognostic value. However, the initial patterns 
suggest a significant association between HER2 and some of the DCIS 
clinical characteristics, which are associated with higher risk of recurrence, 
including tumour size, cytonuclear grade and the presence of comedo-type 
necrosis. This could potentially indicate a role for total HER2 level 
assessment and the risk of local recurrence in DCIS, and warrants further 
investigation.  
 
DCIS is rarely tested routinely for HER2 (for example the College of America 
Pathologist’s protocol does not include HER2 as a minimum dataset item 
(Lester, Bose et al. 2009)) as trastuzumab or other anti-HER2 targeted agents 
are not currently given to patients with DCIS, although ongoing trials are 
studying the promise of treating HER2 positive invasive tumours with 
trastuzumab and/or lapatininb and/or pertuzumab (Lee-Hoeflich, Crocker et al. 
2008, Gianni, Pienkowski et al. 2011, Baselga, Cortés et al. 2012, Blackwell, 
Burstein et al. 2012). However, our findings indicate that there may be value 
in assessing HER family member’s status and interactions in DCIS in the 
samples collected in these studies; these parameters may provide a 
predictive biomarker. 
 
Personalized medicine is intended to match the profile of an individual’s 
tumour to the opportunities to treat and respond to specific treatment whilst 
not eliciting toxicity. The statistical patterns of prognostic relationships for 
candidate drivers of disease provide a guide as to what might be important in 
terms of targeting the properties of tumours. However, it is the individual 
molecular profile that should be informing the physician in terms of treatment 
guidance. Hence, the association of over-expression in a pathway with a poor 
prognosis, as appears to be the case for HER2 and breast cancer, on an 
individual case basis needs to be addressed by determining whether 
elements in the pathway are indeed over-expressed, but also in determining if 
the pathway is switched on and, as demonstrated here, these may not 
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correlate on an individual patient basis. As illustrated in Chapter 5 (Figure 
5:9), just under 10% of patients had highly phosphorylated HER2 without high 
level HER2 expression. This is a substantial proportion of all invasive breast 
cancers and if responsive to adjuvant drug intervention would make a 
significant impact. 	
7.4 Limitations of the study 
The major limitation of the study is the small number of invasive and DCIS 
patients examined in this study with a history of local recurrence. Local 
recurrence is, fortunately, less commonly seen than in historical series of both 
invasive and in situ carcinoma because of modern treatment regimens 
including adequate surgery with radiotherapy. We were, however, able to 
study and provide evidence of the possible significant role of the studied 
biomarkers on breast cancer patients prognosis, despite the small size of 
cases and limitations in the number of events (particularly for the DCIS 
cases). 
7.5 Future studies 
We have been able to identify and study the prognostic role of 9 different 
biomarkers in breast cancers and some interesting data was obtained. Our 
results indicate a potentially significant influence of HER phosphorylation (and 
associations) as well as absolute expression on a breast cancer patient’s 
prognosis. Future work is needed to evaluate this in a larger cohort of 
patients.  
 
Using PLA or other similar techniques (as described here) it will be of 
particular importance to look at HER2 phosphorylation and co-expression in 
clinical trial cohorts of HER2 positive patients treated with HER2 targeted 
agents, to see if there is a relationship between response and resistance. 
Additionally, it will be important to study the relationship between HER2 
phosphorylation and mutation status in invasive lobular carcinoma.  
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Future work could also apply the PLA technique on DCIS in the presence of 
invasive cancer (i.e. in situ disease that has already progresses) to determine 
if the level of phosphorylated HER2 in the two adjacent components is 
different. One valuable attribute of the biomarker methodologies developed 
here is that they allow the detection of clonal heterogeneity, unlike for 
example ELISA or mass spectrometry based analytical procedures. It is 
expected that understanding this functional heterogeneity will be important. 
 
The future of applying such observations is in the prospective testing of drug 
treatment directed at the pathway in question, to determine if there is 
predictable patient benefit. This is not a trivial undertaking in breast cancer, 
where progression can occur over years as opposed to months after 
diagnosis, but for well tolerated targeted small molecule therapies this would 
seem to be the way forward. 
 
Can the molecular pathology community embrace different technologies that 
enable these functional attributes of proteins to be more routinely captured?   
The ultimate route to this is going to be in the continued pioneering or use of 
these types of technologies to a point where there is a compelling prognostic 
case for implementation clinically. This is not likely to come at the first attempt 
but will take some time. It is possible that the route to acceptance will come 
from some companion diagnostic, developed within a targeted drug 
development programme.  
 
In summary 
The aim of this study is not to replace current proven and established 
methods of protein determination. However, the findings in this thesis provide 
evidence of the importance of investigating HER dimer formation and 
activation status, rather than simple protein expression in breast cancer 
patients.  The value in these findings is that there are already several 
available agents that are directed at these proteins – they should be exploited 
in treatments. These functional attributes are in the vanguard of personalized 
medicine. 
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ProteinG modules full length sequences constructed:	
GST-RAR-15nm-ProteinG(C1+C3)-S-EE-HIS 
GST sequence  
3C protease recognition sequence  
RAR DNA BD  
MyoVI linker(15nm)  




STOP codon  
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GST-RAR-G/S-ProteinG(C1+C3)-S-EE-HIS 
 
GST sequence  
3C protease recognition sequence  
RAR DNA BD  
G/S Linker  
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GST-RXR-E3-ProteinG(C1+C3)-S-EE-HIS 
GST sequence  
3C protease recognition sequence  
RXR DNA BD  
E3 Linker  




STOP codon  
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GST-RXR-K3-ProteinG(C1+C3)-S-EE-HIS 
 
GST sequence  
3C protease recognition sequence  
RXR DNA BD  
K3 Linker  




STOP codon  
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